View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($)	12 Months Ended
Document and Entity Information - USD ($)	Dec. 31, 2015	Feb. 29, 2016	Jun. 30, 2015
Document Entity Information [Abstract]
Entity Registrant Name	BioScrip, Inc.
Entity Central Index Key	0001014739
Current Fiscal Year End Date	--12-31
Entity Filer Category	Accelerated Filer
Document Type	10-K
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Amendment Flag	false
Entity Common Stock, Shares Outstanding		68,767,613
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float			$ 249,493,062

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Current assets
Cash and cash equivalents	$ 15,577	$ 740
Receivables, less allowance for doubtful accounts of $59,689 and $66,405 at December 31, 2015 and December 31, 2014, respectively	108,365	131,656
Inventory	42,983	37,215
Prepaid expenses and other current assets	20,046	9,054
Assets held for sale	0	9,550
Total current assets	186,971	188,215
Property and equipment, net	31,939	38,171
Goodwill	308,729	560,579
Intangible assets, net	5,128	10,269
Deferred financing costs	12,577	13,463
Other non-current assets	1,161	1,272
Non-current assets held for sale	0	12,744
Total assets	546,505	824,713
Current liabilities
Current portion of long-term debt	27,665	5,395
Accounts payable	65,077	89,203
Amounts due to plan sponsors	3,491	4,869
Accrued interest	6,898	6,853
Accrued expenses and other current liabilities	52,918	46,957
Liabilities held for sale	0	9,976
Total current liabilities	156,049	163,253
Long-term debt, net of current portion	406,319	418,408
Deferred taxes	236	18,118
Other non-current liabilities	1,861	8,129
Total liabilities	564,465	607,908
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 635,822 shares issued and outstanding; and, $69,702 liquidation preference as of December 31, 2015. No convertible preferred stock was authorized or outstanding as of December 31, 2014.	62,918	0
Stockholders’ (deficit) equity
Preferred stock, $.0001 par value; 4,175,000 and 5,000,000 shares authorized as of December 31, 2015 and 2014, respectively; no shares issued and outstanding as of December 31, 2015 and 2014, respectively	0	0
Common stock, $.0001 par value; 125,000,000 shares authorized; 71,421,664 and 71,274,064 shares issued and 68,767,613 and 68,636,965 shares outstanding as of December 31, 2015 and 2014, respectively	8	8
Treasury stock, 2,654,051 and 2,637,099 shares, at cost, as of December 31, 2015 and 2014, respectively	(10,737)	(10,679)
Additional paid-in capital	531,764	529,682
Accumulated deficit	(601,913)	(302,206)
Total stockholders’ (deficit) equity	(80,878)	216,805
Total liabilities and stockholders’ (deficit) equity	$ 546,505	$ 824,713

CONSOLIDATED BALANCE SHEETS (Parentheticals) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Statement of Financial Position [Abstract]
Allowance for doubtful accounts	$ 59,689	$ 66,405
Series A preferred stock, par value (in USD per share)	$ 0.0001	$ 0
Series A preferred stock, shares authorized (in shares)	825,000	0
Series A preferred stock, shares issued (in shares)	635,822	0
Series A preferred stock, shares outstanding (in shares)	635,822	0
Series A preferred stock, liquidation preference	$ 69,702	$ 0
Preferred stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized (in shares)	4,175,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par value (in USD per share)	$ 0.0001	$ 0.0001
Common stock, shares authorized (in shares)	125,000,000	125,000,000
Common stock, shares issued (in shares)	71,421,664	71,274,064
Common stock, shares outstanding (in shares)	68,767,613	68,636,965
Treasury stock (in shares)	2,654,051	2,637,099

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Statement [Abstract]
Net revenue	$ 982,223	$ 922,654	$ 696,473
Cost of revenue (excluding depreciation expense)	721,308	671,901	489,823
Gross profit	260,915	250,753	206,650
Other operating expenses	165,998	166,552	127,200
Bad debt expense	41,042	79,547	19,516
General and administrative expenses	42,524	49,314	47,897
Impairment of goodwill	251,850	0	0
Restructuring, integration, and other expenses, net	24,405	30,206	18,062
Depreciation and amortization expense	22,743	22,943	20,226
Loss from continuing operations	(287,647)	(97,809)	(26,251)
Interest expense, net	37,313	40,918	44,130
Loss from continuing operations, before income taxes	(324,960)	(138,727)	(70,381)
Income tax provision (benefit)	(21,532)	11,193	1,260
Loss from continuing operations, net of income taxes	(303,428)	(149,920)	(71,641)
Income from discontinued operations, net of income taxes	3,721	2,452	1,987
Net loss	(299,707)	(147,468)	(69,654)
Accrued dividends on preferred stock	(6,120)	0	0
Deemed dividends on preferred stock	(3,690)	0	0
Loss attributable to common stockholders	$ (309,517)	$ (147,468)	$ (69,654)
Loss per common share:
Loss from continuing operations, basic and diluted (in USD per share)	$ (4.56)	$ (2.19)	$ (1.11)
Income (loss) from discontinued operations, basic and diluted (in USD per share)	0.05	0.04	0.03
Income (loss), basic and diluted (in USD per share)	$ (4.51)	$ (2.15)	$ (1.08)
Weighted average common shares outstanding, basic and diluted	68,710	68,476	64,560

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' (DEFICIT) EQUITY - USD ($) $ in Thousands	Total	Common Stock	Treasury Stock	Additional Paid-in Capital	Accumulated Deficit
Beginning Balance at Dec. 31, 2012	$ 293,409	$ 6	$ (10,311)	$ 388,798	$ (85,084)
Net proceeds of public stock offering	118,382	1		118,381
Exercise of stock options	2,549			2,549
Compensation under employee stock compensation plan	9,498			9,498
Exercise of warrants	399			399
Net income (loss)	(69,654)				(69,654)
Ending Balance at Dec. 31, 2013	354,583	7	(10,311)	519,625	(154,738)
Exercise of stock options	1,468	1		1,467
Surrender of stock to satisfy minimum tax withholding	(368)		(368)
Compensation under employee stock compensation plan	8,590			8,590
Net income (loss)	(147,468)				(147,468)
Ending Balance at Dec. 31, 2014	216,805	8	(10,679)	529,682	(302,206)
Exercise of stock options	2			2
Surrender of stock to satisfy minimum tax withholding	(58)		(58)
Issuance of Series A convertible preferred stock and warrants	6,581			6,581
Accrued dividends on preferred stock	(6,120)			(6,120)
Deemed dividends on preferred stock	(3,690)			(3,690)
Compensation under employee stock compensation plan	5,309			5,309
Net income (loss)	(299,707)				(299,707)
Ending Balance at Dec. 31, 2015	$ (80,878)	$ 8	$ (10,737)	$ 531,764	$ (601,913)

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Cash flows from operating activities:
Net income (loss)	$ (299,707)	$ (147,468)	$ (69,654)
Less: Income from discontinued operations, net of income taxes	3,721	2,452	1,987
Loss from continuing operations, net of income taxes	(303,428)	(149,920)	(71,641)
Adjustments to reconcile net loss from continuing operations to net cash (used in) operating activities:
Depreciation and amortization	22,743	22,943	20,226
Impairment of goodwill	251,850	0	0
Amortization of deferred financing costs and debt discount	3,440	4,153	2,259
Change in fair value of contingent consideration	(30)	(7,364)	(5,786)
Change in deferred income tax	(20,089)	9,359	4,801
Compensation under stock-based compensation plans	4,513	8,570	9,450
Loss on extinguishment of debt	0	2,373	15,898
Equity in earnings of unconsolidated affiliate	0	0	675
Changes in assets and liabilities, net of acquired businesses:
Receivables, net of bad debt expense	16,455	27,695	(40,002)
Inventory	(5,769)	(2,952)	4,939
Prepaid expenses and other assets	170	5,474	(584)
Accounts payable	(24,129)	27,093	22,726
Claims payable	0	0	0
Amounts due to plan sponsors	(1,377)	562	(13,094)
Accrued interest	44	4,681	(3,627)
Accrued expenses and other liabilities	(6,682)	7,310	(3,294)
Net cash provided by (used in) operating activities from continuing operations	(62,289)	(40,023)	(57,054)
Net cash provided by (used in) operating activities from discontinued operations	(2,453)	8,607	2,474
Net cash provided by (used in) operating activities	(64,742)	(31,416)	(54,580)
Cash flows from investing activities:
Purchases of property and equipment, net	(11,544)	(13,829)	(25,599)
Cash consideration paid for acquisitions, net of cash acquired	0	(454)	(282,998)
Net cash proceeds from sale of unconsolidated affiliate	0	852	8,617
Cash advances to unconsolidated affiliate	0	0	(2,363)
Net cash (used in) investing activities from continuing operations	(11,544)	(13,431)	(302,343)
Net cash provided by investing activities from discontinued operations	24,565	57,688	0
Net cash provided by (used in) investing activities	13,021	44,257	(302,343)
Cash flows from financing activities:
Proceeds from public stock offering	0	0	118,382
Proceeds from issuance of convertible preferred stock and warrants, net of issuance costs	59,691	0	0
Proceeds from senior notes due 2021, net of discount, lenders' fees and other expenses	0	194,539	0
Proceeds from senior credit facilities, net of fees paid to issuers	0	0	378,091
Repayment of 10 1/4% senior unsecured notes	0	0	(237,397)
Deferred and other financing costs	(2,630)	(1,135)	0
Borrowings on revolving credit facility	203,663	244,700	449,559
Repayments on revolving credit facility	(193,663)	(279,703)	(409,559)
Principal payments of long-term debt	0	(172,243)	(5,000)
Repayments of capital leases	(395)	(360)	(802)
Net proceeds from exercise of employee stock compensation plans	(50)	1,468	2,549
Surrender of stock to satisfy minimum tax withholding	(58)	(368)	0
Net cash provided by (used in) financing activities	66,558	(13,102)	295,823
Net change in cash and cash equivalents	14,837	(261)	(61,100)
Cash and cash equivalents - beginning of period	740	1,001	62,101
Cash and cash equivalents - end of period	15,577	740	1,001
DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid during the period for interest	34,302	34,133	25,589
Cash paid during the period for income taxes, net of refunds	$ 114	$ 1,651	$ 3,137

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parentheticals)	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 25, 2010
Unsecured Debt \| 2015 Notes
Debt Instrument [Line Items]
Stated interest rate	10.25%	10.25%	10.25%	10.25%

NATURE OF BUSINESS

12 Months Ended

Dec. 31, 2015

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Nature of Business

NATURE OF BUSINESS

Corporate Organization and Business

BioScrip, Inc. and subsidiaries (the “Company” or “BioScrip”) is a national provider of infusion service that partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, the Company aims to provide cost-effective care that is driven by clinical excellence, customer service and values that promote positive outcomes and an enhanced quality of life for those whom we serve.

The Company’s platform provides nationwide service capabilities and the ability to deliver clinical management services that offer patients a high-touch, community-based and home-based care environment. The Company’s core services are provided in coordination with, and under the direction of, the patient’s physician. The Company's multidisciplinary team of clinicians, including pharmacists, nurses, dietitians and respiratory therapists, work with the physician to develop a plan of care suited to the patient’s specific needs. Whether in the home, physician office, ambulatory infusion center, skilled nursing facility or other alternate sites of care, the Company provides products, services and condition-specific clinical management programs tailored to improve the care of individuals with complex health conditions such as gastrointestinal abnormalities, infectious diseases, cancer, multiple sclerosis, organ and blood cell transplants, bleeding disorders, immune deficiencies and heart failure.

On August 27, 2015, the Company completed the sale of substantially all of the Company’s PBM Services segment (the “PBM Business”) to ProCare Pharmacy Benefit Manager Inc. (see Note 6 - Discontinued Operations). As a result of the sale of the PBM Business, the Company no longer has multiple operating segments. The change reflects how the Company's chief operating decision maker reviews the Company’s results in terms of allocating resources and assessing performance.

Basis of Presentation

The Company’s Consolidated Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”).

Reclassifications

With the sale of the PBM Business on August 27, 2015 and the Company’s Home Health Services segment (the “Home Health Business”) on March 31, 2014, all prior period financial statements have been reclassified to include the PBM Business and Home Health Business as discontinued operations.

During 2015, the Company reclassified the statement of operations to reflect the information that the Company believes to be most relevant to users of the financial statements. All of the prior period financial statements were reclassified to reflect the classification change. The reclassification of the statement of operations includes:


•	Product revenue and service revenue in the former statement of operations are now grouped to net revenue with the impact of the sale of PBM Business; Cost of product revenue and cost of service revenue in the former statement of operations are grouped to net cost of revenue (excluding depreciation expense).


•	Depreciation expense included separately in cost of product revenue and selling, general and administrative expenses in the former statement of operations is now grouped in line item: depreciation and amortization expense.


•	Selling, general and administrative expenses in the former statement of operations is split into two line items: other operating expenses, and general and administrative expenses; In connection with this reclassification, the Company no longer allocates general and administrative expenses to field office expenses.


•	Acquisition and integration expenses, restructuring and other expenses, and change in fair value of contingent consideration in the former statement of operations are grouped to one line item: Restructuring, integration expenses, and other expenses, net.


•	Interest expense and loss on extinguishment of debt in the former statement of operations are grouped to one line item: interest expense, net.

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Consolidation

The Consolidated Financial Statements include the accounts of the Company and its wholly-owned subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Use of Estimates

The preparation of financial statements in conformity with GAAP requires management to make certain estimates and assumptions. These estimates and assumptions affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.

Fair Value Measurements

The fair value measurement accounting standard, ASC Topic 820, Fair Value Measurement (“ASC 820”), provides a framework for measuring fair value and defines fair value as the price that would be received to sell an asset or paid to transfer a liability. Fair value is a market-based measurement that should be determined using assumptions that market participants would use in pricing an asset or liability. The standard establishes a valuation hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on independent market data sources. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available.

The valuation hierarchy is composed of three categories. The categorization within the valuation hierarchy is based on the lowest level of input that is significant to the fair value measurement. The categories within the valuation hierarchy are described as follows:


•	Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.


•	Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.


•	Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.

Cash and Cash Equivalents

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents.

Receivables

Receivables include amounts due from government sources, such as Medicare and Medicaid programs, Managed Care Organizations and other commercial insurance; amounts due from patient co-payments; amounts due from pharmaceutical manufacturers for rebates; and service fees resulting from the distribution of certain drugs through retail pharmacies.

Allowance for Doubtful Accounts

The allowance for doubtful accounts is based on estimates of losses related to receivable balances. The risk of collection varies based upon the product, the payor (commercial health insurance and government) and the patient’s ability to pay the amounts not reimbursed by the payor. We estimate the allowance for doubtful accounts based on several factors including the age of the outstanding receivables, the historical experience of collections, adjusting for current economic conditions and, in some cases, evaluating specific customer accounts for the ability to pay. Collection agencies are employed and legal action is taken when we determine that taking collection actions is reasonable relative to the probability of receiving payment on amounts owed. Management judgment is used to assess the collectability of accounts and the ability of our customers to pay. Judgment is also used to assess trends in collections and the effects of systems and business process changes on our expected collection rates. The Company reviews the estimation process quarterly and makes changes to the estimates as necessary. When it is determined that a customer account is uncollectible, that balance is written off against the existing allowance.

Change in Estimate of the Collectability of Accounts Receivable

The Company experienced deterioration in the aging of certain accounts receivable in 2014 primarily due to delays and disruptions related to the integration of its acquisitions in 2013. As a result, the Company materially changed its estimates based on actual collection experience during and after the acquisition disruption period from 2014. The 2015 estimation process is unchanged from the process established in 2014.

We believe we are adequately reserved on these balances over 180 days; however, there is a higher risk of collection on these balances than the overall accounts receivable. The Company has slightly increased the allowance for doubtful accounts as a percentage of total accounts receivable to 35.5% at December 31, 2015 compared to 33.5% at December 31, 2014. However, since the gross accounts receivable balance decreased, the allowance for doubtful accounts balance decreased by $6.7 million from December 31, 2014.

The following table sets forth the aging of our net accounts receivable (net of allowance for contractual adjustments and prior to allowance for doubtful accounts), aged based on date of service and categorized based on the three primary overall types of accounts receivable characteristics (in thousands):



	December 31, 2015							December 31, 2014
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days		Total
Government	$	19,944	$	11,369	$	31,313		$	25,812	$	13,036	$	38,848
Commercial	103,357		22,345		125,702			108,439		35,313		143,752
Patient	5,014		6,025		11,039			4,899		10,562		15,461
Gross accounts receivable	$	128,315	$	39,739	168,054			$	139,150	$	58,911	198,061
Allowance for doubtful accounts					(59,689		)					(66,405		)
Net accounts receivable					$	108,365						$	131,656

Allowance for Contractual Discounts

The Company is reimbursed by payors for products and services the Company provides. Payments for medications and services covered by payors average less than billed charges. The Company monitors revenue and receivables from payors for each of our branches and records an estimated contractual allowance for certain revenue and receivable balances as of the revenue recognition date to properly account for anticipated differences between amounts estimated in our billing system and amounts reimbursed. Accordingly, the total revenue and receivables reported in our financial statements are recorded at the amounts expected to be received from these payors. For the significant portion of the Company’s revenue, the contractual allowance is estimated based on several criteria, including unbilled claims, historical trends based on actual claims paid, current contract and reimbursement terms and changes in customer base and payor/product mix. Contractual allowance estimates are adjusted to actual amounts as cash is received and claims are settled. We do not believe these changes in estimates are material. The billing functions for the remaining portion of the Company’s revenue are largely computerized, which enables on-line adjudication (i.e., submitting charges to third-party payors electronically with simultaneous feedback of the amount the primary insurance plan expects to pay) at the time of sale to record net revenue, exposure to estimating contractual allowance adjustments is limited on this portion of the business.

Inventory

Inventory is recorded at the lower of cost or market. Cost is determined using specific item or the first-in, first-out method. Inventory consists principally of purchased prescription drugs and related supplies. Included in inventory is a reserve for inventory waste and obsolescence.

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	years	-	5	years
Office equipment				5	years
Vehicles	4	years	-	5	years
Medical equipment	13	months	-	5	years
Furniture and fixtures				5	years

Leasehold improvements and assets leased under capital leases are depreciated using a straight-line basis over the related lease term or estimated useful life of the assets, whichever is less. The cost and related accumulated depreciation of assets sold or retired are removed from the accounts with the gain or loss, if applicable, recorded in the statement of operations. Maintenance and repair costs are expensed as incurred.

Costs relating to the development of software for internal purposes are charged to expense until technological feasibility is established in accordance with FASB ASC Topic 350, Intangibles – Goodwill and Other (“ASC 350”). Thereafter, the remaining software production costs up to the date placed into production are capitalized and included in Property and Equipment. Costs of customization and implementation of computer software purchased for internal use are likewise capitalized. Depreciation of the capitalized amounts commences on the date the asset is ready for its intended use and is calculated using the straight-line method over the estimated useful life of the software.

Goodwill

Goodwill is not subject to amortization and is tested for impairment annually and whenever events or circumstances exist that indicate that the carrying value of goodwill may no longer be recoverable in accordance with ASC 350. Management considers the Company’s business as a whole to be its reporting unit for purpose of testing for impairment since the Company no longer has multiple operating segments with the sale of the PBM Business. Management may choose to undertake a qualitative assessment in order to assess whether a quantitative analysis is required. In determining whether management will utilize the qualitative assessment in any one year, management will consider overall economic factors as well as the passage of time between the last quantitative assessment. In the event management determines that a quantitative assessment is required, this quantitative impairment testing is based on a two-step process. The first step compares the fair value of the reporting unit to its carrying amount including goodwill. If the first step quantitative analysis indicates that the fair value of the reporting unit is less than its carrying amount, the second step quantitative analysis must be performed to determine the implied fair value of reporting unit goodwill. The measurement of possible impairment is based on the comparison of the implied fair value of reporting unit goodwill to its carrying value.

Intangible Assets

The Company evaluates the useful lives of its intangible assets to determine if they are finite or indefinite-lived. Finite-lived intangible assets, primarily acquired customer relationships, trademarks and non-compete agreements, are amortized on a straight-line basis over their estimated useful lives.

Impairment of Long Lived Assets

The Company evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long lived assets, including intangible assets, may warrant revision or that the remaining balance of an asset may not be recoverable. The measurement of possible impairment is based on the ability to recover the balance of assets from expected future operating cash flows on an undiscounted basis. Impairment losses, if any, are determined based on the fair value of the asset, calculated as the present value of related cash flows using discount rates that reflect the inherent risk of the underlying business.

Amounts due to Plan Sponsors

Amounts due to Plan Sponsors primarily represent payments received from Plan Sponsors in excess of the contractually required reimbursement. These amounts are refunded to Plan Sponsors. These payables also include the sharing of manufacturers’ rebates with Plan Sponsors.

Contingent Consideration

Liabilities that may be owed to sellers after the closing of an acquisition transaction are recorded at fair value as of the opening balance sheet established for the acquired target. These contingent consideration provisions are frequently referred to as earnouts and are the subject of negotiation between the seller and the buyer. An earnout provision can compensate the seller with the value they believe the asset will deliver while also providing downside risk protection to the buyer should projections not materialize. As such, the terms of potential earnouts vary with each transaction. Fair value is assigned using multiple payout scenarios which each have a probability assigned based on factors including actual performance, evidence of business plans that have been implemented, and current market conditions that influence the ability to achieve the earnout. The probable payout amount is discounted to the current balance sheet date using a risk free rate. Each quarter, the fair value of the contingent consideration is updated to reflect relevant factors such as post-closing operating results and future forecasts for the acquired business or entity. The fair value of contingent consideration may be included in current liabilities or other non-current liabilities depending on the payment date specified in the purchase agreement.

Revenue Recognition

The Company generates revenue principally through the provision of infusion services to provide clinical management services and the delivery of cost effective prescription medications. Prescription drugs are dispensed either through a pharmacy participating in the Company’s pharmacy network or a pharmacy owned by the Company. Fee-for-service agreements includes pharmacy agreements, where we dispense prescription medications through the Company’s pharmacy facilities.

FASB ASC Subtopic 605-25, Revenue Recognition: Multiple-Element Arrangements (“ASC 605-25”), addresses situations in which there are multiple deliverables under one revenue arrangement with a customer and provides guidance in determining whether multiple deliverables should be recognized separately or in combination. The Company provides a variety of therapies to patients. For infusion-related therapies, the Company frequently provides multiple deliverables of drugs and related nursing services. After applying the criteria from ASC 605-25, the Company concluded that separate units of accounting exist in revenue arrangements with multiple deliverables. Drug revenue is recognized at the time the drug is shipped, and nursing revenue is recognized on the date of service. The Company allocates revenue consideration based on the relative fair value as determined by the Company’s best estimate of selling price to separate the revenue where there are multiple deliverables under one revenue arrangement.

The Company also recognizes nursing revenue as the estimated net realizable amounts from patients and third party payors for the infusion services rendered and products provided. This revenue is recognized as the treatment plan is administered to the patient and is recorded at amounts estimated to be received under reimbursement or payment arrangements with payors.

Under the Medicare Prospective Payment System program, net revenue is recorded based on a reimbursement rate which varies based on the severity of the patient’s condition, service needs and certain other factors. Revenue is recognized ratably over a 60-day episode period and is subject to adjustment during this period if there are significant changes in the patient’s condition during the treatment period or if the patient is discharged but readmitted to another agency within the same 60-day episodic period. Medicare cash receipts under the prospective payment system are initially recognized as deferred revenue and are subsequently recognized as revenue over the 60-day episode period. The process for recognizing revenue under the Medicare program is based on certain assumptions and judgments, the appropriateness of the clinical assessment of each patient at the time of certification, and the level of adjustments to the fixed reimbursement rate relating to patients who receive a limited number of visits, have significant changes in condition or are subject to certain other factors during the episode.

Cost of Revenue

Cost of revenue includes the costs of prescription medications, shipping and other direct and indirect costs, claims processing operations, and nursing services, offset by volume and prompt pay discounts received from pharmaceutical manufacturers and distributors and total manufacturer rebates.

Rebates

Manufacturers’ rebates are generally volume-based incentives that are earned and recorded upon purchase of the inventory. Rebates are recorded as a reduction of both inventory and cost of goods sold.

Lease Accounting

The Company accounts for operating leasing transactions by recording rent expense on a straight-line basis over the expected term of the lease starting on the date it gains possession of leased property. The Company includes tenant improvement allowances and rent holidays received from landlords and the effect of any rent escalation clauses, as adjustments to straight-line rent expense over the expected term of the lease.

Capital lease transactions are reflected as a liability at the inception of the lease based on the present value of the minimum lease payments or, if lower, the fair value of the property. Assets recorded under capital leases are depreciated in the same manner as owned property.

Income Taxes

As part of the process of preparing the Company’s Consolidated Financial Statements, management is required to estimate income taxes in each of the jurisdictions in which it operates. The Company accounts for income taxes under ASC Topic 740, Income Taxes (“ASC 740”). ASC 740 requires the use of the asset and liability method of accounting for income taxes. Under this method, deferred taxes are determined by calculating the future tax consequences attributable to differences between the financial accounting and tax bases of existing assets and liabilities. A valuation allowance is recorded against deferred tax assets when, in the opinion of management, it is more likely than not that the Company will not be able to realize the benefit from its deferred tax assets.

The Company files income tax returns, including returns for its subsidiaries, as prescribed by Federal tax laws and the tax laws of the state and local jurisdictions in which it operates. The Company’s uncertain tax positions are related to tax years that remain subject to examination and are recognized in the Consolidated Financial Statements when the recognition threshold and measurement attributes of ASC 740 are met. Interest and penalties related to unrecognized tax benefits are recorded as income tax expense.

Financial Instruments

The Company’s financial instruments consist mainly of cash and cash equivalents, receivables, accounts payable, accrued interest and its line of credit. The carrying amounts of cash and cash equivalents, receivables, accounts payable, accrued interest and its line of credit approximate fair value due to their fully liquid or short-term nature.

Accounting for Stock-Based Compensation

The Company accounts for stock-based compensation expense under the provisions of ASC Topic 718, Compensation – Stock Compensation (“ASC 718”). At December 31, 2015, the Company has two stock-based compensation plans pursuant to which incentive stock options (“ISOs”), non-qualified stock options (“NQSOs”), stock appreciation rights (“SARs”), restricted stock, performance shares and performance units may be granted to employees and non-employee directors. Option and stock awards are typically settled by issuing authorized but unissued shares of the Company.

The Company accounts for its stock-based awards to employees and non-employees directors using the fair value method. The fair value of each option award is based on several criteria including, but not limited to, the valuation model used and associated input factors including principally stock price volatility and, to a lesser extent, expected term, dividend rate, and risk-free interest rate. The input factors used in the valuation model are based on subjective future expectations combined with management judgment. The fair value of each stock award is determined based on the closing price of the underlying common stock on the date of grant. The fair value of the award is amortized to expense on a straight-line basis over the requisite service period. The Company expenses restricted stock awards based on vesting requirements, including time elapsed, market conditions and/or performance conditions. Because of these requirements, the weighted average period for which the expense is recognized varies. The Company expenses SAR awards based on vesting requirements. In addition, because they are settled with cash, the fair value of the SAR awards are revalued on a quarterly basis.

Recent Accounting Pronouncements

In November 2015, the FASB issued ASU 2015-17 as part of its Simplification Initiative. The amendments eliminate the guidance in Topic 740, Income Taxes, that required an entity to separate deferred tax liabilities and assets between current and noncurrent amounts in a classified balance sheet. Rather, deferred taxes will be presented as noncurrent under the new standard. The amendments in this Update are effective for financial statements issued for annual periods beginning after December 15, 2017, and interim periods within annual periods beginning after December 15, 2018. Earlier application is permitted for all entities as of the beginning of an interim or annual reporting period. The Company elected to early adopt this guidance during the annual reporting period ended on December 31, 2015. There was no financial statement impact as a result of the Company’s early adoption of this guidance.

In August 2015, the FASB issued an update 2015-14—Revenue from Contracts with Customers (Topic 606): Deferral of the Effective Date. The amendments in this Update defer the effective date of Update 2014-09 for all entities by one year. Public business entities, certain not-for-profit entities, and certain employee benefit plans should apply the guidance in Update 2014-09 to annual reporting periods beginning after December 15, 2017, including interim reporting periods within that reporting period. Earlier application is permitted only as of annual reporting periods beginning after December 15, 2016, including interim reporting periods within that reporting period. The Company is still assessing the impact of this new standard on the results of the Company.

In July 2015, the FASB issued an update 2015-11—Inventory (Topic 330): Simplifying the Measurement of Inventory effective for fiscal years beginning after December 15, 2016, including interim periods within those fiscal years. The amendments in this update should be applied prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently still assessing the impact of this new standard on the results of the Company.

In April 2015, the Financial Accounting Standards Board (“FASB”) issued ASU 2015-03 “Interest - Imputation of Interest (subtopic 835-20): Simplifying the Presentation of Debt Issuance Costs” (“ASU 2015-03”). ASU 2015-03 requires that debt issuance costs related to a recognized debt liability be presented in the balance sheet as a direct deduction from the carrying amount of that debt liability, consistent with debt discounts. ASU 2015-03 is effective for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016. Early adoption is permitted and will be applied on a retrospective basis. As of December 31, 2015 we have $3.3 million and $12.6 million of deferred financing costs that would be reclassified from a current and a long-term asset, respectively, to a reduction in the carrying amount of our debt.

In April 2015, the FASB issued update 2015-05—Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Customer’s Accounting for Fees Paid in a Cloud Computing Arrangement which is effective for annual periods, including interim periods within those annual periods, beginning after December 15, 2015. Early adoption is permitted for all entities. The Company is still assessing the impact of this new standard on the results of the Company.

In February 2015, the FASB issued update 2015-02—Consolidation (Topic 810): Amendments to the Consolidation Analysis which is effective for public business entities for fiscal years, and for interim periods within those fiscal years, beginning after December 15, 2015. Early adoption is permitted, including adoption in an interim period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. A reporting entity may apply the amendments in this Update using a modified retrospective approach by recording a cumulative-effect adjustment to equity as of the beginning of the fiscal year of adoption. A reporting entity also may apply the amendments retrospectively. The Company has assessed the impact of this guidance and it is not expected to have a material impact on the Company’s Consolidated Financial Statements.

In November 2014, the FASB issued ASU 2014-16 “Derivatives and Hedging (Topic 815): Determining Whether the Host Contract in a Hybrid Financial Instrument Issued in the Form of a Share Is More Akin to Debt or to Equity” (“ASU 2014-16”). ASU 2014-16 requires an entity to determine the nature of the host contract by considering the economic characteristics and risks of the entire hybrid financial instrument issued in the form of a share, including the embedded derivative feature that is being evaluated for separate accounting from the host contract when evaluating whether the host contract is more akin to debt or equity. ASU 2014-16 is effective for fiscal years beginning after December 15, 2015, and interim periods within fiscal years beginning after December 15, 2016 and is not expected to have a material impact on the Company’s Consolidated Financial Statements.

In August 2014, the FASB issued update No. 2014-15—Presentation of Financial Statements—Going Concern (Subtopic 205-40): Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern for all entities, the new requirements are effective for annual periods ending after December 15, 2016, and interim periods within annual periods beginning after December 15, 2016. Early application is permitted. The Company is still assessing the impact of this new standard on the results of the Company.

In June 2014, the FASB issued update No. 2014-12—Compensation—Stock Compensation (Topic 718): Accounting for Share-Based Payments When the Terms of an Award Provide That a Performance Target Could Be Achieved after the Requisite Service Period (a consensus of the FASB Emerging Issues Task Force) which is effective for annual periods and interim periods within those annual periods, beginning after December 15, 2015. An entity may apply the standards (1) prospectively to all share-based payment awards that are granted or modified on or after the effective date, or (2) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earliest annual period presented in the financial statements and to all new or modified awards thereafter. Earlier application is permitted. The Company is still assessing the impact of this new standard on the results of the Company.

LOSS PER SHARE

12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Loss Per Share

LOSS PER SHARE

Loss Per Share

The Company presents basic and diluted loss per share (“LPS”) for its common stock, par value $.0001 per share (“Common Stock”). Basic LPS is calculated by dividing the net loss attributable to common stockholders of the Company by the weighted average number of shares of Common Stock outstanding during the period. Diluted LPS is determined by adjusting the profit or loss attributable to stockholders and the weighted average number of shares of Common Stock outstanding adjusted for the effects of all dilutive potential common shares comprised of options granted, unvested restricted stocks, stock appreciation rights, warrants and Series A convertible preferred stock. Potential Common Stock equivalents that have been issued by the Company related to outstanding stock options, unvested restricted stock and warrants are determined using the treasury stock method, while potential common shares related to Series A Convertible Preferred Stock are determined using the “if converted” method.

The Company's Series A Convertible Preferred Stock, par value $.0001 per share (the “Series A Preferred Stock”), is considered a participating security, which means the security may participate in undistributed earnings with Common Stock. The holders of the Series A Preferred Stock would be entitled to share in dividends, on an as-converted basis, if the holders of Common Stock were to receive dividends. The Company is required to use the two-class method when computing LPS when it has a security that qualifies as a participating security. The two-class method is an earnings allocation formula that determines LPS for each class of common stock and participating security according to dividends declared (or accumulated) and participation rights in undistributed earnings. In determining the amount of net earnings to allocate to common stockholders, earnings are allocated to both common and participating securities based on their respective weighted-average shares outstanding during the period. Diluted LPS for the Company’s Common Stock is computed using the more dilutive of the two-class method or the if-converted method.

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Year Ended December 31,
	2015			2014			2013
Numerator:
Loss from continuing operations, net of income taxes	$	(303,428	)	$	(149,920	)	$	(71,641	)
Income from discontinued operations, net of income taxes	3,721			2,452			1,987
Net loss	(299,707		)	(147,468		)	(69,654		)
Accrued dividends on Series A Preferred Stock	(6,120		)	—			—
Deemed dividends on Series A Preferred Stock	(3,690		)	—			—
Loss attributable to common stockholders	$	(309,517	)	$	(147,468	)	$	(69,654	)

Denominator - Basic and Diluted:
Weighted average number of common shares outstanding	68,710			68,476			64,560
Loss Per Common Share:
Loss from continuing operations, basic and diluted	$	(4.56	)	$	(2.19	)	$	(1.11	)
Income (loss) from discontinued operations, basic and diluted	0.05			0.04			0.03
Income (loss) per common share, basic and diluted	$	(4.51	)	$	(2.15	)	$	(1.08	)

The loss attributable to common stockholders is used as the basis of determining whether the inclusion of common stock equivalents would be anti-dilutive. Accordingly, the computation of diluted shares for the years ended December 31, 2015, 2014 and 2013 excludes the effect of securities issued in connection with the PIPE Transaction and the Rights Offering (see Note 4 - Stockholders’ (Deficit) Equity), as well as stock options and restricted stock awards, as their inclusion would be anti-dilutive to loss attributable to common stockholders.

STOCKHOLDERS' (DEFICIT) EQUITY

12 Months Ended

Dec. 31, 2015

Stockholders' Equity Attributable to Parent [Abstract]

Stockholders' (Deficit) Equity

STOCKHOLDERS’ (DEFICIT) EQUITY

Securities Purchase Agreement

On March 9, 2015, the Company entered into a securities purchase agreement (the “Purchase Agreement”) with Coliseum Capital Partners L.P., a Delaware limited partnership, Coliseum Capital Partners II, L.P., a Delaware limited partnership, and Blackwell Partners, LLC, Series A, a Georgia limited liability company (collectively, the “PIPE Investors”). Pursuant to the terms of the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (the “PIPE Transaction”) an aggregate of (a) 625,000 shares of Series A Preferred Stock at a purchase price per share of $100.00, (b) 1,800,000 Class A warrants (the “Class A Warrants”), and (c) 1,800,000 Class B warrants (the “Class B Warrants” and, together with Class A Warrants, the “PIPE Warrants”), for gross proceeds of $62.5 million. The initial conversion price for the Series A Preferred Stock is $5.17. The PIPE Warrants may be exercised to acquire shares of Common Stock. Pursuant to an addendum (the “Warrant Addendum”), dated as of March 23, 2015, to the Warrant Agreement, dated as of March 9, 2015, with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.

As disclosed in the Company’s definitive proxy materials relating to the Company’s 2015 annual meeting of stockholders held on May 11, 2015 (the “2015 Annual Meeting”), the Company sought stockholder approval to remove certain conversion and voting restrictions affecting the Series A Preferred Stock and exercise restrictions affecting the PIPE Warrants (the “Stockholder Approval”). Until Stockholder Approval was obtained, the terms of the Series A Preferred Stock and the PIPE Warrants contained caps on the conversion of the Series A Preferred Stock into Common Stock and on the exercise of the PIPE Warrants to purchase Common Stock (the “Conversion Caps”) and a cap on the voting power (the “Voting Cap” and, together with the Conversion Caps, the “Caps”) that prevented the issuance of Common Stock if a single holder would own or vote more than 19.99% of the Common Stock or have more than 19.99% of the voting power. As a result of obtaining Stockholder Approval on May 11, 2015, the Caps and other restrictions and conditions relating to the holders and their respective affiliates’ ability to vote and convert their shares of Series A Preferred Stock and exercise the PIPE Warrants ceased to apply.

The Purchase Agreement contains customary representations, warranties and covenants, including covenants relating to, among other things, information rights, the Company’s financial reporting, tax matters, listing compliance under the NASDAQ Global Market, Stockholder Approval, use of proceeds, and potential requirements under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended to make a notice filing with respect to the exercise of the PIPE Warrants.

The Company repaid approximately $45.3 million of the Revolving Credit Facility indebtedness and accrued interest, representing 77% of the PIPE Transaction’s net proceeds.

The PIPE Transaction was the subject of a putative securities class action lawsuit (see Note 11 - Commitments and Contingencies).

The proceeds from the Purchase Agreement were allocated among the instruments based on their relative fair values as follows (in thousands):



	Relative Fair Value Allocation
Financial instruments:	March 9, 2015
Series A Preferred Stock ¹	$	59,355
PIPE Warrants ²	3,145
Total Investment	$	62,500

¹ The fair value of the Series A Preferred Stock was determined using a binomial lattice model using the following assumptions: volatility of 55%, risk-free rate of 0.92%, and a dividend rate of 11.5%. The model also utilized various assumptions about the time to maturity and conditions under which conversion features would be exercised.

² The fair value of the PIPE Warrants was determined using the Black Scholes model using the following assumptions: volatility of 55%, risk-free rate of 0.92%, and stated exercise prices. The model also utilized various assumptions about the time to maturity and conditions under which exercise would occur.

Series A Convertible Preferred Stock

In connection with the PIPE Transaction, the Company authorized 825,000 shares and issued 625,000 shares of Series A Preferred Stock at $100.00 per share.

The Series A Preferred Stock may, at the option of the holder, be converted into Common Stock. The conversion rate in effect at any applicable time for conversion of each share of Series A Preferred Stock into Common Stock will be the quotient obtained by dividing the Liquidation Preference then in effect by the conversion price then in effect, plus cash in lieu of fractional shares. The initial conversion price for the Series A Preferred Stock is $5.17, but is subject to adjustment from time to time upon the occurrence of certain events, including in the event of a stock split, a reverse stock split, or a dividend of Junior Securities (defined below) to the Company’s common stockholders.

Upon any voluntary or involuntary liquidation, dissolution or winding up of the Company (each, a Liquidation Event), after satisfaction of all liabilities and obligations to creditors of the Company and distribution of any assets of the Company to the holders of any stock or debt that is senior to the Series A Preferred Stock, and before any distribution or payment shall be made to holders of any Junior Securities, each holder of Series A Preferred Stock will be entitled to (i) convert their shares of Series A Preferred Stock into Common Stock and receive their pro rata share of consideration distributed to the holders of Common Stock, or (ii) receive, out of the assets of the Company or proceeds thereof (whether capital or surplus) legally available therefor, an amount per share of Series A Preferred Stock equal to the Liquidation Preference. The initial Liquidation Preference was equal to $100.00 per share which may be adjusted from time to time by the accrual of non-cash dividends. As of December 31, 2015, the Liquidation Preference was $68.6 million. However, if, at any applicable date of determination of the Liquidation Preference, (i) any cash dividend has been declared but is unpaid or (ii) the Company has given notice (or failed to give such notice) of its intention to pay a cash dividend but such cash dividend has not yet been declared by the Company’s board of directors (the “Board”), then such cash dividends shall be deemed, for purposes of calculating the applicable Liquidation Preference, to be Accrued Dividends. Accrued Dividends are paid upon the occurrence of a Liquidation Event and upon conversion or redemption of the Series A Preferred Stock.

The Company may pay a noncumulative cash dividend on each share of the Series A Preferred Stock when, as and if declared by the Board at a rate of 8.5% per annum on the liquidation preference then in effect. Cash dividends, if declared, are payable quarterly in arrears on January 1, April 1, July 1 and October 1 of each year, commencing on the first calendar day of the first July or October following the date of original issuance of the Series A Preferred Stock. If declared, cash dividends will begin to accrue on the first day of the applicable quarterly dividend period. In the event the Company does not declare and pay a cash dividend, the Liquidation Preference of the Series A Preferred Stock will be increased to an amount equal to the Liquidation Preference in effect at the start of the applicable quarterly dividend period, plus an amount equal to such then applicable Liquidation Preference multiplied by 11.5% per annum. If the Company pays a dividend or makes a distribution on the outstanding Common Stock (other than in Junior Securities, as defined below), the Company must, at the same time, pay each holder of the Series A Preferred Stock a dividend equal to the dividend the holder would have received if all of the holder’s shares of Series A Preferred Stock were converted into Common Stock immediately prior to the record date for the dividend payment (“Participating Dividend”). The Company would not be required to pay the Participating Dividend if the Company dividend or distribution was in Common Stock, a security ranking equal to or junior to Common Stock, or a security convertible into Common Stock or a security ranking equal to or junior to Common Stock (“Junior Securities”). Instead, where the Company makes a dividend or distribution of a Junior Security, the holder of Series A Preferred Stock is entitled to anti-dilution protection in the form of an adjustment to the conversion price of the Series A Preferred Stock. Unless and until the Company obtains the required consent and/or amendment from the Company’s lenders under the Company’s Senior Credit Facilities (as defined below), the Company will not be permitted to pay cash dividends.

From and after the tenth anniversary of the original issuance of the Series A Preferred Stock, each holder of shares of Series A Preferred Stock will have the right to request that the Company redeem, in full, out of funds legally available, by irrevocable written notice to the Company, all of such holder’s shares of Series A Preferred Stock at a redemption price per share equal to the Liquidation Preference then in effect per share of Series A Preferred Stock. From and after the tenth anniversary of the original issuance of the Series A Preferred Stock, the Company may redeem the outstanding Series A Preferred Stock, in whole or in part, at a price per share equal to the Liquidation Preference then in effect.

The Series A Preferred Stock will, with respect to dividend rights and rights upon liquidation, winding up or dissolution, rank senior to the Company’s Common Stock and each other class or series of shares that the Company may issue in the future that do not expressly provide that such class or series ranks equally with, or senior to, the Series A Preferred Stock, with respect to dividend rights and/or rights upon liquidation, winding up or dissolution. The Series A Preferred Stock will also rank junior to the Company’s existing and future indebtedness. Holders of shares of Series A Preferred Stock will be entitled to vote with the holders of shares of Common Stock (and any other class or series similarly entitled to vote with the holders of Common Stock) and not as a separate class, at any annual or special meeting of stockholders of the Company, and may act by written consent in the same manner as the holders of Common Stock, on an as-converted basis. So long as shares of the Series A Preferred Stock represent at least five percent (5%) of the outstanding voting stock of the Company, a majority of the voting power of the Series A Preferred Stock shall have the right to designate one (1) member to the Company’s Board who shall be appointed to a minimum of two (2) committees of the Board.

The following sets forth the initial carrying value of the Series A Preferred Stock which is classified as temporary equity (mezzanine equity) on the Consolidated Balance Sheet (in thousands):



	Carrying Value
Series A Preferred Stock:	March 9, 2015
Issuance date liquidation preference	$	62,500
Discount related to warrant value ¹	(3,145		)
Discount related to beneficial conversion feature ²	(3,145		)
Discount related to issuance costs ³	(3,830		)
Initial carrying value of Series A Preferred Stock	$	52,380

¹The discount related to the PIPE Warrants represents the difference between the redemption value of the Series A Preferred Stock and its allocated proceeds. The discount is accreted over the period from issuance to first available redemption and are presented as a deemed dividend on the Statement of Operations.

² The value assigned to the Beneficial Conversion Feature (BCF) reflects the difference between the initial fair value assigned to the Series A Preferred Stock and the conversion value. The BCF value is accreted over the period from issuance date to first date conversion to common shares may take place and is presented as a deemed dividend on the Statement of Operations.

³ The Company incurred issuance costs of $4.0 million associated with the PIPE Transaction. The issuance costs were allocated to the Series A Preferred Stock and PIPE Warrants based on the relative fair value of each instrument or $3.8 million and $0.2 million, respectively. The issuance costs are accreted over the period from issuance to first available redemption and are presented as a deemed dividend on the Statement of Operations.

PIPE Warrants

In connection with the PIPE Transaction, the Company issued 1,800,000 Class A Warrants and 1,800,000 Class B Warrants which may be exercised to acquire shares of Common Stock. The rights and terms of Class A Warrants and Class B Warrants are identical except for the exercise price. Pursuant to the Warrant Addendum with the PIPE Investors, the PIPE Investors paid the Company $0.5 million in the aggregate, and the per share exercise price of the Class A Warrants and Class B Warrants was set at $5.17 and $6.45, respectively, reduced from $5.295 to $5.17 and from $6.595 to $6.45, respectively.

The PIPE Warrants are exercisable for a ten year term and may only be exercised for cash. The number of shares of Common Stock that may be acquired upon exercise of the PIPE Warrants is subject to anti-dilution adjustments for stock splits, subdivisions, reclassifications or combinations, or the issuance of Common Stock for a consideration per share less than 85% of the market price per share immediately prior to such issuance. Upon the occurrence of certain business combinations the PIPE Warrants will be converted into the right to acquire shares of stock or other securities or property (including cash) of the successor entity.

The PIPE Warrants became exercisable on May 11, 2015, the date Stockholder Approval was obtained at the 2015 Annual Meeting.

The following sets forth the carrying value of the PIPE Warrants which is classified as equity on the Consolidated Balance Sheet (in thousands):



	Carrying Value
PIPE Warrants	March 9, 2015
Fair value allocated to PIPE Warrants	$	3,145
Discount related to issuance costs	(203		)
Carrying value of PIPE Warrants	$	2,942

The Company entered into a registration rights agreement (the “Registration Rights Agreement”) with the PIPE Investors that will, among other things and subject to certain exceptions, require the Company, upon the request of the holders of the Series A Preferred Stock to register the Common Stock of the Company issuable upon conversion of the Series A Preferred Stock or exercise of the PIPE Warrants. Pursuant to the terms of the Registration Rights Agreement, these registration rights will not become effective until one year after the closing date of the PIPE Transaction and the costs incurred in connection with such registrations will be borne by the Company.

Rights Offering

On June 30, 2015, the Company commenced a rights offering (the “Rights Offering”) pursuant to which the Company distributed subscription rights to purchase units consisting of (1) Series A Preferred Stock, each share convertible into shares of Common Stock at a conversion price of $5.17 per share, (2) Class A warrants to purchase one share of Common Stock at a price of $5.17 per share (the “Public Class A Warrants”), and (3) Class B warrants to purchase one share of Common Stock at a price of $6.45 per share (the “Public Class B Warrants” and, together with the Public Class A Warrants, the “Public Warrants”). The Rights Offering expired on July 27, 2015 and was completed on July 31, 2015. Stockholders of the Company exercised subscription rights to purchase 10,822 units, consisting of an aggregate of 10,822 shares of the Series A Preferred Stock, 31,025 Public Class A Warrants, and 31,025 Public Class B Warrants, at a subscription price of $100.00 per unit. Pursuant to the Rights Offering, the Company raised gross proceeds of approximately $1.1 million.

With the exception of the expiration date, the Class A Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class A Warrants issued pursuant to the Rights Offering. Similarly, with the exception of the expiration date, the Class B Warrants issued pursuant to the PIPE Transaction, as amended by the Warrant Addendum, have the same terms as the Public Class B Warrants issued pursuant to the Rights Offering.

Carrying Value of Series A Preferred Stock

As of December 31, 2015, the following values were accreted as described above and recorded as a reduction of additional paid in capital in Stockholders’ Equity and a deemed dividend on the Statement of Operations. In addition, dividends were accrued at 11.5% from the date of issuance to December 31, 2015. The following table sets forth the activity recorded during the year ended December 31, 2015 related to the Series A Preferred Stock (in thousands) issued for both the PIPE Transactions and the Rights Offering.



Series A Preferred Stock carrying value at issuance	$	53,108
Accretion of discount related to beneficial conversion feature	3,690
Dividends recorded through December 31, 2015¹	6,120
Series A Preferred Stock carrying value December 31, 2015	$	62,918

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

Treasury Stock

During the years ended December 31, 2015 and 2014, 16,952 and 54,579 shares, respectively, were surrendered to satisfy tax withholding obligations on the vesting of restricted stock awards. The Company holds a total of 2,654,051 shares of treasury stock at December 31, 2015 acquired under current and prior repurchase programs as well as forfeitures to satisfy tax obligations in the vesting of restricted stock awards. During the year ended December 31, 2015, no shares of treasury stock were acquired or issued.

Common Stock Purchase Warrants Issued in 2010

In connection with the acquisition of Critical Homecare Solutions Holdings, Inc. (“CHS”) in March 2010, the Company issued 3.4 million warrants exercisable for the Company’s Common Stock (the “2010 Warrants”). The 2010 Warrants had a five year term with an exercise price of $10.00 per share. They were exercisable at any time prior to the expiration date of March 25, 2015. The Company determined that the 2010 Warrants meet the conditions for equity classification in accordance with GAAP. Therefore, the 2010 Warrants were classified as equity and included in additional paid-in capital.

No 2010 Warrants were exercised during the years ended December 31, 2015 and 2014. As of December 31, 2015, all remaining 2010 Warrants have expired.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

ACQUISITIONS

12 Months Ended

Dec. 31, 2015

Business Combinations [Abstract]

Acquisitions

ACQUISITIONS

CarePoint Partners Holdings LLC

On August 23, 2013, the Company closed on the acquisition of substantially all of the assets and assumption of certain liabilities that constituted the home infusion business (the “CarePoint Business”) of CarePoint Partners Holdings LLC, a Delaware limited liability company, and its subsidiaries (collectively “CarePoint”). CarePoint was a provider of home and alternate-site infusion therapy for patients with complex, acute and chronic illnesses. CarePoint serviced approximately 20,500 patients annually through 28 sites of service in nine states in the East Coast and Gulf Coast regions.

The cash purchase price paid at closing was $211.1 million. The purchase agreement contemplated a targeted level of net working capital. Subsequent to the closing, the Company and the sellers agreed that additional net working capital adjustments of approximately $1.8 million were due to the Company. These working capital adjustments were primarily related to the value of accounts receivable and prepaid expenses as of the date of acquisition. The Company received payment for these amounts during the year ended December 31, 2014.

In addition, the purchase agreement provided that the purchase price could be increased by contingent consideration of $10.0 million if the CarePoint Business achieved a specified level of product gross profit during the one-year period following the closing date. If the specified level of product gross profit was not achieved, no contingent consideration would be due to the sellers. At the date of acquisition, the fair value of the $10.0 million contingent consideration was estimated at $9.8 million. The fair value of the contingent consideration was determined using Level 3 inputs based on the present value of various payout scenarios, weighted on the basis of probability. The most important factor in determining the probability of payout at various balance sheet dates has been the business forecasts and actual results for the CarePoint Business standalone and merged market sites.

As of December 31, 2015, the fair value of the contingent consideration was remeasured in light of the fact that the Company’s calculations showed that the required product gross profit was not achieved during the measurement period and uncertainties about the potential for CarePoint to dispute the Company’s calculation and pursue arbitration. As a result, the fair value of the contingent consideration was estimated at $4.6 million at December 31, 2015. Should it be determined that the required product gross profit was achieved, an additional expense of $5.4 million will be recorded over and above the accrual of $4.6 million estimated at December 31, 2015. Should CarePoint choose not to dispute the calculation of gross profit, or should an arbitrator rule in favor of the Company, the liability for contingent consideration will be reversed and additional income of $4.6 million will be recorded. The liability for the contingent consideration is included in accrued expenses and other current liabilities in the accompanying Consolidated Balance Sheets.

The Company funded the cash payment at closing with a combination of cash on hand and $150.0 million in borrowings under the Senior Credit Facilities (see Note 10 - Debt).

The table below summarizes the Company’s assessment of the fair values of the assets acquired and liabilities assumed as of the date of closing of the acquisition of the CarePoint Business (in thousands):



	Fair Value
Cash	$	14
Accounts receivable	15,917
Inventories	3,184
Other current assets	215
Property and equipment	3,266
Identifiable intangible assets⁽¹⁾	16,700
Current liabilities	(8,697		)
Non-current liabilities	(721		)
Total identifiable net assets	29,878
Goodwill	189,214
Total cash and fair value of contingent consideration	$	219,092


(1)	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets (in thousands):



	Weighted- Average Useful Lives	Amounts Recognized as of the Closing Date
Customer relationships	2 - 4 years	$	13,600
Trademarks	2 years	2,600
Non-compete agreements	5 years	500
Total identifiable intangible assets acquired		$	16,700

The excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of goodwill represents the value the Company expects to be created by combining the various operations of the CarePoint Business with the Company’s operations, including the expansion into new infusion markets, the opportunity to consolidate and upgrade certain existing facilities, access to new patients and potential cost savings and synergies. The CarePoint transaction was structured such that the amount allocated to goodwill will be deductible for income tax purposes in accordance with applicable tax rules.

HomeChoice Partners, Inc.

On February 1, 2013, the Company acquired 100% of the ownership interest in HomeChoice Partners, Inc., a Delaware corporation (“HomeChoice”). Prior to the Company's acquisition, HomeChoice was a provider of alternate-site infusion pharmacy services that serviced approximately 15,000 patients annually and had 14 infusion pharmacy locations in Pennsylvania, the District of Columbia, Maryland, Virginia, North Carolina, South Carolina, Georgia, Missouri and Alabama.

The cash purchase price of the HomeChoice acquisition was $72.9 million paid at the closing date. In addition, the purchase agreement provides that the purchase price could be increased by contingent consideration of up to $10.0 million if HomeChoice were to attain certain performance milestones in the first year following the closing and an additional $10.0 million if HomeChoice were to attain certain performance milestones in the second year following the closing, for total possible contingent consideration of up to $20.0 million.

At the date of acquisition, the fair value of the potential contingent consideration, using Level 3 inputs, was estimated at $8.0 million. The $20.0 million maximum contingent consideration was established using aggressive growth targets meant to achieve operating results in excess of transaction valuation model assumptions. Given the aggressiveness of the earnout target threshold, the Company assigned less than 50% probability of payout among the various payout scenarios considered.

While the acquisition has generated revenues as expected in the transaction valuation model, the performance milestones were not achieved during the measurement period. As a result, the fair value of the contingent consideration was reduced to $0 as of December 31, 2015. The $0 million, $2.1 million and $5.9 million of income resulting from the reduction in the fair value of the contingent liability is included in restructuring, integration, and other expenses, net in the accompanying Consolidated Statements of Operations for the years ended December 31, 2015, 2014 and 2013, respectively.

The Company funded the acquisition with a combination of cash and its prior credit facility with Healthcare Finance Group.

The table below summarizes the Company’s assessment of the fair values of the assets acquired and liabilities assumed as of the acquisition date of HomeChoice (in thousands):



	Fair Value
Accounts receivable	$	9,693
Inventories	1,984
Other current assets	154
Property and equipment	2,432
Identifiable intangible assets⁽¹⁾	4,000
Other non-current assets	30
Current liabilities	(4,073		)
Total identifiable net assets	14,220
Goodwill	66,701
Total cash and fair value of contingent consideration	$	80,921


(1)	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets (in thousands):



	Weighted- Average Useful Lives	Amounts Recognized at the Closing Date
Customer relationships	5 mo. - 3 years	$	2,000
Trademarks	23 months	1,000
Non-compete agreements	1 year	1,000
Total identifiable intangible assets acquired		$	4,000

The excess of the purchase price over the fair value of tangible and identifiable intangible assets acquired and liabilities assumed in the acquisition was allocated to goodwill. The value of goodwill represented the value the Company expected to be created by combining the various operations of HomeChoice with the Company’s operations, including the expansion into new infusion markets, the opportunity to consolidate and upgrade certain existing facilities, access to new patients and potential cost savings and synergies. The HomeChoice transaction was structured such that the amount allocated to goodwill will be deductible for income tax purposes in accordance with applicable tax rules.

Integration Expense

Integration expenses in restructuring, integration, and other expenses, net in the accompanying Consolidated Statements of Operations for the years ended December 31, 2015, 2014 and 2013 include the following costs related to the CarePoint Business acquisition and the HomeChoice acquisition (in thousands):



	Year Ended December 31,
	2015		2014		2013
Legal and professional fees	$	1,033	$	6,931	$	5,113
Financial advisory fees	—		—		2,413
Employee costs including redundant salaries and benefits and severance	—		2,016		3,554
Facilities consolidation and discontinuation	488		1,401		1,621
Bad debt expense and contractual adjustments related to acquired accounts receivable	—		5,430		—
Legal settlement	—		334		2,300
Other	219		1,812		1,129
Total	$	1,740	$	17,924	$	16,130

- Definition

The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1497-128463

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1490-128463

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1392-128463

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1486-128463

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4845-128472

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1500-128463

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1524-128463

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e7000-128479

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4922-128472

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4934-128472

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=56956791&loc=d3e4926-128472

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=56956515&loc=d3e1383-128463

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 805
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=35744584&loc=d3e6996-128479

+ Details

DISCONTINUED OPERATIONS

12 Months Ended

Dec. 31, 2015

Discontinued Operations and Disposal Groups [Abstract]

Discontinued Operations

DISCONTINUED OPERATIONS

Sale of PBM Services

On August 27, 2015, the Company completed the sale of substantially all of the Company’s PBM Services segment (as defined above, the “PBM Business”) pursuant to an Asset Purchase Agreement dated as of August 9, 2015 (the “Asset Purchase Agreement”), by and among the Company, BioScrip PBM Services, LLC and ProCare Pharmacy Benefit Manager Inc. (the “PBM Buyer”). Under the Asset Purchase Agreement, the PBM Buyer agreed to acquire substantially all of the assets used solely in connection with the PBM Business and to assume certain PBM Business liabilities (the “PBM Sale”). On the Closing Date, pursuant to the terms of the Asset Purchase Agreement, the Company received total cash consideration of approximately $24.6 million, including an adjustment for estimated Closing Date net working capital. On October 20, 2015, the Company finalized working capital adjustment negotiations in relation to the PBM Sale whereby the Company agreed to repay approximately $1.0 million to the PBM Buyer. The Company used the net proceeds from the PBM Sale to pay down a portion of the Company’s outstanding debt.

The sale of the PBM Business was consistent with the Company’s continuing strategic evaluation of its non-core businesses and its decision to continue to focus growth initiatives and capital in the Infusion Services business. As a result, the Company has reclassified its operations to discontinued operations for all prior periods in the accompanying Consolidated Financial Statements.

As of the August 27, 2015 closing date of the sale of the PBM Business, the carrying value of the net assets of the PBM Business was as follows (in thousands):



	Carrying Value
Net accounts receivable	$	7,163
Total current assets	7,163
Property and equipment, net	175
Goodwill	12,744
Total assets	20,082
Amounts due to plan sponsors	6,950
Total liabilities	6,950
Net assets	$	13,132

The operating results included in discontinued operations of the PBM Business for the years ended December 31, 2015, 2014 and 2013 are summarized as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Revenue	$	44,375		$	61,401		$	72,986
Gross profit	$	9,763		$	17,635		$	42,819
Other operating expenses	5,444			10,878			26,797
Bad debt expense	(45		)	27			109
Income (loss) from operations	4,364			6,730			15,913
Gain on sale before income taxes	(11,424		)	—			—
Financial advisory fee and legal expenses	1,731			—			—
Other income and expenses, net	1,898			(6		)	—
Income (loss) before income taxes	12,159			6,736			15,913
Income tax expense (benefit)	206			198			1,263
Income (loss) from discontinued operations, net of income taxes	$	11,953		$	6,538		$	14,650

Sale of Home Health Business

On March 31, 2014, the Company completed the sale of substantially all of the Company’s Home Health Services segment (the “Home Health Business”) pursuant to the Stock Purchase Agreement dated as of February 1, 2014 (the “Stock Purchase Agreement”). Pursuant to the terms of the Stock Purchase Agreement, as amended, the Company received total consideration of approximately $59.5 million paid in cash (the “Purchase Price”) at closing. The Company used a portion of the net proceeds from the sale to pay down a portion of the Company’s outstanding debt. Subsequently, the Purchase Price was adjusted for net working capital of the divested Home Health Business companies (the “Subject Companies”) as of the closing date that resulted in an additional payment to the Company of approximately $1.1 million. As a result of this adjustment, the final Purchase Price received by the Company was approximately $60.6 million. The Company has classified the net proceeds received from this sale in cash provided by investing activities from discontinued operations in the accompanying consolidated statements of cash flows.

The sale of the Home Health Business was consistent with the Company’s continuing strategic evaluation of its non-core businesses and its decision to continue to focus growth initiatives and capital in the Infusion Services business. As a result, the Company decided in the second quarter of 2014 to cease the material portion of its Home Health operations at the one location excluded from the Stock Purchase Agreement, as amended, and reclassified its operations to discontinued operations for all prior periods in the accompanying Consolidated Financial Statements.

As of the March 31, 2014 closing date of the sale of the Home Health Business, the carrying value of the net assets of the Subject Companies was as follows (in thousands):



	Carrying Value
Net accounts receivable	$	12,597
Prepaid expenses and other current assets	242
Total current assets	12,839
Property and equipment, net	402
Goodwill	33,784
Intangible assets	15,400
Other non-current assets	28
Total assets	62,453
Accounts payable	673
Amounts due to plan sponsors	229
Accrued expenses and other current liabilities	3,008
Total liabilities	3,910
Net assets	$	58,543

The pre-tax gain on sale of the Home Health Business is approximately $2.1 million based on the March 31, 2014 net asset balances above and before financial advisory fees, legal expenses and other one-time transactions costs and including the net working capital adjustment. The net assets of the Subject Companies have been reclassified to discontinued operations for all prior periods in the accompanying Consolidated Financial Statements.

The operating results included in discontinued operations of the Home Health Business for the years ended December 31, 2015, 2014 and 2013 are summarized as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Revenue	$	—		$	18,551		$	72,737
Gross profit	$	—		$	6,918		$	28,201
Other operating expenses	417			8,219			23,464
Bad debt expense	—			902			1,338
Income (loss) from operations	(417		)	(2,203		)	3,399
Gain on sale before income taxes	—			(2,067		)	—
Financial advisor fee and legal expenses	—			2,875			—
Impairment of assets	—			452			—
Other costs and expenses	861			47			(1		)
Income (loss) before income taxes	(1,278		)	(3,510		)	3,400
Income tax expense (benefit)	—			(4,257		)	15
Income from discontinued operations, net of income taxes	$	(1,278	)	$	747		$	3,385

Pharmacy Services Asset Sale

On February 1, 2012, the Company entered into a Community Pharmacy and Mail Business Purchase Agreement by and among Walgreen Co. and certain subsidiaries and the Company and certain subsidiaries (collectively, the “Sellers”) with respect to the sale of certain assets, rights and properties relating to the Sellers’ traditional and specialty pharmacy mail operations and community retail pharmacy stores.

The operating results included in discontinued operations of the divested traditional and specialty pharmacy mail operations and community pharmacies for the years ended December 31, 2015, 2014 and 2013 are summarized as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Revenue	$	—		$	—		$	(75	)
Gross profit	$	—		$	(439	)	$	(519	)
Other operating expenses	4,485			3,995			7,118
Legal fees and settlement expense	1,312			—			15,000
Other (income) expense, including gain on sale	1,157			399			(6,589		)
Income (loss) from discontinued operations, net of income taxes	$	(6,954	)	$	(4,833	)	$	(16,048	)

Other operating expenses during the years ended December 31, 2015, 2014 and 2013 primarily consist of legal fees related to the legal proceedings. In January 2016, the Company paid the remaining liability of $6.2 million, including interest, related to the Settlement Agreements and $0.2 million of fees to the Relator (each, as defined below). See discussion in Note 11 - Commitments and Contingencies.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

+ Details

GOODWILL AND INTANGIBLE ASSETS

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill and Intangible Assets

GOODWILL AND INTANGIBLE ASSETS

Goodwill, and the changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014, are as follows (in thousands):



	Infusion Services
Balance at December 31, 2013	$	558,593
Acquisitions	—
Other adjustments	1,986
Balance at December 31, 2014	560,579
Acquisitions	—
Impairment	(251,850		)
Balance at December 31, 2015	$	308,729

At December 31, 2014, goodwill of $12.7 million related to the PBM Business that was sold on August 27, 2015 is included in non-current assets of discontinued operations in the accompanying Consolidated Balance Sheets (see Note 6 - Discontinued Operations).

In accordance with ASC 350, Intangibles--Goodwill and Other, the Company evaluates goodwill for impairment on an annual basis and whenever events or circumstances exist that indicates that the carrying value of goodwill may no longer be recoverable. Management may choose to undertake a qualitative assessment (step zero approach) in order to assess whether a quantitative analysis is required. In determining whether management will utilize the qualitative assessment in any one year, management will consider overall economic factors as well as the passage of time between the last quantitative assessment. In the event management determines that a quantitative assessment is required, this quantitative impairment testing is based on a two-step process. The first step quantitative analysis compares the fair value of a reporting unit with its carrying amount, including goodwill. If the first step indicates that the fair value of the reporting unit is less than its carrying amount, the second step quantitative analysis must be performed to determine the implied fair value of reporting unit goodwill. The measurement of possible impairment is based upon the comparison of the implied fair value of reporting unit to its carrying value.

In the first quarter of 2015, we performed our annual goodwill impairment test and estimated the fair value of each of our reporting units as of the end of our most recent fiscal year. We concluded that the estimated fair value determined under our testing approach for each of our reporting units, as of December 31, 2014, was reasonable. In each case, the estimated fair value exceeded the respective carrying value. We concluded that the goodwill assigned to each reporting unit, as of March 31, 2015, was not impaired and that neither reporting unit was at risk of failing Step 1 of the goodwill impairment test as prescribed under the ASC.

In the second quarter of 2015, business conditions had not significantly improved and our stock price declined. As a result, we concluded that it was appropriate for us to perform a quantitative Step 1 interim goodwill impairment test as of June 30, 2015. Taking into consideration our updated business outlook for the remainder of fiscal 2015, we updated our future cash flow assumptions for our Infusion Services reporting unit and calculated updated estimates of fair value using the three method valuation approach. After updating our assumptions and projections, we then calculated an estimate of fair value for the reporting unit, consistent with our annual impairment test on December 31, 2014. As of June 30, 2015, we determined that our Infusion Services reporting unit had an indication of impairment and we proceeded to a Step 2 analysis to determine the amount of the goodwill impairment.

Our fair value for each reporting unit is determined based on a guideline public company analysis or market approach which utilizes current earnings multiples of comparable publicly-traded companies, a guideline transaction analysis which utilizes select actual comparable industry transactions and a discounted cash flow analysis which uses significant unobservable inputs, or level 3 inputs, as defined by the fair value hierarchy. We have equally weighted the valuation of our reporting units based on the three methods. We believe that this weighting is appropriate.

The Step 2 analysis included determining the fair value of inventory, intangible assets, debt, and other current assets and liabilities, as well as fair values of equipment and fixtures. Key assumptions used in the impairment test included: growth rates ranging from 3.0% to 5.0%, EBITDA margins of 6% to 8%, and discount rates applied ranging from 9.0% to 11.0%.

The accounting principles regarding goodwill acknowledge that the observed market prices of individual trades of a company's stock (and thus its computed market capitalization) may not be representative of the fair value of the company as a whole. Additional value may arise from the ability to take advantage of synergies and other benefits that flow from control over another entity. Consequently, measuring the fair value of a collection of assets and liabilities that operate together in a controlled entity is different from measuring the fair value of that entity's individual common stock. In most industries, including ours, an acquiring entity typically is willing to pay more for equity securities that give it a controlling interest than an investor would pay for a number of equity securities representing less than a controlling interest. We have taken into consideration the current trends in our market capitalization and the current book value of our equity in relation to fair values arrived at in our interim fiscal 2015 goodwill impairment analysis, including the implied control premium, and have deemed the result to be reasonable.

Our goodwill impairment analysis is sensitive to changes in key assumptions used in our analysis, such as expected future cash flows, the degree of volatility in equity and debt markets, and our stock price. If the assumptions used in our analysis are not realized, it is possible that an impairment charge may need to be recorded in the future. We cannot accurately predict the amount and timing of any impairment of goodwill or other intangible assets. Further, as we continue to work towards a turnaround of our business, we will need to continue to evaluate the carrying value of our goodwill. Any additional impairment charges that we may take in the future could be material to our results of operations and financial condition.

During the third quarter of 2015, the Company finalized its second quarter impairment assessment and as a result the Company recorded a total impairment charge of $251.9 million year to date, all of which related to our Infusion Services business. The Company evaluated goodwill for possible impairment during the quarter ending December 31, 2015 utilizing the step zero approach which was utilized in light of the recent detailed analysis performed in the second quarter and completed in the third quarter. In light of this assessment the Company determined that a two-steps approach analysis was not required and likewise no further impairment charge was needed.

Intangible assets consisted of the following as of December 31, 2015 and 2014 (in thousands):



	December 31, 2015							December 31, 2014
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite Lived Assets
Infusion customer relationships	$	25,650	$	(20,789	)	$	4,861	$	25,650	$	(16,615	)	$	9,035
Infusion trademarks	6,200		(6,200		)	—		6,200		(5,333		)	867
Non-compete agreements	1,500		(1,233		)	267		1,500		(1,133		)	367
	$	33,350	$	(28,222	)	$	5,128	$	33,350	$	(23,081	)	$	10,269

Finite lived intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:



	Estimated Useful Life
Infusion customer relationships	5	months	-	4	years
Infusion trademarks	23	months	-	3	years
Non-compete agreements	1	year	-	5	years

Total amortization expense of intangible assets was $5.1 million, $6.6 million, and $6.7 million for the years ended December 31, 2015, 2014, and 2013, respectively. Amortization expense is expected to be the following (in thousands):



Year ending December 31,	Estimated Amortization
2016	$	3,078
2017	1,983
2018	67
2019	—
2020	—
Thereafter	—
Total estimated amortization expense	$	5,128

- Definition

The entire disclosure for the aggregate amount of goodwill and a description of intangible assets, which may include (a) for amortizable intangible assets (also referred to as finite-lived intangible assets), the carrying amount, the amount of any significant residual value, and the weighted-average amortization period, (b) for intangible assets not subject to amortization (also referred to as indefinite-lived intangible assets), the carrying amount, and (c) the amount of research and development assets acquired and written off in the period, including the line item in the income statement in which the amounts written off are aggregated, if not readily apparent from the income statement. Also discloses (a) for amortizable intangibles assets in total and by major class, the gross carrying amount and accumulated amortization, the total amortization expense for the period, and the estimated aggregate amortization expense for each of the five succeeding fiscal years, (b) for intangible assets not subject to amortization the carrying amount in total and by major class, and (c) for goodwill, in total and for each reportable segment, the changes in the carrying amount of goodwill during the period (including the aggregate amount of goodwill acquired, the aggregate amount of impairment losses recognized, and the amount of goodwill included in the gain (loss) on disposal of a reporting unit). If any part of goodwill has not been allocated to a reportable segment, discloses the unallocated amount and the reasons for not allocating. For each impairment loss recognized related to an intangible asset (excluding goodwill), discloses: (a) a description of the impaired intangible asset and the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method for determining fair value, (c) the caption in the income statement or the statement of activities in which the impairment loss is aggregated, and (d) the segment in which the impaired intangible asset is reported. For each goodwill impairment loss recognized, discloses: (a) a description of the facts and circumstances leading to the impairment, (b) the amount of the impairment loss and the method of determining the fair value of the associated reporting unit, and (c) if a recognized impairment loss is an estimate not finalized and the reasons why the estimate is not final. May also disclose the nature and amount of any significant adjustments made to a previous estimate of an impairment loss.

+ References + Details

STATEMENTS OF OPERATIONS DISCLOSURE

12 Months Ended

Dec. 31, 2015

Restructuring and Related Activities [Abstract]

Statements of Operations Disclosure

STATEMENTS OF OPERATIONS DISCLOSURE


•	Product revenue and service revenue in the former statement of operations are now grouped to net revenue with the impact of the sale of PBM Business; Cost of product revenue and cost of service revenue in the former statement of operations are grouped to net cost of revenue (excluding depreciation expense).


•	Depreciation expense included separately in cost of product revenue and selling, general and administrative expenses in the former statement of operations is now grouped in line item: depreciation and amortization expense.


•	Selling, general and administrative expenses in the former statement of operations is split into two line items: other operating expenses, and general and administrative expenses; In connection with this reclassification, the Company no longer allocates general and administrative expenses to field office expenses.


•	Acquisition and integration expenses, restructuring and other expenses, and change in fair value of contingent consideration in the former statement of operations are grouped to one line item: Restructuring, integration expenses, and other expenses, net.


•	Interest expense and loss on extinguishment of debt in the former statement of operations are grouped to one line item: interest expense, net.

Other operating expenses

Other operating expenses consist primarily of wages and benefits, travel expenses, professional services and field office expenses for our healthcare professionals engaged in the providing infusion services to our patients.

General and administrative expenses

General and administrative expenses consist primarily of wages and benefits for corporate overhead personnel and certain corporate level professional service fees, including legal, accounting, and IT fees.

Restructuring, integration, and other expenses, net

Restructuring, integration and other expenses include non-operating costs associated with restructuring and integration initiatives such as employee severance costs, certain legal and professional fees, training costs, redundant wage costs, impacts recorded from the change in contingent consideration obligations, and other costs related to contract terminations and closed branches/offices.

Restructuring, integration, and other expenses, net in the Consolidated Statements of Operations for the years ended December 31, 2015, 2014, and 2013 consisted of the following (in thousands):



	Year Ended December 31,
	2015		2014			2013
Restructuring expense	$	22,635	$	19,646		$	7,718
Integration expenses	1,740		17,924			16,130
Change in fair value of contingent consideration	30		(7,364		)	(5,786		)
Total restructuring, integration, and other expense, net	24,405		30,206			18,062

On August 10, 2015, the Company announced a plan to implement a new operations financial improvement plan (the “Financial Improvement Plan”) as part of an initiative to accelerate long-term growth, reduce costs and increase operating efficiencies. In connection with the Financial Improvement Plan, the Company consolidated most corporate functions from our Eden Prairie, Minnesota corporate office and our Elmsford, New York executive office into our new executive and corporate office located in Denver, Colorado. The Financial Improvement Plan was substantially completed by the end of 2015.

PROPERTY AND EQUIPMENT

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property and Equipment

PROPERTY AND EQUIPMENT

Property and equipment consists of the following (in thousands):



	December 31,
	2015			2014
Computer and office equipment	$	22,561		$	22,662
Software capitalized for internal use	15,600			14,914
Vehicles	1,938			2,106
Medical equipment	28,423			27,668
Work in progress	6,624			3,287
Furniture and fixtures	4,543			4,487
Leasehold improvements	14,285			13,690
Property and equipment, gross	93,974			88,814
Less: Accumulated depreciation	(62,035		)	(50,643		)
Property and equipment, net	$	31,939		$	38,171

Work in progress at December 31, 2015 and 2014 includes $1.8 million and $0.6 million, respectively, of internally developed software costs to be capitalized upon completion.

Depreciation expense, including expense related to assets under capital lease, for the years ended December 31, 2015, 2014 and 2013 was $17.6 million, $16.4 million, and $13.4 million, respectively. Depreciation expense for the years ended December 31, 2015, 2014 and 2013 includes $2.5 million, $2.4 million, and $1.7 million, respectively, related to costs related to software capitalized for internal use.

Impairment

The Company, which assesses the impairment of its assets whenever events or changes in circumstances indicate that the carrying value may not be recoverable, has determined that no such events or changes have occurred and therefore, no impairment charge in relation to property, plant and equipment was incurred during the year ended December 31, 2015.

DEBT

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Debt

DEBT

As of December 31, 2015 and 2014 the Company’s debt consisted of the following (in thousands):



	December 31,
	2015		2014
Revolving Credit Facility	$	15,000	$	5,000
Term Loan Facilities	222,757		222,757
2021 Notes, net of unamortized discount	196,038		195,462
Capital leases	189		584
Total Debt	433,984		423,803
Less: Current portion	27,665		5,395
Long-term debt, net of current portion	$	406,319	$	418,408

Senior Credit Facilities

On July 31, 2013, the Company entered into (i) a senior secured first-lien revolving credit facility in an aggregate principal amount of $75.0 million (the “Revolving Credit Facility”), (ii) a senior secured first-lien term loan B in an aggregate principal amount of $250.0 million (the “Term Loan B Facility”) and (iii) a senior secured first-lien delayed draw term loan B in an aggregate principal amount of $150.0 million (the “Delayed Draw Term Loan Facility” and, together with the Revolving Credit Facility and the Term Loan B Facility, the “Senior Credit Facilities”) with SunTrust Bank, Jefferies Finance LLC and Morgan Stanley Senior Funding, Inc.

The Senior Credit Facilities contain customary events of default that include, among others, non-payment of principal, interest or fees, violation of covenants, inaccuracy of representations and warranties, bankruptcy and insolvency events, material judgments, cross-defaults to material indebtedness, events constituting a change of control and any other development that results in, or would reasonably be expected to result in, a material adverse effect to the debtor’s ability to perform its obligation under the facility. The occurrence of certain events of default may increase the applicable rate of interest by 2% and could result in the acceleration of the Company’s obligations under the Senior Credit Facilities to pay the full amount of the obligations.

The proceeds of the Term Loan B Facility were used to refinance certain existing indebtedness of the Company, including the payment of the purchase price for the 10.25% senior unsecured notes (the “2015 Notes”) tendered and accepted for purchase in the Offer (defined below) and the payment of the redemption price for the 2015 Notes that remained outstanding after completion of the Offer. The Delayed Draw Term Loan Facility and the Revolving Credit Facility were used to fund a portion of the CarePoint Business acquisition and may be used for other general corporate purposes of the Company, including acquisitions, investments, capital expenditures and working capital needs.

On December 23, 2013, the Company entered into the First Amendment to the Senior Credit Facilities pursuant to which the Company obtained the required consent of the lenders to enter into the Settlement Agreements (see Note 11 - Commitments and Contingencies) and to begin making payments, in accordance with the payment terms, on the settlement amount of $15.0 million. In exchange for this consent, the Company paid the lenders a fee of $0.5 million and included this amount in loss from discontinued operations in the Consolidated Statements of Operations.

On January 31, 2014, the Company entered into the Second Amendment to the Senior Credit Facilities, which, among other things (i) provides additional flexibility with respect to compliance with the maximum net leverage ratio for the fiscal quarters ending December 31, 2013 through and including December 31, 2014, (ii) provides additional flexibility under the indebtedness covenants to permit the Company to obtain up to $150.0 million of second-lien debt and issue up to $250.0 million of unsecured bonds, provided that 100% of the net proceeds are applied first to the Revolving Credit Facility, with no corresponding permanent commitment reduction, and then on a pro rata basis to the Term Loan B Facility and the Delayed Draw Term Loan Facility (collectively, the “Term Loan Facilities”), (iii) provides the requisite flexibility to sell non-core assets, subject to the satisfaction of certain conditions, and (iv) increased the applicable interest rates for each of the Term Loan Facilities to the Eurodollar rate plus 6.00% or the base rate plus 5.00%, until the occurrence of certain pricing decrease triggering events, as defined in the amendment. Upon the occurrence of a pricing decrease triggering event, the interest rates for the Senior Credit Facilities may revert to the Eurodollar rate plus 5.25% or the base rate plus 4.25%.

On March 1, 2015, the Company entered into the Third Amendment to the Senior Credit Facilities (the “Third Amendment”), which establishes an alternate leverage test for the fiscal quarters ending March 31, 2015 through and including March 31, 2016. The maximum net leverage ratio for these quarters is consistent with that in effect for the prior four fiscal quarters. The Third Amendment eliminated the need to meet progressively lower leverage ratio requirements at each quarter end date for the next four quarters. The Third Amendment also provides for certain additional financial reporting.

On August 6, 2015, the Company entered into a Fourth Amendment to its Senior Credit Facilities (the “Fourth Amendment”). The Fourth Amendment, among other things, provides additional relief with respect to measuring compliance with the maximum first lien net leverage ratio for the fiscal quarters ending September 30, 2015 through and including March 31, 2017 and modifies and extends an alternate leverage test for the fiscal quarters ending September 30, 2015 through and including March 31, 2017. The levels for the maximum first lien net leverage ratio for certain of these quarters were increased by the Fourth Amendment. The availability of the alternative first lien net leverage ratio is subject to a number of conditions, including a minimum liquidity requirement and a maximum utilization test that requires the Revolving Credit Facility balance to remain under $60.0 million for the alternative first lien net leverage ratio to apply.

On October 9, 2015, the Company entered into the Fifth Amendment to the Senior Credit facilities (the “Fifth Amendment”), The Fifth Amendment directly modifies the definition of a “Continuing Director” in full as, “with respect to any period, any individuals (A) who were members of the board of directors or other equivalent governing body of the Borrower on the first day of such period, (B) whose election or nomination to that board or equivalent governing body was approved by individuals referred to in clause (A) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body, or (C) whose election or nomination to that board or other equivalent governing body was approved by individuals referred to in clauses (A) and (B) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body.” This amended definition also indirectly modifies the definition of a “Change in Control.”

As discussed below, the net proceeds of approximately $194.5 million from the issuance on February 11, 2014 of 8.875% senior notes due 2021 (the “2021 Notes”) were used to repay $59.3 million of the Revolving Credit Facility and $135.2 million of the Term Loan Facilities. In addition, approximately $54.2 million of the net proceeds from the sale of the Home Health Business (see Note 6 - Discontinued Operations) were used to repay $17.2 million of the Revolving Credit Facility and $37.0 million of the Term Loan Facilities. The Senior Credit Facilities are secured by substantially all of the Company’s and its subsidiaries’ assets.

The partial repayments of the Senior Credit Facilities as a result of the issuance of the 2021 Notes and from the sale of the Home Health Business were pricing decrease triggering events that resulted in the interest rates reverting to the Eurodollar rate plus 5.25% or the base rate plus 4.25%.

In connection with the PIPE Transaction (see Note 4 - Stockholder’s Equity), the Company was required to use at least 75% of the net proceeds for the repayment of outstanding indebtedness. The Company repaid approximately $45.3 million of the Revolving Credit Facility indebtedness and accrued interest from those proceeds. In addition, the Company repaid $22.7 million of the Revolving Credit facility indebtedness from the net proceeds from the sale of the PBM Business.

As of December 31, 2015, the interest rate related to the Revolving Credit Facility is approximately 7.75% and the interest rate related to the Term Loan Facilities is approximately 6.50%. The interest rates may vary in the future depending on the Company’s consolidated net leverage ratio.

The Revolving Credit Facility matures on July 31, 2018 at which time all principal amounts outstanding are due and payable. The Term Loan Facilities require quarterly principal repayments of $3.1 million beginning March 31, 2016 until their July 31, 2020 maturity at which time the remaining principal amount of approximately $166.3 million is due and payable.

At December 31, 2015, the Company had an outstanding amount of $15.0 million drawn down and borrowing capacity of $54.6 million (or borrowing capacity of $39.6 million to remain subject to the alternate leverage test) under its Revolving Credit Facility after considering outstanding letters of credit totaling $5.4 million.

2021 Notes

On February 11, 2014, the Company issued $200.0 million aggregate principal amount of the 2021 Notes. The 2021 Notes are senior unsecured obligations of the Company and are fully and unconditionally guaranteed by all existing and future subsidiaries of the Company. The 2021 Notes were offered in the United States to qualified institutional buyers in reliance on Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”), and outside the United States to non-U.S. persons in reliance on Regulation S under the Securities Act pursuant to an Indenture (the “2021 Notes Indenture”), dated February 11, 2014, by and among the Company, the guarantors named therein and U.S. Bank National Association, as trustee.

Interest on the 2021 Notes accrues at a fixed rate of 8.875% per annum and is payable in cash semi-annually, in arrears, on February 15 and August 15 of each year, commencing on August 15, 2014. The debt discount of $5.0 million at issuance is being amortized as interest expense through maturity which will result in the accretion over time of the outstanding debt balance to the principal amount. The 2021 Notes are the Company’s senior unsecured obligations and rank equally in right of payment with all of its other existing and future senior unsecured indebtedness and senior in right of payment to all of its existing and future subordinated indebtedness.

The 2021 Notes are guaranteed on a full, joint and several basis by each of the Company’s existing and future domestic restricted subsidiaries that is a borrower under any of the Company’s credit facilities or that guarantees any of the Company’s debt or that of any of its restricted subsidiaries, in each case incurred under the Company’s credit facilities. As of December 31, 2015, the Company does not have any independent assets or operations, and as a result, its direct and indirect subsidiaries (other than minor subsidiaries), each being 100% owned by the Company, are fully and unconditionally, jointly and severally, providing guarantees on a senior unsecured basis to the 2021 Notes.

The Company may redeem some or all of the 2021 Notes prior to February 15, 2017 by paying a “make-whole” premium. The Company may redeem some or all of the 2021 Notes on or after February 15, 2017 at specified redemption prices. In addition, prior to February 15, 2017, the Company may redeem up to 35% of the 2021 Notes with the net proceeds of certain equity offerings at a price of 108.88% plus accrued and unpaid interest, if any. The Company is obligated to offer to repurchase the 2021 Notes at a price of 101% of their principal amount plus accrued and unpaid interest, if any, as a result of certain change of control events. These restrictions and prohibitions are subject to certain qualifications and exceptions.

The 2021 Notes Indenture contains covenants that, among other things, limit the Company’s ability and the ability of certain of the Company’s subsidiaries to (i) grant liens on its assets, (ii) make dividend payments, other distributions or other restricted payments, (iii) incur restrictions on the ability of the Company’s restricted subsidiaries to pay dividends or make other payments, (iv) enter into sale and leaseback transactions, (v) merge, consolidate, transfer or dispose of substantially all of their assets, (vi) incur additional indebtedness, (vii) make investments, (viii) sell assets, including capital stock of subsidiaries, (ix) use the proceeds from sales of assets, including capital stock of restricted subsidiaries, and (x) enter into transactions with affiliates. In addition, the 2021 Notes Indenture requires, among other things, the Company to provide financial and current reports to holders of the 2021 Notes or file such reports electronically with the U.S. Securities and Exchange Commission (the “SEC”). These covenants are subject to a number of exceptions, limitations and qualifications set forth in the 2021 Notes Indenture.

Pursuant to the terms of the Second Amendment to the Senior Credit Facilities, the Company used the net proceeds of the 2021 Notes of approximately $194.5 million to repay $59.3 million of the Revolving Credit Facility and $135.2 million of the Term Loan Facilities.

Fair Value of Financial Instruments

The following details our financial instruments where the carrying value and the fair value differ:



Financial Instrument	Carrying Value as of December 31, 2015		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Term Loan Facilities	$	222,757	$	—	$	196,500	$	—
2021 Notes	196,038		—		167,650		—
Total	$	418,795	$	—	$	364,150	$	—

The fair value hierarchy for disclosure of fair value measurements is as follows:

Level 1: Quoted prices (unadjusted) in active markets for identical assets or liabilities.

Level 2: Quoted prices, other than quoted prices included in Level 1, which are observable for the assets or liabilities, either directly or indirectly.

Level 3: Inputs that are unobservable for the assets or liabilities.

Financial assets with carrying values approximating fair value include cash and cash equivalents and accounts receivable. Financial liabilities with carrying values approximating fair value include accounts payable and capital leases. The carrying value of these financial assets and liabilities approximates fair value due to their short maturities.

Deferred Financing Costs

In connection with the Senior Credit Facilities and the 2021 Notes, the Company incurred underwriting fees, agent fees, legal fees and other expenses of approximately $24.6 million and $0.5 million, respectively. The deferred financing costs are reflected as additional issuance costs and amortized as an adjustment of interest expense over the remaining term of the Senior Credit Facilities using the effective interest method.

Future Maturities

The estimated future maturities of the Company’s long-term debt as of December 31, 2015, are as follows (in thousands):



Year Ending December 31,	Amount
2016	$	12,550
2017	12,550
2018	12,550
2019	12,550
2020	172,557
Thereafter	200,000
Total future maturities	$	422,757

Interest Expense, net

Interest expense, including loss on extinguishment of debt, consisted of the following for each of the three years ended December 31, 2015, 2014 and 2013 (in thousands):



	Year ended December 31,
	2015			2014			2013
Revolving Credit Facility	$	2,190		$	1,829		$	873
Term Loan Facilities	14,680			16,820			10,313
2021 Notes	17,603			15,926			—
Prior Credit Facility	—			—			765
2015 Notes	—			—			13,960
Amortization of deferred financing costs	2,864			3,691			2,259
Amortization of debt discount	576			462			—
Loss on extinguishment of debt	—			2,373			15,898
Expense allocated to discontinued operations	—			—			41
Other, net	(600		)	(183		)	21
Interest expense, net	$	37,313		$	40,918		$	44,130

The weighted average interest rate on the Company’s short-term borrowings under its revolving credit facilities during the years ended December 31, 2015 and 2014 was 11.69% and 12.26%, respectively.

Liquidity

As of the date of this Annual Report, the Company expects that cash generated from operating activities combined with available borrowings capacity under the Revolving Credit Facility will be sufficient to fund anticipated working capital, information technology systems investments, scheduled principal and interest repayments and other cash needs for at least the next twelve months, based on historical levels.

Cash receipts improved in the second half of 2015 as the Company increased cash collections and reduced days sales outstanding (“DSO”). The Company’s plan in 2016 is to continue to reduce DSO and tightly manage operating expenses. The covenant is a consolidated first lien net leverage ratio which uses first lien debt net of cash divided by last twelve months Adjusted EBITDA as defined in the Senior Credit Facility. Should DSO rise, or if other unforeseen needs for liquidity develop, or if the Company does not manage cash to ensure compliance with debt covenants, the Company may evaluate financing arrangements to meet its working capital requirements. The Company regularly evaluates market conditions and financing options to improve its current liquidity profile and enhance its financial flexibility. These options may include, but is not limited to, opportunities to raise additional funds through the issuance of various forms of equity and/or debt securities or other instruments, the sale of assets or refinancing all or a portion of the Company’s indebtedness. However, there is no assurance that, if necessary, the Company would be able to raise capital to provide required liquidity.

COMMITMENTS AND CONTINGENCIES

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Commitments and Contingencies

COMMITMENTS AND CONTINGENCIES

Legal Proceedings

Settlement of PBM Services Arbitration Matter

On December 7, 2015, the Company executed a settlement agreement associated with the third party processor it had historically engaged to process PBM Services cash card claims. The settlement agreement fully resolved the PBM Services arbitration matter related to the third party processor’s discontinuation of payments due to the Company. The legal settlement included the Company’s full cash collection of the $6.8 million receivable due to the Company from the unrelated third party processor.

Breach of Contract Litigation in the Delaware Court of Chancery

On November 3, 2015, Walgreen Co. and various affiliates (“Walgreens”) filed a lawsuit in the Delaware Court of Chancery against the Company and certain of its subsidiaries (collectively, the “Defendants”). The complaint alleges that the Company breached certain non-compete provisions contained in the Community Pharmacy and Mail Business Purchase Agreement dated as of February 1, 2012, by and among Walgreens and certain subsidiaries and the Company and certain subsidiaries. The complaint seeks both money damages and injunctive relief. On December 7, 2015, the Defendants filed a motion to dismiss the case. Walgreens filed an answering brief on January 11, 2016 and the Defendants filed a reply on January 25, 2016. Oral argument on the motion to dismiss is scheduled for March 11, 2016. The Company believes that the allegations in the complaint are without merit and intends to vigorously defend against the claims. Due to the inherent uncertainty in litigation, however, the Company can provide no assurance as to the outcome of the matter or reasonably estimate a range of possible loss at this time.

McCormack Shareholder Class Action Litigation in the Delaware Court of Chancery

On September 8, 2015, Thomas McCormack (the “Plaintiff”) filed a complaint in the Court of Chancery of the State of Delaware against the Company, the Board, and SunTrust Bank (“SunTrust”), as administrative agent, captioned Thomas McCormack v. BioScrip, Inc. et al., C.A. No. 11480-CB, alleging that the adoption of what the Plaintiff referred to as a “Proxy Put” or “Dead Hand Proxy Put” in the Company’s July 31, 2013 credit agreement (the “Credit Agreement”), as amended from time to time, constituted a breach of the Board’s fiduciary duty. Among other things, the Plaintiff sought a declaration that the Proxy Put was invalid, unenforceable, and severable from the Credit Agreement. While the Company and SunTrust deny completely all of the allegations of wrongdoing in the complaint, on October 9, 2015, the requisite lenders approved, and the Company and SunTrust executed, the Fifth Amendment to eliminate the so-called “Dead Hand Proxy Put.” As a result of the amendment, the Plaintiff agreed that his claims were moot, and the Company agreed to pay $130,000 in fees and expenses to the Plaintiff’s counsel. On January 14, 2016, the Court entered a Stipulation and Order (the “Order”) providing that the Plaintiff’s action will be dismissed with prejudice only as to the Plaintiff and the case will be closed. The Court has not passed on the amount of fees and expenses. The Company filed an affidavit notifying the Court of its compliance with the Order, which resulted in the action being dismissed and the case closed.

Cline and Rubin Shareholder Class Action Litigation in the Delaware Court of Chancery

As previously disclosed, on April 9, 2015, two separate putative class action lawsuits were filed in the Delaware Court of Chancery (the “Chancery Court”) by purported stockholders Lawrence Cline and Roger Rubin (“Plaintiffs”), respectively, in connection with the Purchase Agreement dated March 9, 2015, with the PIPE Investors, against the Company, directors of the Company and the PIPE Investors. Pursuant to the Purchase Agreement, the Company issued and sold to the PIPE Investors in a private placement (as defined above, the “PIPE Transaction”) an aggregate of (a) 625,000 shares of Series A Preferred Stock, (b) 1,800,000 PIPE Class A Warrants, and (c) 1,800,000 PIPE Class B Warrants. On April 17, 2015, the two separate class action lawsuits were consolidated by order of the Chancery Court as In re BioScrip, Inc. Stockholder Litigation, Consol. C.A. 10893-VCG (the “Delaware Action”). On April 30, 2015, the Company entered into a memorandum of understanding (the “Memorandum of Understanding”) to settle the Delaware Action. The parties entered into a stipulation of settlement on May 11, 2015 (the “Stipulation of Settlement”).

The Company sought and obtained at the 2015 Annual Meeting on May 11, 2015, Stockholder Approval to remove certain conversion and voting restrictions affecting the Series A Preferred Stock and exercise restrictions affecting the PIPE Warrants (as defined above, the “Stockholder Approval”) and, therefore, subject to court approval of the settlement, the Delaware Action was set to be dismissed with prejudice by the Chancery Court in accordance with the terms of the Stipulation of Settlement. The Chancery Court held a hearing on July 29, 2015, to consider the fairness of the Settlement and award of Plaintiffs’ attorneys’ fees. The order approving the Settlement and award of $750,000 in attorneys’ fees and expenses to Plaintiff’s counsel was issued on July 29, 2015.

The Company carries insurance coverage in such amounts as it believes to be reasonable under the circumstances, which covered a certain percentage of the attorneys’ fees award. The final resolution of the Delaware Action did not have a material adverse effect on results of operations, financial position, liquidity or capital resources.

Derivative Lawsuit in the Delaware Court of Chancery

On May 7, 2015, a derivative complaint was filed in the Delaware Court of Chancery by the Park Employees’ & Retirement Board Employees’ Annuity & Benefit Fund of Chicago (the “Derivative Complaint”). The Derivative Complaint names as defendants certain current and former directors of the Company, consisting of Richard M. Smith, Myron Holubiak, Charlotte Collins, Samuel Frieder, David Hubers, Richard Robbins, Stuart Samuels and Gordon Woodward (collectively, the “Director Defendants”), certain current and former officers of the Company, consisting of Kimberlee Seah, Hai Tran and Patricia Bogusz (collectively the “Officer Defendants”), Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., and Jefferies LLC. The Company is also named as a nominal defendant in the Derivative Complaint. The Derivative Complaint was filed in the Delaware Court of Chancery as Park Employees and Retirement Board Employees’ Annuity and Benefit Fund of Chicago v. Richard M. Smith, Myron Z. Holubiak, Charlotte W. Collins, Samuel P. Frieder, David R. Huber, Richard L. Robbins, Stuart A. Samuels, Gordon H. Woodward, Kimberlee C. Seah, Hai V.Tran, Patricia Bogusz, Kohlberg & Co., L.L.C., Kohlberg Management V, L.L.C., Kohlberg Investors V, L.P., Kohlberg Partners V, L.P., Kohlberg TE Investors V, L.P., KOCO Investors V, L.P., Jefferies LLC and BioScrip, Inc., C.A. No. 11000-VCG (Del. Ch. Ct., May 7, 2015).

The Derivative Complaint alleges generally that certain defendants breached their fiduciary duties with respect to the Company’s public disclosures, oversight of Company operations, secondary stock offerings and stock sales. The Derivative Complaint also contends that certain defendants aided and abetted those alleged breaches. The damages sought are not quantified but include, among other things, claims for money damages, restitution, disgorgement, equitable relief, reasonable attorneys’ fees, costs and expenses, and interest. The Derivative Complaint incorporates the same factual allegations from In re BioScrip, Inc., Securities Litigation (described below). On June 16, 2015, all defendants moved to dismiss the case. Briefing for the motion to dismiss was completed on November 30, 2015, and the court heard oral argument on the motion to dismiss on January 12, 2016. During the hearing, the court requested additional briefing, which was completed on February 12, 2016.

The Company, Director Defendants and the Officer Defendants deny any allegations of wrongdoing in this lawsuit. The Company and those persons believe all of the claims in this lawsuit are without merit and intend to vigorously defend against these claims. However, there is no assurance that the defense will be successful or that insurance will be available or adequate to fund any settlement, judgment or litigation costs associated with this action. Certain of the defendants have sought indemnification from the Company pursuant to certain indemnification agreements, for which there may be no insurance coverage. Additional similar lawsuits may be filed. The Company is unable to predict the outcome or reasonably estimate a range of possible loss at this time. While no assurance can be given as to the ultimate outcome of this matter, the Company believes that the final resolution of this action is not likely to have a material adverse effect on results of operations, financial position, liquidity or capital resources.

Prior State Regulatory Matter

The Company has accrued an estimate of a potential loss as of December 31, 2015 in connection with a pending regulatory and various other matters related to certain discontinued operations of the Company. The accrual recorded is not a material amount and represents the Company’s best estimate of the exposure.

United States Attorney’s Office for the Southern District of New York and New York State Attorney General investigation

Effective January 8, 2014, the Company entered into the Federal Settlement Agreement with the U.S. Department of Justice (the “DOJ”) and David M. Kester (the “Relator”). The Federal Settlement Agreement represented the federal and private component of the Company’s agreement to settle all civil claims under the False Claims Act and related statutes and all common law claims (collectively, the “Claims”) that could have been brought by the DOJ and Relator in the qui tam lawsuit filed in the Southern District of New York (the “SDNY”) by the Relator relating to the distribution of the Novartis Pharmaceutical Corporation’s product Exjade® (the “Medication”) by the Company’s legacy specialty pharmacy division (the “Legacy Division”) that was divested in May 2012 (the “Civil Action”). Until January 8, 2014, the Company was prohibited from publicly disclosing any information related to the existence of the Civil Action. On January 8, 2014, the Civil Action was unsealed and made public on order of the court. Effective February 11, 2014, the Company entered into the State Settlement Agreements with the Settling States. The State Settlement Agreements represented the state component of the Company’s agreement to settle the Claims that could have been brought by the Settling States that arose out of the Legacy Division’s distribution of the Medication.

With the execution of the Federal Settlement Agreement and the State Settlement Agreements (collectively, the “Settlement Agreements”), the Civil Action has been fully resolved, and the Company also expects to be fully resolved the federal and state claims that were or could have been raised in the Civil Action. All federal claims and all state claims by the Settling States that have been or could be brought against it in the Civil Action have been dismissed with prejudice. The State Settlement Agreements expressly recognize and affirmatively provide that, by entering into the State Settlement Agreements, the Company has not made any admission of liability and the Company expressly denies the allegations in the Civil Action.

Under the Settlement Agreements, the Company paid an aggregate of $15.0 million, plus interest (at an annual rate of 3.25%) in three annual payments from January 2014 through January 2016. The Settlement Agreements represented a compromise to avoid the costs, distraction and uncertainty of protracted litigation. The Settlement Agreements do not include any admission of wrongdoing, illegal activity, or liability by the Company or its employees, directors, officers or agents.

During the year ended December 31, 2013, the Company included in its results of discontinued operations an accrual of $15.0 million in connection with the government’s investigation regarding certain operations of the Legacy Division. In January 2016, the Company paid $6.2 million, including interest, related to the Settlement Agreements and $0.2 million of fees to the Relator.

Securities Class Action Litigation in the Southern District of New York

On September 30, 2013, a putative securities class action lawsuit was filed in the United States District Court for the Southern District of New York (“SDNY”) against the Company and certain of its officers on behalf of the putative class of purchasers of our securities between August 8, 2011 and September 20, 2013, inclusive.

On November 15, 2013, a putative securities class action lawsuit was filed in SDNY against the Company and certain of its directors and officers and certain underwriters in the Company’s April 2013 underwritten public offering of its common stock, on behalf of the putative class of purchasers of our securities between August 8, 2011 and September 23, 2013, inclusive.

On December 19, 2013, the SDNY entered an order consolidating the two class action lawsuits as In re BioScrip, Inc., Securities Litigation, No. 13-cv-6922 (AJN) and appointing an interim lead plaintiff. The Company denies any allegations of wrongdoing in the consolidated class action lawsuit. The lead plaintiff filed a consolidated complaint on February 19, 2014 against the Company, certain of its directors and officers, certain underwriters in the Company’s April 2013 underwritten public offering of its common stock, and a certain stockholder of the Company. The consolidated complaint is brought on behalf of a putative class of purchasers of the Company’s securities between November 9, 2012 and November 6, 2013, inclusive, and persons and entities who purchased the Company’s securities pursuant or traceable to two underwritten public offerings of the Company’s common stock conducted in April 2013, and August 2013. The consolidated complaint alleges generally that the defendants made material misstatements and/or failed to disclose matters related to the Legacy Division’s distribution of Novartis Pharmaceutical Corporation’s product Exjade® (the “Medication”) as well as the Company’s PBM Services segment. The consolidated complaint asserts claims under Sections 11, 12(a)(2) and 15 of the Securities Act and Sections 10(b) and 20(a) of the Exchange Act and Rule 10b-5 promulgated thereunder. All defendants in the case moved to dismiss the consolidated complaint on April 28, 2014. On March 31, 2015, the SDNY granted in part and denied in part the defendants’ motions to dismiss. On April 14, 2015, a motion to reconsider a portion of the denial of the motions to dismiss was filed on behalf of all the remaining defendants. Plaintiffs filed their opposition to that motion on April 28, 2015. On June 5, 2015, the SDNY denied the defendants’ motion to reconsider.

On September 25, 2015, the parties entered mediation concerning all pending claims. In October 2015, the parties reached an agreement in principle to settle all claims in the action (the “Proposed Settlement”), the terms and conditions of which were filed with the SDNY on December 18, 2015. The Company has agreed to the Proposed Settlement without any admission of liability or wrongdoing and solely in order to avoid the costs, distraction, and uncertainty of litigation.

On February 11, 2016, the Court granted preliminary approval for the settlement, certified a class of plaintiffs for settlement only, approved of the form of and mailing of notice to the stockholder class, and scheduled a final fairness hearing for June 13, 2016. The Proposed Settlement remains subject to final court approval. Until final approval is obtained and until any other conditions precedent in the Proposed Settlement are completed or satisfied, there can be no assurance that this matter will in fact be resolved pursuant to the terms of the Proposed Settlement.

The Company carries insurance coverage in such amounts as it believes to be reasonable under the circumstances, but there is no assurance that insurance will be available or adequate to fund any settlement, judgment or litigation costs associated with this action. While no assurance can be given as to the ultimate outcome of this matter, the Company believes that the final resolution of this action is not likely to have a material adverse effect on results of operations, financial position, liquidity or capital resources.

Government Regulation

Various federal and state laws and regulations affecting the healthcare industry do or may impact the Company’s current and planned operations, including, without limitation, federal and state laws prohibiting kickbacks in government health programs, federal and state antitrust and drug distribution laws, and a wide variety of consumer protection, insurance and other state laws and regulations. While management believes the Company is in substantial compliance with all existing laws and regulations material to the operation of its business, such laws and regulations are often uncertain in their application to our business practices as they evolve and are subject to rapid change. As controversies continue to arise in the healthcare industry, federal and state regulation and enforcement priorities in this area can be expected to increase, the impact of which cannot be predicted.

From time to time, the Company responds to investigatory subpoenas and requests for information from governmental agencies and private parties. The Company cannot predict with certainty what the outcome of any of the foregoing might be. While the Company believes it is in substantial compliance with all laws, rules and regulations that affects its business and operations, there can be no assurance that the Company will not be subject to scrutiny or challenge under one or more existing laws or that any such challenge would not be successful. Any such challenge, whether or not successful, could have a material effect upon the Company’s Consolidated Financial Statements. A violation of the Federal anti-kickback statute, for example, may result in substantial criminal penalties, as well as suspension or exclusion from the Medicare and Medicaid programs. Moreover, the costs and expenses associated with defending these actions, even where successful, can be significant. Further, there can be no assurance the Company will be able to obtain or maintain any of the regulatory approvals that may be required to operate its business, and the failure to do so could have a material effect on the Company’s Consolidated Financial Statements.

Leases

The Company leases its facilities and certain equipment under various operating leases with third parties. The majority of these leases contain escalation clauses that increase base rent payments based upon either the Consumer Price Index or an agreed upon schedule.

In addition, the Company utilizes capital leases agreements with third parties to obtain certain assets such as telecommunications equipment and vehicles. Interest rates on capital leases are both fixed and variable and range from 3% to 7%.

As of December 31, 2015, future minimum lease payments under operating and capital leases were as follows (in thousands):



	Operating Leases		Capital Leases		Total
2016	$	8,271	$	122	$	8,393
2017	7,267		62		7,329
2018	5,284		11		5,295
2019	3,048		—		3,048
2020	1,565		—		1,565
2021 and Thereafter	1,111		—		1,111
Total Future Minimum Lease Payments	$	26,546	$	195	$	26,741

Rent expense for leased facilities and equipment was approximately $7.2 million, $7.6 million and $7.9 million for the years ended December 31, 2015, 2014 and 2013, respectively.

Purchase Commitments

As of December 31, 2015, the Company had commitments to purchase prescription drugs from drug manufacturers of approximately $38.5 million in 2016. These purchase commitments are made at levels expected to be used in the normal course of business.

OPERATING AND REPORTABLE SEGMENTS	12 Months Ended
OPERATING AND REPORTABLE SEGMENTS	Dec. 31, 2015
Segment Reporting [Abstract]
Operating and Reportable Segments	OPERATING AND REPORTABLE SEGMENTS As noted within Note 6 - Discontinued Operations, the Company completed the disposal of the PBM Business (and reporting segment) on August 27, 2015. As a result of this disposal, Infusion Services is the only remaining operating segment. On an ongoing basis the Company will no longer report operating segments until a change in the business facilitates the need to do so.

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

CONCENTRATION OF RISK	12 Months Ended
CONCENTRATION OF RISK	Dec. 31, 2015
Risks and Uncertainties [Abstract]
Concentration of Risk	CONCENTRATION OF RISK Customer and Credit Concentration Risk The Company provides trade credit to its customers in the normal course of business. One commercial payor, United Healthcare, accounted for approximately 24%, 22% and 22% of revenue during the years ended December 31, 2015, 2014 and 2013, respectively. Medicare accounted for 10%, 11% and 11% of revenue during the years ended December 31, 2015, 2014 and 2013, respectively. Therapy Revenue Concentration Risk The Company sells products related to the Immune Globulin (IG) therapy, which represented 17%, 17%, and 19% of revenue during the years ended December 31, 2015, 2014 and 2013, respectively.

INCOME TAXES

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Income Taxes

INCOME TAXES

The Company’s federal and state income tax provision (benefit) from continuing operations is summarized in the following table (in thousands):



	Year Ended December 31,
	2015			2014			2013
Current
Federal	$	—		$	(886	)	$	(866	)
State	(76		)	(41		)	(1,412		)
Total current	(76		)	(927		)	(2,278		)
Deferred
Federal	(18,293		)	9,951			3,281
State	(3,163		)	2,169			257
Total deferred	(21,456		)	12,120			3,538
Total tax provision (benefit)	$	(21,532	)	$	11,193		$	1,260

The effect of temporary differences that give rise to a significant portion of deferred taxes is as follows (in thousands):



	December 31,
	2015			2014
Deferred tax assets:
Reserves not currently deductible	$	27,467		$	28,387
Net operating loss carryforwards	91,350			65,097
Goodwill and intangibles (tax deductible)	34,983			8,458
Accrued expenses	654			32
Property basis differences	1,021			301
Stock based compensation	8,245			8,201
Other	715			610
Total deferred tax assets	164,435			111,086
Deferred tax liabilities:
Indefinite-lived goodwill and intangibles	(236		)	(18,118		)
Less: valuation allowance	(164,435		)	(111,086		)
Net deferred tax liability	(236		)	(18,118		)
Deferred taxes	$	(236	)	$	(18,118	)

The Company continually assesses the necessity of a valuation allowance. Based on this assessment, the Company concluded that a valuation allowance, in the amount of $164.4 million and $111.1 million, was required as of December 31, 2015 and 2014, respectively. If the Company determines in a future period that it is more likely than not that part or all of the deferred tax assets will be realized, the Company will reverse part or all of the valuation allowance.

At December 31, 2015, the Company had federal net operating loss (“NOL”) carryforwards of approximately $243.0 million, of which $18.4 million is subject to an annual limitation, which will begin expiring in 2026 and later. Of the Company’s $243.0 million federal NOLs, $18.0 million will be recorded in additional paid-in capital when realized as these NOLs are related to the exercise of non-qualified stock options and restricted stock grants. The Company has post-apportioned state NOL carryforwards of approximately $322.7 million, the majority of which will begin expiring in 2017 and later.

The Company’s reconciliation of the statutory rate to the effective income tax rate from continuing operations is as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Tax (benefit) provision at statutory rate	$	(113,736	)	$	(48,554	)	$	(24,633	)
State tax (benefit) provision, net of federal taxes	(8,356		)	(3,959		)	(3,239		)
Valuation allowance changes affecting income tax expense	57,023			63,641			29,805
Change in tax contingencies	(37		)	(109		)	(1,157		)
Non-deductible transaction costs	—			—			317
Goodwill impairment	43,362			—			—
Other	212			174			167
Tax provision (benefit)	$	(21,532	)	$	11,193		$	1,260

As of December 31, 2015, the Company had $1.1 million of gross unrecognized tax benefits, of which $0.1 million, if recognized, would favorably affect the effective income tax rate in future periods. A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Unrecognized tax benefits balance at January 1,	$	1,096		$	1,172		$	2,754
Lapse of statute of limitations	(29		)	(76		)	(1,582		)
Unrecognized tax benefits balance at December 31,	$	1,067		$	1,096		$	1,172

The Company’s policy for recording interest and penalties associated with uncertain tax positions is to record such items as a component of income tax expense in the Consolidated Statements of Operations. As of December 31, 2015 and 2014, the Company had approximately $0.1 million and $0.1 million of accrued interest related to uncertain tax positions, respectively.

The Company files income tax returns, including returns for its subsidiaries, with federal, state and local jurisdictions. The Company’s uncertain tax positions are related to tax years that remain subject to examination. As of December 31, 2015, U.S. tax returns for the years 2011 through 2014 remain subject to examination by federal tax authorities. Tax returns for the years 2010 through 2014 remain subject to examination by state and local tax authorities for a majority of the Company's state and local filings.

STOCK-BASED COMPENSATION

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Stock-Based Compensation

STOCK-BASED COMPENSATION

BioScrip Equity Incentive Plans

Under the Company’s Amended and Restated 2008 Equity Incentive Plan (the “2008 Plan”), the Company may issue, among other things, incentive stock options, non-qualified stock options , stock appreciation rights (“SARs”), restricted stock grants, restricted stock units, performance shares and performance units to key employees and directors. While SARS are authorized under the 2008 Plan, they may also be issued outside of the plan. The 2008 Plan is administered by the Company's Management Development and Compensation Committee (the “Compensation Committee”), a standing committee of the Board of Directors.

On May 8, 2014, the Company’s stockholders (i) approved an amendment to the 2008 Plan to increase the number of authorized shares of common stock available for issuance by 2,500,000 shares (the “2014 Additional Shares”) to 9,355,000 shares and to clarify that cash dividends or dividend equivalents may not be paid to holders of unvested restricted stock units, restricted stock grants and performance units until such awards are vested and non-forfeitable; and (ii) re-approved the material terms of the performance goals that are a part of the 2008 Plan. On September 19, 2014, the Company filed a Registration Statement on Form S-8 to register the issuance of the 2014 Additional Shares that were approved by the Company’s stockholders on May 8, 2014.

As of December 31, 2015, there were 1,240,811 shares that remained available for grant under the 2008 Plan.

Employee Stock Purchase Plan

On May 7, 2013, the Company’s stockholders approved the BioScrip, Inc. Employee Stock Purchase Plan (the “ESPP”). The ESPP Plan is administered by the Compensation Committee. The ESPP provides all eligible employees, as defined under the ESPP, the opportunity to purchase up to a maximum number of shares of Common Stock of the Company as determined by the Compensation Committee. Participants in the ESPP may acquire the Common Stock at a cost of 85% of the lower of the fair market value on the first or last day of the quarterly offering period. The Company filed a Registration Statement on Form S-8 to register 750,000 shares of Common Stock, par value $0.0001 per share, for issuance under the ESPP.

As of December 31, 2015, there were 564,441 shares that remained available for grant under the ESPP. During the year ended December 31, 2015, the ESPP’s third-party service provider purchased 185,559 shares on the open market and delivered these shares to the Company’s employees pursuant to the ESPP, and the Company recorded $0.1 million of expense related to the ESPP.

BioScrip/CHS Equity Plan

In connection with the May 8, 2014 amendment to the 2008 Plan noted above, the Company determined to cease issuance of awards under the BioScrip/CHS 2006 Equity Incentive Plan. As of December 31, 2015, no shares remained available under the BioScrip/CHS Plan.

Stock Options

Options granted under the Equity Compensation Plans: (a) typically vest over a three-year period and, in certain instances, fully vest upon a change in control of the Company, (b) have an exercise price that may not be less than 100% of its fair market value on the date of grant and (c) are generally exercisable for ten years after the date of grant, subject to earlier termination in certain circumstances.

Option expense is amortized on a straight-line basis over the requisite service period. The Company recognized compensation expense related to stock options of $4.8 million, $6.9 million, and $6.0 million, in the years ended December 31, 2015, 2014 and 2013, respectively.

The weighted-average, grant-date fair value of options granted during the years ending December 31, 2015, 2014 and 2013 was $2.25, $4.32, and $6.24, respectively. The fair value of stock options granted was estimated on the date of grant using a binomial model for grants issued through June 30, 2015 and a Black-Scholes option-pricing model for grants issued beginning July 1, 2015. The assumptions used to compute the fair value of options for the years ending December 31, 2015, 2014 and 2013 were:



	2015		2014		2013
Expected volatility	62.3	%	61.0	%	61.8	%
Risk-free interest rate	2.20	%	2.50	%	2.13	%
Expected life of options	8.9 years		5.7 years		5.5 years
Dividend rate	—		—		—

A summary of stock option activity for the Equity Compensation Plans through December 31, 2015 was as follows:



	Options		Weighted Average Exercise Price		Aggregate Intrinsic Value (thousands)		Weighted Average Remaining Contractual Life
Balance at December 31, 2014	6,837,006		$	7.65	$	4,150	7.4 years
Granted	1,436,500		$	3.02
Exercised	(600	)	$	2.73
Forfeited and expired	(1,637,309	)	$	8.42
Balance at December 31, 2015	6,635,597		$	6.46	$	2	5.8 years
Outstanding options less expected forfeitures at December 31, 2015	6,335,391		$	6.51	$	2	5.7 years
Exercisable at December 31, 2015	4,384,108		$	7.05	$	2	4.2 years

Cash received from option exercises under share-based payment arrangements for the years ended December 31, 2015, 2014, and 2013 was $1.6 thousand, $1.5 million, and $2.5 million, respectively.

The maximum term of stock options under these plans is ten years. Options outstanding as of December 31, 2015 expire on various dates ranging from March 2016 through September 2025. The following table outlines our outstanding and exercisable stock options as of December 31, 2015:



	Options Outstanding				Options Exercisable
Range of Option Exercise Price	Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Options Exercisable	Weighted Average Exercise Price
$1.71 - $4.13	1,567,250	$	2.66	8.0 years	348,250	$	2.47
$4.14 - $8.25	3,885,681	$	6.51	5.0 years	3,110,026	$	6.34
$8.26- $12.38	762,500	$	10.39	5.5 years	619,168	$	10.25
$12.39 - $14.44	412,166	$	12.91	6.0 years	301,331	$	12.9
$14.45 - $18.57	8,000	$	16.63	7.6 years	5,333	$	16.63
All options	6,635,597	$	6.46	5.8 years	4,384,108	$	7.05

As of December 31, 2015 there was $4.3 million of unrecognized compensation expense related to unvested option grants that is expected to be recognized over a weighted-average period of 2.0 years. The total intrinsic value of options exercised during the years December 31, 2015, 2014 and 2013 was $1.5 thousand, $0.6 million, and $3.8 million, respectively.

As compensation expense for options granted is recorded over the requisite service period of options, future stock-based compensation expense may be greater as additional options are granted.

Restricted Stock

Under the Equity Compensation Plans, stock grants subject solely to an employee’s or director’s continued service with the Company will not become fully vested less than (a) three years from the date of grant to employees and, in certain instances, may fully vest upon a change in control of the Company, and (b) one year from the date of grant for directors. Stock grants subject to the achievement of performance conditions will not vest less than one year from the date of grant. Such performance shares may vest after one year from grant. No such time restrictions applied to stock grants made under the Company’s prior equity compensation plans.

The Company recognized compensation expense related to restricted stock awards of $0.4 million, $1.6 million, and $3.5 million for the years ended December 31, 2015, 2014 and 2013, respectively.

Since the Company records compensation expense for restricted stock awards based on the vesting requirements, which generally includes time elapsed, market conditions and/or performance conditions, the weighted average period over which the expense is recognized varies. Also, future equity-based compensation expense may be greater if additional restricted stock awards are made.

A summary of restricted stock award activity through December 31, 2015 was as follows:



	Restricted Stock		Weighted Average Grant Date Fair Value		Weighted Average Remaining Recognition Period
Balance at December 31, 2014	179,997		$	9.31	0.4 years
Granted	68,000		$	3.55
Awards Vested	(147,000	)	$	4.92
Canceled	(50,999	)	$	11.77
Balance at December 31, 2015	49,998		$	11.89	2.2 years

As of December 31, 2015, there was no unrecognized compensation expense related to unvested restricted stock awards. The total grant date fair value of awards vested during the years ended December 31, 2015, 2014 and 2013 was $0.2 million, $3.5 million, and $0.5 million, respectively. The total fair value of restricted stock awards vested during the years December 31, 2015, 2014 and 2013 was $0.5 million, $2.0 million, and $0.5 million, respectively.

Performance Units

Under the 2008 Plan, the Compensation Committee may grant performance units to key employees. The Compensation Committee will establish the terms and conditions of any performance units granted, including the performance goals, the performance period and the value for each performance unit. If the performance goals are satisfied, the Company would pay the key employee an amount in cash equal to the value of each performance unit at the time of payment. In no event may a key employee receive an amount in excess of $1.0 million with respect to performance units for any given year. As of December 31, 2015, no performance units have been granted under the 2008 Plan.

Stock Appreciation Rights

The Company has outstanding cash-based phantom stock appreciation rights (“SARs”), which are independent of the Company's 2008 Equity Incentive Plan, with respect to 300,000 shares of the Company's common stock. The SARs vest in three equal annual installments and will fully vest in connection with a change of control (as defined in the grantee’s employment agreement). The SARs may be exercised, in whole or in part, to the extent each SAR has been vested and will receive in cash the amount by which the closing stock price on the exercise date exceeds the Grant Price, if any. Upon the exercise of any SARs, as soon as practicable under the applicable federal and state securities laws, the grantee may be required to use the net after-tax proceeds of such exercise to purchase shares of the Common Stock from the Company at the closing stock price of the Common Stock on that date and hold such shares of Common Stock for a period of not less than one year from the date of purchase, except that the grantee will not be required to purchase any shares of Common Stock if the SAR is exercised on or after a change of control of the Company. The grantee’s right to exercise the SAR will expire on the earliest of (1) the tenth anniversary of the grant date, or (2) under certain conditions as a result of termination of the grantee’s employment.

A summary of SAR activity through December 31, 2015 was as follows:



	Stock Appreciation Rights		Weighted Average Exercise Price		Weighted Average Remaining Recognition Period
Balance at December 31, 2014	320,000		$	6.65	0.3 years
Granted	—		$	—
Exercised	—		$	—
Canceled	(20,000	)	$	9.16
Balance at December 31, 2015	300,000		$	6.48	0.0 years

The SARs are recorded as a liability in other non-current liabilities in the accompanying Consolidated Balance Sheets. Compensation expense (benefit) related to the SARs for the year ended December 31, 2015, 2014 and 2013 was $(913) thousand, $(20) thousand and $(48) thousand. As of December 31, 2015 all outstanding SARs were fully vested. In addition, because they are settled with cash, the fair value of the SAR awards is revalued on a quarterly basis. During the years ended December 31, 2015, 2014 and 2013, the Company did not paid cash related to the exercise of SAR awards.

DEFINED CONTRIBUTION PLAN	12 Months Ended
DEFINED CONTRIBUTION PLAN	Dec. 31, 2015
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Defined Contribution Plan	DEFINED CONTRIBUTION PLAN The Company maintains a deferred compensation plan under Section 401(k) of the Internal Revenue Code. Under the Plan, employees may elect to defer up to 100% of their salary, subject to Internal Revenue Service limits, and the Company may make a discretionary matching contribution. The Company recorded matching contributions in other operating expense, and general and administrative expenses in the Consolidated Statements of Operations of $1.3 million, $1.6 million and $0.5 million during the years ended December 31, 2015, 2014 and 2013, respectively.

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

12 Months Ended

Dec. 31, 2015

Selected Quarterly Financial Information [Abstract]

Selected Quarterly Financial Data (Unaudited)

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED)

A summary of unaudited quarterly financial information for the years ended December 31, 2015 and 2014 is as follows (in thousands except per share data):



	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Year ended December 31, 2015
Revenue	$	244,357		$	246,897		$	247,224		$	243,745
Gross profit	64,955			64,818			65,233			65,909
Loss from continuing operations, before income taxes	(15,367		)	(264,822		)	(28,791		)	(15,980		)
Net loss from discontinued operations, net of income taxes	(2,379		)	94			7,457			(1,451		)
Net loss	$	(19,674	)	$	(244,807	)	$	(16,783	)	$	(18,443	)

Loss per share from continuing operations, basic and diluted	$	(0.28	)	$	(3.62	)	$	(0.38	)	$	(0.28	)
Loss per share from discontinued operations, basic and diluted	(0.03		)	—			0.11			(0.02		)
Loss per share, basic and diluted	$	(0.31	)	$	(3.62	)	$	(0.27	)	$	(0.30	)

Year ended December 31, 2014
Revenue	$	221,341		$	230,111		$	231,458		$	239,744
Gross profit	62,139			62,249			62,687			63,678
Loss from continuing operations, before income taxes	(23,606		)	(17,221		)	(37,274		)	(60,626		)
Net income (loss) from discontinued operations, net of income taxes	1,783			466			494			(291		)
Net loss	$	(25,314	)	$	(19,818	)	$	(38,710	)	$	(63,626	)

Loss per share from continuing operations, basic and diluted	$	(0.40	)	$	(0.30	)	$	(0.57	)	$	(0.92	)
Income (loss) per share from discontinued operations, basic and diluted	0.03			0.01			0.01			—
Loss per share, basic and diluted	$	(0.37	)	$	(0.29	)	$	(0.56	)	$	(0.92	)

With the sale of the PBM Business on August 27, 2015 and Home Health Business on March 31, 2014 (see Note 6 - Discontinued Operations), all prior period financial statements have been reclassified to include the PBM Business and Home Health Business as discontinued operations.

SUBSEQUENT EVENTS	12 Months Ended
SUBSEQUENT EVENTS	Dec. 31, 2015
Subsequent Events [Abstract]
Subsequent Events	SUBSEQUENT EVENTS The Company has evaluated all events and transactions that occurred after December 31, 2015. During this period, the Company had no material subsequent events requiring recognition in the consolidated financial statements.

Schedule II -- Valuation and Qualifying Accounts

12 Months Ended

Dec. 31, 2015

Valuation and Qualifying Accounts [Abstract]

Schedule II -- Valuation and Qualifying Accounts

Bioscrip, Inc. and Subsidiaries

Schedule II-- Valuation and Qualifying Accounts

(in thousands)



	Balance at Beginning of Period		Write-Off of Receivables			Charged to Costs and Expenses		Balance at End of Period
Year ended December 31, 2013
Allowance for doubtful accounts	$	20,760	$	(22,541	)	$	19,516	$	17,735
Year ended December 31, 2014
Allowance for doubtful accounts	$	17,735	$	(30,877	)	$	79,547	$	66,405
Year ended December 31, 2015
Allowance for doubtful accounts	$	66,405	$	(47,758	)	$	41,042	$	59,689

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Consolidation

Use of Estimates

Fair Value Measurements


•	Level 1 - Inputs to the fair value measurement are quoted prices in active markets for identical assets or liabilities.


•	Level 2 - Inputs to the fair value measurement include quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, and inputs other than quoted prices that are observable for the asset or liability, either directly or indirectly.


•	Level 3 - Inputs to the fair value measurement are unobservable inputs or valuation techniques.

Cash and Cash Equivalents

Highly liquid investments with a maturity of three months or less when purchased are classified as cash equivalents.

Receivables

Allowance for Doubtful Accounts

Allowance for Contractual Discounts

Inventory

Property and Equipment

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	years	-	5	years
Office equipment				5	years
Vehicles	4	years	-	5	years
Medical equipment	13	months	-	5	years
Furniture and fixtures				5	years

Goodwill

Intangible Assets

Impairment of Long Lived Assets

Amounts due to Plan Sponsors

Contingent Consideration

Financial Instruments

Accounting for Stock-Based Compensation

Recent Accounting Pronouncements

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

12 Months Ended

Dec. 31, 2015

Accounting Policies [Abstract]

Aging of net accounts receivable



	December 31, 2015							December 31, 2014
	0 - 180 days		Over 180 days		Total			0 - 180 days		Over 180 days		Total
Government	$	19,944	$	11,369	$	31,313		$	25,812	$	13,036	$	38,848
Commercial	103,357		22,345		125,702			108,439		35,313		143,752
Patient	5,014		6,025		11,039			4,899		10,562		15,461
Gross accounts receivable	$	128,315	$	39,739	168,054			$	139,150	$	58,911	198,061
Allowance for doubtful accounts					(59,689		)					(66,405		)
Net accounts receivable					$	108,365						$	131,656

Estimated useful lives of assets

Property and equipment is stated at cost less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of assets as follows:



Asset	Useful Life
Computer hardware and software	3	years	-	5	years
Office equipment				5	years
Vehicles	4	years	-	5	years
Medical equipment	13	months	-	5	years
Furniture and fixtures				5	years

LOSS PER SHARE (Tables)

12 Months Ended

Dec. 31, 2015

Earnings Per Share [Abstract]

Computation of basic and diluted loss per common share

The following table sets forth the computation of basic and diluted loss per common share (in thousands, except for per share amounts):



	Year Ended December 31,
	2015			2014			2013
Numerator:
Loss from continuing operations, net of income taxes	$	(303,428	)	$	(149,920	)	$	(71,641	)
Income from discontinued operations, net of income taxes	3,721			2,452			1,987
Net loss	(299,707		)	(147,468		)	(69,654		)
Accrued dividends on Series A Preferred Stock	(6,120		)	—			—
Deemed dividends on Series A Preferred Stock	(3,690		)	—			—
Loss attributable to common stockholders	$	(309,517	)	$	(147,468	)	$	(69,654	)

Denominator - Basic and Diluted:
Weighted average number of common shares outstanding	68,710			68,476			64,560
Loss Per Common Share:
Loss from continuing operations, basic and diluted	$	(4.56	)	$	(2.19	)	$	(1.11	)
Income (loss) from discontinued operations, basic and diluted	0.05			0.04			0.03
Income (loss) per common share, basic and diluted	$	(4.51	)	$	(2.15	)	$	(1.08	)

STOCKHOLDERS' (DEFICIT) EQUITY (Tables)

12 Months Ended

Dec. 31, 2015

Stockholders' Equity Attributable to Parent [Abstract]

Schedule of allocation of proceeds from the Purchase Agreement based on relative fair values

The proceeds from the Purchase Agreement were allocated among the instruments based on their relative fair values as follows (in thousands):



	Relative Fair Value Allocation
Financial instruments:	March 9, 2015
Series A Preferred Stock ¹	$	59,355
PIPE Warrants ²	3,145
Total Investment	$	62,500

Carrying value of Series A Preferred Stock

The following sets forth the initial carrying value of the Series A Preferred Stock which is classified as temporary equity (mezzanine equity) on the Consolidated Balance Sheet (in thousands):



	Carrying Value
Series A Preferred Stock:	March 9, 2015
Issuance date liquidation preference	$	62,500
Discount related to warrant value ¹	(3,145		)
Discount related to beneficial conversion feature ²	(3,145		)
Discount related to issuance costs ³	(3,830		)
Initial carrying value of Series A Preferred Stock	$	52,380

The following table sets forth the activity recorded during the year ended December 31, 2015 related to the Series A Preferred Stock (in thousands) issued for both the PIPE Transactions and the Rights Offering.



Series A Preferred Stock carrying value at issuance	$	53,108
Accretion of discount related to beneficial conversion feature	3,690
Dividends recorded through December 31, 2015¹	6,120
Series A Preferred Stock carrying value December 31, 2015	$	62,918

¹Dividends recorded reflect the increase in the Liquidation Preference associated with unpaid dividends.

Carrying value of 2015 Warrants

The following sets forth the carrying value of the PIPE Warrants which is classified as equity on the Consolidated Balance Sheet (in thousands):



	Carrying Value
PIPE Warrants	March 9, 2015
Fair value allocated to PIPE Warrants	$	3,145
Discount related to issuance costs	(203		)
Carrying value of PIPE Warrants	$	2,942

- Definition

Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.

+ References + Details

ACQUISITIONS (Tables)

12 Months Ended

Dec. 31, 2015

Business Acquisition [Line Items]

Acquisition and integration expenses



	Year Ended December 31,
	2015		2014		2013
Legal and professional fees	$	1,033	$	6,931	$	5,113
Financial advisory fees	—		—		2,413
Employee costs including redundant salaries and benefits and severance	—		2,016		3,554
Facilities consolidation and discontinuation	488		1,401		1,621
Bad debt expense and contractual adjustments related to acquired accounts receivable	—		5,430		—
Legal settlement	—		334		2,300
Other	219		1,812		1,129
Total	$	1,740	$	17,924	$	16,130

CarePoint Partners Holding LLC

Business Acquisition [Line Items]

Fair values of assets acquired and liabilities assumed



	Fair Value
Cash	$	14
Accounts receivable	15,917
Inventories	3,184
Other current assets	215
Property and equipment	3,266
Identifiable intangible assets⁽¹⁾	16,700
Current liabilities	(8,697		)
Non-current liabilities	(721		)
Total identifiable net assets	29,878
Goodwill	189,214
Total cash and fair value of contingent consideration	$	219,092


(1)	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets (in thousands):



	Weighted- Average Useful Lives	Amounts Recognized as of the Closing Date
Customer relationships	2 - 4 years	$	13,600
Trademarks	2 years	2,600
Non-compete agreements	5 years	500
Total identifiable intangible assets acquired		$	16,700

HomeChoice Partners, Inc.

Business Acquisition [Line Items]

Fair values of assets acquired and liabilities assumed

The table below summarizes the Company’s assessment of the fair values of the assets acquired and liabilities assumed as of the acquisition date of HomeChoice (in thousands):



	Fair Value
Accounts receivable	$	9,693
Inventories	1,984
Other current assets	154
Property and equipment	2,432
Identifiable intangible assets⁽¹⁾	4,000
Other non-current assets	30
Current liabilities	(4,073		)
Total identifiable net assets	14,220
Goodwill	66,701
Total cash and fair value of contingent consideration	$	80,921


(1)	The following table summarizes the amounts and useful lives assigned to identifiable intangible assets (in thousands):



	Weighted- Average Useful Lives	Amounts Recognized at the Closing Date
Customer relationships	5 mo. - 3 years	$	2,000
Trademarks	23 months	1,000
Non-compete agreements	1 year	1,000
Total identifiable intangible assets acquired		$	4,000

DISCONTINUED OPERATIONS (Tables)

12 Months Ended

Dec. 31, 2015

PBM Services

Discontinued Operations

Summary of Carrying Value of Net Assets, Segment One

The operating results included in discontinued operations of the PBM Business for the years ended December 31, 2015, 2014 and 2013 are summarized as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Revenue	$	44,375		$	61,401		$	72,986
Gross profit	$	9,763		$	17,635		$	42,819
Other operating expenses	5,444			10,878			26,797
Bad debt expense	(45		)	27			109
Income (loss) from operations	4,364			6,730			15,913
Gain on sale before income taxes	(11,424		)	—			—
Financial advisory fee and legal expenses	1,731			—			—
Other income and expenses, net	1,898			(6		)	—
Income (loss) before income taxes	12,159			6,736			15,913
Income tax expense (benefit)	206			198			1,263
Income (loss) from discontinued operations, net of income taxes	$	11,953		$	6,538		$	14,650

As of the August 27, 2015 closing date of the sale of the PBM Business, the carrying value of the net assets of the PBM Business was as follows (in thousands):



	Carrying Value
Net accounts receivable	$	7,163
Total current assets	7,163
Property and equipment, net	175
Goodwill	12,744
Total assets	20,082
Amounts due to plan sponsors	6,950
Total liabilities	6,950
Net assets	$	13,132

Home Health Services

Discontinued Operations

Summary of Carrying Value of Net Assets, Segment One

As of the March 31, 2014 closing date of the sale of the Home Health Business, the carrying value of the net assets of the Subject Companies was as follows (in thousands):



	Carrying Value
Net accounts receivable	$	12,597
Prepaid expenses and other current assets	242
Total current assets	12,839
Property and equipment, net	402
Goodwill	33,784
Intangible assets	15,400
Other non-current assets	28
Total assets	62,453
Accounts payable	673
Amounts due to plan sponsors	229
Accrued expenses and other current liabilities	3,008
Total liabilities	3,910
Net assets	$	58,543

Summary of Operating Results

The operating results included in discontinued operations of the Home Health Business for the years ended December 31, 2015, 2014 and 2013 are summarized as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Revenue	$	—		$	18,551		$	72,737
Gross profit	$	—		$	6,918		$	28,201
Other operating expenses	417			8,219			23,464
Bad debt expense	—			902			1,338
Income (loss) from operations	(417		)	(2,203		)	3,399
Gain on sale before income taxes	—			(2,067		)	—
Financial advisor fee and legal expenses	—			2,875			—
Impairment of assets	—			452			—
Other costs and expenses	861			47			(1		)
Income (loss) before income taxes	(1,278		)	(3,510		)	3,400
Income tax expense (benefit)	—			(4,257		)	15
Income from discontinued operations, net of income taxes	$	(1,278	)	$	747		$	3,385

Pharmacy Services Asset Sale

Discontinued Operations

Summary of Operating Results



	Year Ended December 31,
	2015			2014			2013
Revenue	$	—		$	—		$	(75	)
Gross profit	$	—		$	(439	)	$	(519	)
Other operating expenses	4,485			3,995			7,118
Legal fees and settlement expense	1,312			—			15,000
Other (income) expense, including gain on sale	1,157			399			(6,589		)
Income (loss) from discontinued operations, net of income taxes	$	(6,954	)	$	(4,833	)	$	(16,048	)

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

+ Details

GOODWILL AND INTANGIBLE ASSETS (Tables)

12 Months Ended

Dec. 31, 2015

Goodwill and Intangible Assets Disclosure [Abstract]

Goodwill by operating and reportable segment

Goodwill, and the changes in the carrying amount of goodwill for the years ended December 31, 2015 and 2014, are as follows (in thousands):



	Infusion Services
Balance at December 31, 2013	$	558,593
Acquisitions	—
Other adjustments	1,986
Balance at December 31, 2014	560,579
Acquisitions	—
Impairment	(251,850		)
Balance at December 31, 2015	$	308,729

Intangible assets

Intangible assets consisted of the following as of December 31, 2015 and 2014 (in thousands):



	December 31, 2015							December 31, 2014
	Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount		Gross Carrying Amount		Accumulated Amortization			Net Carrying Amount
Finite Lived Assets
Infusion customer relationships	$	25,650	$	(20,789	)	$	4,861	$	25,650	$	(16,615	)	$	9,035
Infusion trademarks	6,200		(6,200		)	—		6,200		(5,333		)	867
Non-compete agreements	1,500		(1,233		)	267		1,500		(1,133		)	367
	$	33,350	$	(28,222	)	$	5,128	$	33,350	$	(23,081	)	$	10,269

Finite lived intangible assets estimated useful lives

Finite lived intangible assets are amortized on a straight-line basis over their estimated useful lives as follows:



	Estimated Useful Life
Infusion customer relationships	5	months	-	4	years
Infusion trademarks	23	months	-	3	years
Non-compete agreements	1	year	-	5	years

Estimated amortization expense

Amortization expense is expected to be the following (in thousands):



Year ending December 31,	Estimated Amortization
2016	$	3,078
2017	1,983
2018	67
2019	—
2020	—
Thereafter	—
Total estimated amortization expense	$	5,128

STATEMENTS OF OPERATIONS DISCLOSURE (Tables)

12 Months Ended

Dec. 31, 2015

Restructuring and Related Activities [Abstract]

Acquisition, Integration, Restructuring, And Other Expenses

Restructuring, integration, and other expenses, net in the Consolidated Statements of Operations for the years ended December 31, 2015, 2014, and 2013 consisted of the following (in thousands):



	Year Ended December 31,
	2015		2014			2013
Restructuring expense	$	22,635	$	19,646		$	7,718
Integration expenses	1,740		17,924			16,130
Change in fair value of contingent consideration	30		(7,364		)	(5,786		)
Total restructuring, integration, and other expense, net	24,405		30,206			18,062

PROPERTY AND EQUIPMENT (Tables)

12 Months Ended

Dec. 31, 2015

Property, Plant and Equipment [Abstract]

Property and equipment

Property and equipment consists of the following (in thousands):



	December 31,
	2015			2014
Computer and office equipment	$	22,561		$	22,662
Software capitalized for internal use	15,600			14,914
Vehicles	1,938			2,106
Medical equipment	28,423			27,668
Work in progress	6,624			3,287
Furniture and fixtures	4,543			4,487
Leasehold improvements	14,285			13,690
Property and equipment, gross	93,974			88,814
Less: Accumulated depreciation	(62,035		)	(50,643		)
Property and equipment, net	$	31,939		$	38,171

DEBT (Tables)

12 Months Ended

Dec. 31, 2015

Debt Disclosure [Abstract]

Schedule of Debt

As of December 31, 2015 and 2014 the Company’s debt consisted of the following (in thousands):



	December 31,
	2015		2014
Revolving Credit Facility	$	15,000	$	5,000
Term Loan Facilities	222,757		222,757
2021 Notes, net of unamortized discount	196,038		195,462
Capital leases	189		584
Total Debt	433,984		423,803
Less: Current portion	27,665		5,395
Long-term debt, net of current portion	$	406,319	$	418,408

Schedule of Carrying Value and Estimated Fair Value

The following details our financial instruments where the carrying value and the fair value differ:



Financial Instrument	Carrying Value as of December 31, 2015		Markets for Identical Item (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)
Term Loan Facilities	$	222,757	$	—	$	196,500	$	—
2021 Notes	196,038		—		167,650		—
Total	$	418,795	$	—	$	364,150	$	—

Estimated future maturities of debt

The estimated future maturities of the Company’s long-term debt as of December 31, 2015, are as follows (in thousands):



Year Ending December 31,	Amount
2016	$	12,550
2017	12,550
2018	12,550
2019	12,550
2020	172,557
Thereafter	200,000
Total future maturities	$	422,757

Interest expense, net

Interest expense, including loss on extinguishment of debt, consisted of the following for each of the three years ended December 31, 2015, 2014 and 2013 (in thousands):



	Year ended December 31,
	2015			2014			2013
Revolving Credit Facility	$	2,190		$	1,829		$	873
Term Loan Facilities	14,680			16,820			10,313
2021 Notes	17,603			15,926			—
Prior Credit Facility	—			—			765
2015 Notes	—			—			13,960
Amortization of deferred financing costs	2,864			3,691			2,259
Amortization of debt discount	576			462			—
Loss on extinguishment of debt	—			2,373			15,898
Expense allocated to discontinued operations	—			—			41
Other, net	(600		)	(183		)	21
Interest expense, net	$	37,313		$	40,918		$	44,130

COMMITMENTS AND CONTINGENCIES (Tables)

12 Months Ended

Dec. 31, 2015

Commitments and Contingencies Disclosure [Abstract]

Future minimum lease payments under operating and capital leases

As of December 31, 2015, future minimum lease payments under operating and capital leases were as follows (in thousands):



	Operating Leases		Capital Leases		Total
2016	$	8,271	$	122	$	8,393
2017	7,267		62		7,329
2018	5,284		11		5,295
2019	3,048		—		3,048
2020	1,565		—		1,565
2021 and Thereafter	1,111		—		1,111
Total Future Minimum Lease Payments	$	26,546	$	195	$	26,741

INCOME TAXES (Tables)

12 Months Ended

Dec. 31, 2015

Income Tax Disclosure [Abstract]

Federal and state income tax expense (benefit)

The Company’s federal and state income tax provision (benefit) from continuing operations is summarized in the following table (in thousands):



	Year Ended December 31,
	2015			2014			2013
Current
Federal	$	—		$	(886	)	$	(866	)
State	(76		)	(41		)	(1,412		)
Total current	(76		)	(927		)	(2,278		)
Deferred
Federal	(18,293		)	9,951			3,281
State	(3,163		)	2,169			257
Total deferred	(21,456		)	12,120			3,538
Total tax provision (benefit)	$	(21,532	)	$	11,193		$	1,260

Effect of temporary differences that give rise to significant portion of deferred taxes

The effect of temporary differences that give rise to a significant portion of deferred taxes is as follows (in thousands):



	December 31,
	2015			2014
Deferred tax assets:
Reserves not currently deductible	$	27,467		$	28,387
Net operating loss carryforwards	91,350			65,097
Goodwill and intangibles (tax deductible)	34,983			8,458
Accrued expenses	654			32
Property basis differences	1,021			301
Stock based compensation	8,245			8,201
Other	715			610
Total deferred tax assets	164,435			111,086
Deferred tax liabilities:
Indefinite-lived goodwill and intangibles	(236		)	(18,118		)
Less: valuation allowance	(164,435		)	(111,086		)
Net deferred tax liability	(236		)	(18,118		)
Deferred taxes	$	(236	)	$	(18,118	)

Reconciliation of the statutory rate to the effective income tax rate

The Company’s reconciliation of the statutory rate to the effective income tax rate from continuing operations is as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Tax (benefit) provision at statutory rate	$	(113,736	)	$	(48,554	)	$	(24,633	)
State tax (benefit) provision, net of federal taxes	(8,356		)	(3,959		)	(3,239		)
Valuation allowance changes affecting income tax expense	57,023			63,641			29,805
Change in tax contingencies	(37		)	(109		)	(1,157		)
Non-deductible transaction costs	—			—			317
Goodwill impairment	43,362			—			—
Other	212			174			167
Tax provision (benefit)	$	(21,532	)	$	11,193		$	1,260

Reconciliation of beginning and ending amount of gross unrecognized tax benefits

A reconciliation of the beginning and ending amount of gross unrecognized tax benefits is as follows (in thousands):



	Year Ended December 31,
	2015			2014			2013
Unrecognized tax benefits balance at January 1,	$	1,096		$	1,172		$	2,754
Lapse of statute of limitations	(29		)	(76		)	(1,582		)
Unrecognized tax benefits balance at December 31,	$	1,067		$	1,096		$	1,172

STOCK-BASED COMPENSATION (Tables)

12 Months Ended

Dec. 31, 2015

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Weighted-average assumptions

The assumptions used to compute the fair value of options for the years ending December 31, 2015, 2014 and 2013 were:



	2015		2014		2013
Expected volatility	62.3	%	61.0	%	61.8	%
Risk-free interest rate	2.20	%	2.50	%	2.13	%
Expected life of options	8.9 years		5.7 years		5.5 years
Dividend rate	—		—		—

Stock option activity

A summary of stock option activity for the Equity Compensation Plans through December 31, 2015 was as follows:



	Options		Weighted Average Exercise Price		Aggregate Intrinsic Value (thousands)		Weighted Average Remaining Contractual Life
Balance at December 31, 2014	6,837,006		$	7.65	$	4,150	7.4 years
Granted	1,436,500		$	3.02
Exercised	(600	)	$	2.73
Forfeited and expired	(1,637,309	)	$	8.42
Balance at December 31, 2015	6,635,597		$	6.46	$	2	5.8 years
Outstanding options less expected forfeitures at December 31, 2015	6,335,391		$	6.51	$	2	5.7 years
Exercisable at December 31, 2015	4,384,108		$	7.05	$	2	4.2 years

Outstanding and exercisable stock options

The following table outlines our outstanding and exercisable stock options as of December 31, 2015:



	Options Outstanding				Options Exercisable
Range of Option Exercise Price	Outstanding Options	Weighted Average Exercise Price		Weighted Average Remaining Contractual Life	Options Exercisable	Weighted Average Exercise Price
$1.71 - $4.13	1,567,250	$	2.66	8.0 years	348,250	$	2.47
$4.14 - $8.25	3,885,681	$	6.51	5.0 years	3,110,026	$	6.34
$8.26- $12.38	762,500	$	10.39	5.5 years	619,168	$	10.25
$12.39 - $14.44	412,166	$	12.91	6.0 years	301,331	$	12.9
$14.45 - $18.57	8,000	$	16.63	7.6 years	5,333	$	16.63
All options	6,635,597	$	6.46	5.8 years	4,384,108	$	7.05

Restricted stock award activity

A summary of restricted stock award activity through December 31, 2015 was as follows:



	Restricted Stock		Weighted Average Grant Date Fair Value		Weighted Average Remaining Recognition Period
Balance at December 31, 2014	179,997		$	9.31	0.4 years
Granted	68,000		$	3.55
Awards Vested	(147,000	)	$	4.92
Canceled	(50,999	)	$	11.77
Balance at December 31, 2015	49,998		$	11.89	2.2 years

SAR activity

A summary of SAR activity through December 31, 2015 was as follows:



	Stock Appreciation Rights		Weighted Average Exercise Price		Weighted Average Remaining Recognition Period
Balance at December 31, 2014	320,000		$	6.65	0.3 years
Granted	—		$	—
Exercised	—		$	—
Canceled	(20,000	)	$	9.16
Balance at December 31, 2015	300,000		$	6.48	0.0 years

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Tables)

12 Months Ended

Dec. 31, 2015

Selected Quarterly Financial Information [Abstract]

Schedule of Quarterly Financial Information

A summary of unaudited quarterly financial information for the years ended December 31, 2015 and 2014 is as follows (in thousands except per share data):



	First Quarter			Second Quarter			Third Quarter			Fourth Quarter
Year ended December 31, 2015
Revenue	$	244,357		$	246,897		$	247,224		$	243,745
Gross profit	64,955			64,818			65,233			65,909
Loss from continuing operations, before income taxes	(15,367		)	(264,822		)	(28,791		)	(15,980		)
Net loss from discontinued operations, net of income taxes	(2,379		)	94			7,457			(1,451		)
Net loss	$	(19,674	)	$	(244,807	)	$	(16,783	)	$	(18,443	)

Loss per share from continuing operations, basic and diluted	$	(0.28	)	$	(3.62	)	$	(0.38	)	$	(0.28	)
Loss per share from discontinued operations, basic and diluted	(0.03		)	—			0.11			(0.02		)
Loss per share, basic and diluted	$	(0.31	)	$	(3.62	)	$	(0.27	)	$	(0.30	)

Year ended December 31, 2014
Revenue	$	221,341		$	230,111		$	231,458		$	239,744
Gross profit	62,139			62,249			62,687			63,678
Loss from continuing operations, before income taxes	(23,606		)	(17,221		)	(37,274		)	(60,626		)
Net income (loss) from discontinued operations, net of income taxes	1,783			466			494			(291		)
Net loss	$	(25,314	)	$	(19,818	)	$	(38,710	)	$	(63,626	)

Loss per share from continuing operations, basic and diluted	$	(0.40	)	$	(0.30	)	$	(0.57	)	$	(0.92	)
Income (loss) per share from discontinued operations, basic and diluted	0.03			0.01			0.01			—
Loss per share, basic and diluted	$	(0.37	)	$	(0.29	)	$	(0.56	)	$	(0.92	)

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Cash and Cash Equivalents (Details)	12 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Maximum maturity for classification as cash equivalents (in months)	3 months

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Allowance for Doubtful Accounts (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2015 USD ($) accounts_receivable	Dec. 31, 2014 USD ($)
Change in Estimate of the Collectability of Accounts Receivable
Decrease in allowance for doubtful accounts		$ 6,700
Allowance for doubtful accounts, percentage of accounts receivable	35.50%	33.50%
Number of primary overall types of accounts receivable \| accounts_receivable	3
Gross accounts receivable	$ 168,054	$ 198,061
Allowance for doubtful accounts	(59,689)	(66,405)
Net accounts receivable	108,365	131,656
0-180 Days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	128,315	139,150
Over 180 Days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	39,739	58,911
Government
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	31,313	38,848
Government \| 0-180 Days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	19,944	25,812
Government \| Over 180 Days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	11,369	13,036
Commercial
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	125,702	143,752
Commercial \| 0-180 Days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	103,357	108,439
Commercial \| Over 180 Days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	22,345	35,313
Patient
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	11,039	15,461
Patient \| 0-180 Days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	5,014	4,899
Patient \| Over 180 Days
Change in Estimate of the Collectability of Accounts Receivable
Gross accounts receivable	$ 6,025	$ 10,562

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Property and Equipment (Details)	12 Months Ended
	Dec. 31, 2015
Computer hardware and software \| Minimum
Property and Equipment
Useful Life	3 years
Computer hardware and software \| Maximum
Property and Equipment
Useful Life	5 years
Office equipment
Property and Equipment
Useful Life	5 years
Vehicles \| Minimum
Property and Equipment
Useful Life	4 years
Vehicles \| Maximum
Property and Equipment
Useful Life	5 years
Medical equipment \| Minimum
Property and Equipment
Useful Life	13 months
Medical equipment \| Maximum
Property and Equipment
Useful Life	5 years
Furniture and fixtures
Property and Equipment
Useful Life	5 years

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Revenue Recognition (Details)	12 Months Ended
	Dec. 31, 2015
Government
Accounts, Notes, Loans and Financing Receivable [Line Items]
Revenue recognition period for Medicare Prospective Payment System program	60 days

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Accounting for Stock-Based Compensation (Details)	Dec. 31, 2015 stock_compensation_plan
Accounting Policies [Abstract]
Number of stock-based employee compensation plans	2

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES - Recent Accounting Pronouncements (Details) - Effect $ in Millions	Dec. 31, 2015 USD ($)
Current Assets
New Accounting Pronouncement, Early Adoption [Line Items]
Deferred finance costs, net	$ 3.3
Noncurrent Assets
New Accounting Pronouncement, Early Adoption [Line Items]
Deferred finance costs, net	$ 12.6

LOSS PER SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Earnings Per Share [Abstract]
Loss from continuing operations, net of income taxes									$ (303,428)	$ (149,920)	$ (71,641)
Income from discontinued operations, net of income taxes	$ (1,451)	$ 7,457	$ 94	$ (2,379)	$ (291)	$ 494	$ 466	$ 1,783	3,721	2,452	1,987
Net income (loss)	$ (18,443)	$ (16,783)	$ (244,807)	$ (19,674)	$ (63,626)	$ (38,710)	$ (19,818)	$ (25,314)	(299,707)	(147,468)	(69,654)
Accrued dividends on Series A Preferred Stock									(6,120)	0	0
Deemed dividends on Series A Preferred Stock									(3,690)	0	0
Loss attributable to common stockholders									$ (309,517)	$ (147,468)	$ (69,654)
Denominator - Basic and Diluted:
Weighted average number of common shares outstanding									68,710	68,476	64,560
Loss Per Common Share:
Loss from continuing operations, basic and diluted (in USD per share)	$ (0.28)	$ (0.38)	$ (3.62)	$ (0.28)	$ (0.92)	$ (0.57)	$ (0.30)	$ (0.40)	$ (4.56)	$ (2.19)	$ (1.11)
Income (loss) from discontinued operations, basic and diluted (in USD per share)	(0.02)	0.11	0.00	(0.03)	0.00	0.01	0.01	0.03	0.05	0.04	0.03
Income (loss) per common share, basic and diluted (in USD per share)	(0.30)	$ (0.27)	$ (3.62)	$ (0.31)	(0.92)	$ (0.56)	$ (0.29)	$ (0.37)	(4.51)	(2.15)	$ (1.08)
Common stock, par value (in USD per share)	0.0001				0.0001				0.0001	0.0001
Preferred stock, par value (in USD per share)	$ 0.0001				$ 0.0001				$ 0.0001	$ 0.0001

STOCKHOLDERS' (DEFICIT) EQUITY - Securities Purchase Agreement (Details) - USD ($) $ / shares in Units, $ in Thousands			12 Months Ended
	Jul. 27, 2015	Mar. 09, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Mar. 31, 2010
Class of Stock [Line Items]
Series A Preferred Stock		$ 59,355
PIPE Warrants		3,145
Total Investment	$ 1,100	$ 62,500
Series A preferred stock, shares issued (in shares)			635,822	0
Warrants, exercise price (in dollars per share)						$ 10.00
Net proceeds used to repay credit facility			$ 193,663	$ 279,703	$ 409,559
Percentage of proceeds used to repay debt			77.00%
Senior Secured Revolving Credit Facility \| Credit Facility
Class of Stock [Line Items]
Net proceeds used to repay credit facility			$ 45,300
Series A Preferred Stock
Class of Stock [Line Items]
Series A preferred stock, shares issued (in shares)	10,822	625,000
Preferred stock offering price (in dollars per share)		$ 100.00
Price of Warrants (in dollars per share)		$ 5.17
Cap on ownership after conversion, percent			19.99%
Fair value assumptions, volatility (as a percent)		55.00%
Fair value assumptions, risk free interest rate (as a percent)		0.92%
Fair value assumptions, dividend yield (as a percent)		11.50%
Class A Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares)	31,025	1,800,000
Price of Warrants (in dollars per share)	$ 5.17
Warrants, exercise price (in dollars per share)		$ 5.17
Class B Warrants
Class of Stock [Line Items]
Preferred stock offering price (in dollars per share)	$ 100
Warrants outstanding (in shares)	31,025	1,800,000
Warrants, exercise price (in dollars per share)	$ 6.45	$ 6.45
Class A Warrants Prior to Addendum
Class of Stock [Line Items]
Warrants, exercise price (in dollars per share)		5.295
Class B Warrants Prior to Addendum
Class of Stock [Line Items]
Warrants, exercise price (in dollars per share)		$ 6.595
2015 Warrants
Class of Stock [Line Items]
Proceeds from modification of warrant terms		$ 500
Fair value assumptions, volatility (as a percent)		55.00%
Fair value assumptions, risk free interest rate (as a percent)		0.92%

STOCKHOLDERS' (DEFICIT) EQUITY - Series A Convertible Preferred Stock (Details) $ / shares in Units, $ in Thousands		12 Months Ended
	Mar. 09, 2015 USD ($) $ / shares shares	Dec. 31, 2015 USD ($) committee executive shares	Jul. 27, 2015 shares	Dec. 31, 2014 USD ($) shares
Class of Stock [Line Items]
Series A preferred stock, shares authorized (in shares) \| shares	825,000	825,000		0
Series A preferred stock, shares issued (in shares) \| shares		635,822		0
Liquidation preference (in dollars per share) \| $ / shares	$ 100.00
PIPE transaction issuance costs	$ 4,000
Series A preferred stock, liquidation preference		$ 69,702		$ 0
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 635,822 shares issued and outstanding; and, $69,702 liquidation preference as of December 31, 2015. No convertible preferred stock was authorized or outstanding as of December 31, 2014.		$ 62,918		0
2015 Warrants
Class of Stock [Line Items]
PIPE transaction issuance costs	$ 200
Convertible Preferred Stock
Class of Stock [Line Items]
Series A preferred stock, shares issued (in shares) \| shares	625,000		10,822
Preferred stock offering price (in dollars per share) \| $ / shares	$ 100.00
Price of Warrants (in dollars per share) \| $ / shares	$ 5.17
Noncumulative cash dividend rate		8.50%
Additional liquidation preference multiple rate		11.50%
Number of committees board members appointed to		5.00%
Number of members holders may elect to board \| executive		1
Voting threshold to elect board members \| committee		2
PIPE transaction issuance costs	$ 3,800
Series A preferred stock, liquidation preference	62,500	$ 68,600
Series A convertible preferred stock, $.0001 par value; 825,000 shares authorized; 635,822 shares issued and outstanding; and, $69,702 liquidation preference as of December 31, 2015. No convertible preferred stock was authorized or outstanding as of December 31, 2014.	52,380	$ 62,918		$ 53,108
Warrant Value \| Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, discount on issuance	(3,145)
Beneficial Conversion Feature \| Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, discount on issuance	(3,145)
Issuance Costs \| Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, discount on issuance	$ (3,830)

STOCKHOLDERS' (DEFICIT) EQUITY - PIPE Warrants (Details) - USD ($) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Mar. 09, 2015	Mar. 31, 2010	Dec. 31, 2015	Jul. 27, 2015
Class of Stock [Line Items]
Warrants, exercise price (in dollars per share)		$ 10.00
Warrants, exercise term (in years)		5 years
Class of Warrant or Right, Exercise Price of Warrants or Rights, Percentage of Market Price			85.00%
Period registration rights become effective			1 year
Fair value allocated to PIPE Warrants	$ 3,145
Class A Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares)	1,800,000			31,025
Warrants, exercise price (in dollars per share)	$ 5.17
Class B Warrants Prior to Addendum
Class of Stock [Line Items]
Warrants, exercise price (in dollars per share)	$ 6.595
Class B Warrants
Class of Stock [Line Items]
Warrants outstanding (in shares)	1,800,000			31,025
Warrants, exercise price (in dollars per share)	$ 6.45			$ 6.45
Class A Warrants Prior to Addendum
Class of Stock [Line Items]
Warrants, exercise price (in dollars per share)	$ 5.295
2015 Warrants
Class of Stock [Line Items]
Proceeds from modification of warrant terms	$ 500
Warrants, exercise term (in years)			10 years
Discount related to issuance costs	(203)
Carrying value of PIPE Warrants	$ 2,942

STOCKHOLDERS' (DEFICIT) EQUITY - Rights Offering (Details) - USD ($) $ / shares in Units, $ in Thousands	Jul. 27, 2015	Mar. 09, 2015	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2010
Class of Stock [Line Items]
Preferred stock, par value (in USD per share)			$ 0.0001	$ 0.0001
Warrants, exercise price (in dollars per share)					$ 10.00
Series A preferred stock, shares issued (in shares)			635,822	0
Proceeds raised from rights offering	$ 1,100	$ 62,500
Convertible Preferred Stock
Class of Stock [Line Items]
Preferred stock, par value (in USD per share)	$ 5.17
Price of Warrants (in dollars per share)		$ 5.17
Series A preferred stock, shares issued (in shares)	10,822	625,000
Preferred stock offering price (in dollars per share)		$ 100.00
Class B Warrants
Class of Stock [Line Items]
Warrants, exercise price (in dollars per share)	$ 6.45	$ 6.45
Warrants outstanding (in shares)	31,025	1,800,000
Preferred stock offering price (in dollars per share)	$ 100
Class A Warrants
Class of Stock [Line Items]
Price of Warrants (in dollars per share)	$ 5.17
Warrants, exercise price (in dollars per share)		$ 5.17
Warrants outstanding (in shares)	31,025	1,800,000

STOCKHOLDERS' (DEFICIT) EQUITY - Carrying Value of Series A Preferred Stock (Details) - USD ($) $ in Thousands		12 Months Ended
	Mar. 09, 2015	Dec. 31, 2015
Class of Stock [Line Items]
Series A preferred stock carrying value, at issuance		$ 0
Series A preferred stock carrying value, at end of period		62,918
Convertible Preferred Stock
Class of Stock [Line Items]
Fair value assumptions, dividend yield (as a percent)	11.50%
Series A preferred stock carrying value, at issuance		53,108
Dividends Recorded		6,120
Series A preferred stock carrying value, at end of period	$ 52,380	62,918
Beneficial Conversion Feature \| Convertible Preferred Stock
Class of Stock [Line Items]
Accretion of discount related to beneficial conversion feature		$ 3,690

STOCKHOLDERS' (DEFICIT) EQUITY - Treasury Stock (Details) - shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Stockholders' Equity Attributable to Parent [Abstract]
Treasury stock surrendered to satisfy tax withholding obligations (in shares)	16,952	54,579
Treasury stock (in shares)	2,654,051	2,637,099
Treasury shares acquired during the period	0	0
Treasury shares issued during the period	0	0

STOCKHOLDERS' (DEFICIT) EQUITY - Common Stock Purchase Warrants (Details) - $ / shares	1 Months Ended	12 Months Ended
	Mar. 31, 2010	Dec. 31, 2015
Stockholders' Equity Attributable to Parent [Abstract]
Warrants issued (in shares)	3,400,000
Warrants, exercise term (in years)	5 years
Warrants, exercise price (in dollars per share)	$ 10.00
Warrants exercised		0

ACQUISITIONS - CarePoint Business (Details)		12 Months Ended
ACQUISITIONS - CarePoint Business (Details)	Aug. 23, 2013 USD ($) state patient location	Dec. 31, 2015 USD ($)
Minimum \| Customer relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives		5 months
Minimum \| Trademarks
Business Acquisition [Line Items]
Weighted- Average Useful Lives		23 months
Minimum \| Non-compete agreements
Business Acquisition [Line Items]
Weighted- Average Useful Lives		1 year
Maximum \| Customer relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives		4 years
Maximum \| Trademarks
Business Acquisition [Line Items]
Weighted- Average Useful Lives		3 years
Maximum \| Non-compete agreements
Business Acquisition [Line Items]
Weighted- Average Useful Lives		5 years
CarePoint Partners Holding LLC
Business Acquisition [Line Items]
Number of patients \| patient	20,500
Number of locations \| location	28
Number of states with sites of service in East Coast and Gulf Coat regions \| state	9
Cash purchase price paid	$ 211,100,000
Net working capital adjustments due	(1,800,000)
Total possible contingent consideration increase	10,000,000
Initial fair value of contingent consideration	9,800,000
Additional expense to be recorded for contingent consideration if earned		$ 5,400,000
Additional income to be recorded if contingent consideration is reversed		4,600,000
Identifiable intangible assets	16,700,000
Fair value of contingent consideration		$ 4,600,000
CarePoint Partners Holding LLC \| Customer relationships
Business Acquisition [Line Items]
Identifiable intangible assets	$ 13,600,000
CarePoint Partners Holding LLC \| Trademarks
Business Acquisition [Line Items]
Weighted- Average Useful Lives	2 years
Identifiable intangible assets	$ 2,600,000
CarePoint Partners Holding LLC \| Non-compete agreements
Business Acquisition [Line Items]
Weighted- Average Useful Lives	5 years
Identifiable intangible assets	$ 500,000
CarePoint Partners Holding LLC \| Minimum \| Customer relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives	2 years
CarePoint Partners Holding LLC \| Maximum \| Customer relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives	4 years
CarePoint Partners Holding LLC \| Senior Credit Facilities
Business Acquisition [Line Items]
Cash payment funded with borrowings	$ 150,000,000

ACQUISITIONS - HomeChoice Partners, Inc. (Details) patient in Thousands		12 Months Ended
	Feb. 01, 2013 USD ($) patient location	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Minimum \| Customer relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives		5 months
Minimum \| Trademarks
Business Acquisition [Line Items]
Weighted- Average Useful Lives		23 months
Minimum \| Non-compete agreements
Business Acquisition [Line Items]
Weighted- Average Useful Lives		1 year
Maximum \| Customer relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives		4 years
Maximum \| Trademarks
Business Acquisition [Line Items]
Weighted- Average Useful Lives		3 years
Maximum \| Non-compete agreements
Business Acquisition [Line Items]
Weighted- Average Useful Lives		5 years
HomeChoice Partners, Inc.
Business Acquisition [Line Items]
Ownership interest acquired (as a percent)	100.00%
Number of patients \| patient	15
Number of infusion pharmacy locations \| location	14
Cash purchase price paid	$ 72,900,000
First year contingent consideration maximum	10,000,000.0
Second year contingent consideration maximum	10,000,000
Total possible contingent consideration increase	20,000,000
Initial fair value of contingent consideration	8,000,000
Fair value of contingent consideration		$ 0
Reduction in fair value of contingent consideration		$ 0	$ 2,100,000	$ 5,900,000
Identifiable intangible assets	4,000,000
HomeChoice Partners, Inc. \| Customer relationships
Business Acquisition [Line Items]
Identifiable intangible assets	2,000,000
HomeChoice Partners, Inc. \| Trademarks
Business Acquisition [Line Items]
Identifiable intangible assets	$ 1,000,000
Weighted- Average Useful Lives	23 months
HomeChoice Partners, Inc. \| Non-compete agreements
Business Acquisition [Line Items]
Identifiable intangible assets	$ 1,000,000
Weighted- Average Useful Lives	1 year
HomeChoice Partners, Inc. \| Minimum \| Customer relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives	5 months
HomeChoice Partners, Inc. \| Maximum
Business Acquisition [Line Items]
Probability of payout assigned to contingent consideration (as a percent)	50.00%
HomeChoice Partners, Inc. \| Maximum \| Customer relationships
Business Acquisition [Line Items]
Weighted- Average Useful Lives	3 years

ACQUISITIONS - Assets Acquired and Liabilities Assumed (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Aug. 23, 2013	Feb. 01, 2013
Business Acquisition [Line Items]
Goodwill	$ 308,729	$ 560,579
CarePoint Partners Holding LLC
Business Acquisition [Line Items]
Cash			$ 14
Accounts receivable			15,917
Inventories			3,184
Other current assets			215
Property and equipment			3,266
Identifiable intangible assets			16,700
Current liabilities			(8,697)
Non-current liabilities			(721)
Total identifiable net assets			29,878
Goodwill			189,214
Total cash and fair value of contingent consideration			$ 219,092
HomeChoice Partners, Inc.
Business Acquisition [Line Items]
Accounts receivable				$ 9,693
Inventories				1,984
Other current assets				154
Property and equipment				2,432
Identifiable intangible assets				4,000
Other non-current assets				30
Current liabilities				(4,073)
Total identifiable net assets				14,220
Goodwill				66,701
Total cash and fair value of contingent consideration				$ 80,921

ACQUISITIONS - Acquisition and Integration Costs (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Business Combination, Separately Recognized Transactions [Line Items]
Total	$ 22,635	$ 19,646	$ 7,718
Acquisition and Integration Costs \| All Current Acquirees
Business Combination, Separately Recognized Transactions [Line Items]
Legal and professional fees	1,033	6,931	5,113
Financial advisory fees	0	0	2,413
Employee costs including redundant salaries and benefits and severance	0	2,016	3,554
Facilities consolidation and discontinuation	488	1,401	1,621
Bad debt expense and contractual adjustments related to acquired accounts receivable	0	5,430	0
Legal settlement	0	334	2,300
Other	219	1,812	1,129
Total	$ 1,740	$ 17,924	$ 16,130

DISCONTINUED OPERATIONS - Additional Information (Details) - USD ($) $ in Thousands			1 Months Ended	12 Months Ended
	Aug. 27, 2015	Mar. 31, 2014	Jan. 31, 2016	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Oct. 20, 2015
Discontinued Operations
Total consideration received	$ 24,600
PBM Services
Discontinued Operations
Gain on sale before income taxes				$ (11,424)	$ 0	$ 0
Reduction in total consideration							$ 1,000
Home Health Services
Discontinued Operations
Gain on sale before income taxes				$ 0	$ (2,067)	$ 0
Amendment No. 1 \| Home Health Services
Discontinued Operations
Total consideration received		$ 59,500
Additional payment received		1,100
Final Purchase Price received		$ 60,600
Subsequent Event
Discontinued Operations
Payments for legal settlements			$ 6,200
Fees paid to Relator			$ 200

DISCONTINUED OPERATIONS - Carrying Value of Net Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Aug. 27, 2015	Dec. 31, 2014	Mar. 31, 2014
Discontinued Operations
Total current assets	$ 0		$ 9,550
PBM Services
Discontinued Operations
Net accounts receivable		$ 7,163
Total current assets		7,163
Property and equipment, net		175
Goodwill		12,744	$ 12,700
Total assets		20,082
Amounts due to plan sponsors		6,950
Total liabilities		6,950
Net assets		$ 13,132
Home Health Services
Discontinued Operations
Net accounts receivable				$ 12,597
Prepaid expenses and other current assets				242
Total current assets				12,839
Property and equipment, net				402
Goodwill				33,784
Intangible assets				15,400
Other non-current assets				28
Total assets				62,453
Accounts payable				673
Amounts due to plan sponsors				229
Accrued expenses and other current liabilities				3,008
Total liabilities				3,910
Net assets				$ 58,543

DISCONTINUED OPERATIONS - Summary of Operating Results (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Discontinued Operations
Bad debt expense	$ 41,042	$ 79,547	$ 19,516
PBM Services
Discontinued Operations
Revenue	(44,375)	(61,401)	(72,986)
Gross profit	9,763	17,635	42,819
Other operating expenses	5,444	10,878	26,797
Bad debt expense	(45)	27	109
Income (loss) from operations	4,364	6,730	15,913
Gain on sale before income taxes	(11,424)	0	0
Financial advisory fee and legal expenses	1,731	0	0
Other income and expenses, net	1,898	(6)	0
Income (loss) before income taxes	12,159	6,736	15,913
Income tax expense (benefit)	206	198	1,263
Income (loss) from discontinued operations, net of income taxes	11,953	6,538	14,650
Home Health Services
Discontinued Operations
Revenue	0	(18,551)	(72,737)
Gross profit	0	6,918	28,201
Other operating expenses	417	8,219	23,464
Bad debt expense	0	902	1,338
Income (loss) from operations	(417)	(2,203)	3,399
Gain on sale before income taxes	0	(2,067)	0
Financial advisory fee and legal expenses	0	2,875	0
Impairment of assets	0	452	0
Other income and expenses, net	861	47	(1)
Income (loss) before income taxes	(1,278)	(3,510)	3,400
Income tax expense (benefit)	0	(4,257)	15
Income (loss) from discontinued operations, net of income taxes	(1,278)	747	3,385
Pharmacy Services Asset Sale
Discontinued Operations
Revenue	0	0	(75)
Gross profit	0	(439)	(519)
Other operating expenses	4,485	3,995	7,118
Financial advisory fee and legal expenses	(1,312)	0	(15,000)
Other income and expenses, net	(1,157)	(399)	6,589
Income (loss) from discontinued operations, net of income taxes	$ (6,954)	$ (4,833)	$ (16,048)

GOODWILL AND INTANGIBLE ASSETS - Schedule of Changes in Goodwill (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Goodwill [Roll Forward]
Goodwill, beginning balance		$ 560,579
Impairment	$ (251,850)	(251,850)	$ 0	$ 0
Goodwill, ending balance		308,729	560,579
Infusion Services
Goodwill [Roll Forward]
Goodwill, beginning balance		560,579	558,593
Acquisitions		0	0
Other adjustments			1,986
Impairment		(251,850)
Goodwill, ending balance		$ 308,729	$ 560,579	$ 558,593

GOODWILL AND INTANGIBLE ASSETS - Additional Information (Details) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Sep. 30, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Aug. 27, 2015	Mar. 31, 2014
Goodwill [Line Items]
Impairment of goodwill	$ 251,850	$ 251,850	$ 0	$ 0
Depreciation and amortization expense		$ 5,100	6,600	$ 6,700
PBM Services
Goodwill [Line Items]
Goodwill included in non-current assets of discontinued operations			$ 12,700		$ 12,744
Home Health Services
Goodwill [Line Items]
Goodwill included in non-current assets of discontinued operations						$ 33,784
Goodwill \| Minimum
Goodwill [Line Items]
Growth rate		3.00%
EBITDA margin		0.06
Discount rate		9.00%
Goodwill \| Maximum
Goodwill [Line Items]
Growth rate		5.00%
EBITDA margin		0.08
Discount rate		11.00%

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 33,350	$ 33,350
Accumulated Amortization	(28,222)	(23,081)
Net Carrying Amount	5,128	10,269
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	25,650	25,650
Accumulated Amortization	(20,789)	(16,615)
Net Carrying Amount	4,861	9,035
Trademarks
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	6,200	6,200
Accumulated Amortization	(6,200)	(5,333)
Net Carrying Amount	0	867
Non-compete agreements
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,500	1,500
Accumulated Amortization	(1,233)	(1,133)
Net Carrying Amount	$ 267	$ 367

GOODWILL AND INTANGIBLE ASSETS - Finite-Lived Intangible Asset Useful Life (Details)	12 Months Ended
	Dec. 31, 2015
Customer relationships \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	5 months
Customer relationships \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	4 years
Trademarks \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	23 months
Trademarks \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	3 years
Non-compete agreements \| Minimum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	1 year
Non-compete agreements \| Maximum
Finite-Lived Intangible Assets [Line Items]
Estimated useful lives	5 years

GOODWILL AND INTANGIBLE ASSETS - Schedule of Future Amortization (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Goodwill and Intangible Assets Disclosure [Abstract]
2016	$ 3,078
2017	1,983
2018	67
2019	0
2020	0
Thereafter	0
Total estimated amortization expense	$ 5,128	$ 10,269

STATEMENTS OF OPERATIONS DISCLOSURE - Acquisition, Integration, Restructuring, and Other Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Restructuring and Related Activities [Abstract]
Restructuring expense	$ 22,635	$ 19,646	$ 7,718
Integration expenses	1,740	17,924	16,130
Change in fair value of contingent consideration	30	(7,364)	(5,786)
Total restructuring, integration, and other expense, net	$ 24,405	$ 30,206	$ 18,062

PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	12 Months Ended
PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Property and Equipment
Property and equipment, gross	$ 93,974	$ 88,814
Less: Accumulated depreciation	(62,035)	(50,643)
Property and equipment, net	31,939	38,171
Depreciation expense	22,743	22,943	$ 20,226
Depreciation related to software capitalized for internal use	2,500	2,400	1,700
Computer and office equipment
Property and Equipment
Property and equipment, gross	22,561	22,662
Software capitalized for internal use
Property and Equipment
Property and equipment, gross	15,600	14,914
Work in progress	1,800	600
Vehicles
Property and Equipment
Property and equipment, gross	1,938	2,106
Medical equipment
Property and Equipment
Property and equipment, gross	28,423	27,668
Work in progress
Property and Equipment
Property and equipment, gross	6,624	3,287
Furniture and fixtures
Property and Equipment
Property and equipment, gross	4,543	4,487
Leasehold improvements
Property and Equipment
Property and equipment, gross	14,285	13,690
Assets held under capital leases
Property and Equipment
Depreciation expense	$ 17,600	$ 16,400	$ 13,400

DEBT - Schedule of Debt (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term Debt	$ 422,757
Total Debt	433,984	$ 423,803
Less: Current portion	27,665	5,395
Long-term debt, net of current portion	406,319	418,408
Term Loan Facilities
Debt Instrument [Line Items]
Long-term Debt	222,757	222,757
2021 Notes
Debt Instrument [Line Items]
Long-term Debt	196,038	195,462
Capital Lease Obligations
Debt Instrument [Line Items]
Capital leases	189	584
Senior Credit Facilities \| Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Long-term Debt	$ 15,000	$ 5,000

DEBT - Senior Credit Facilities (Details)				12 Months Ended
DEBT - Senior Credit Facilities (Details)	Feb. 11, 2014 USD ($)	Jan. 31, 2014 USD ($)	Dec. 23, 2013 USD ($)	Dec. 31, 2015 USD ($) Quarters	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)	Aug. 06, 2015 USD ($)	Mar. 09, 2015	Mar. 31, 2014 USD ($)	Jul. 31, 2013 USD ($)	Mar. 25, 2010
Debt Instrument [Line Items]
Long-term Debt				$ 422,757,000
Percentage of proceeds to be used to repay debt								75.00%
Net proceeds used to repay credit facility				$ 193,663,000	$ 279,703,000	$ 409,559,000
Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Effective interest rate				7.75%
Repayments of Short-term Debt	$ 59,300,000				17,200,000
Repayment of Long-term Debt				$ 22,700,000
Remaining Borrowing Capacity				54,600,000
Borrowing capacity subject to leverage test				39,600,000
Senior Secured Revolving Credit Facility \| Letter of Credit
Debt Instrument [Line Items]
Long-term Line of Credit				5,400,000
Senior Credit Facilities \| Eurodollar
Debt Instrument [Line Items]
Basis Spread on Variable Rate, Minimum		5.25%
Senior Credit Facilities \| Base Rate
Debt Instrument [Line Items]
Basis Spread on Variable Rate, Minimum		4.25%
2021 Notes
Debt Instrument [Line Items]
Aggregate principal debt amount	$ 200,000,000.0
Long-term Debt				$ 196,038,000	195,462,000
Stated interest rate	8.875%
Proceeds from Issuance of Long-term Debt	$ 194,500,000
Term Loan Facilities
Debt Instrument [Line Items]
Effective interest rate				6.50%
Long-term Debt				$ 222,757,000	222,757,000
Repayments of Short-term Debt					$ 37,000,000
Early Repayment of Senior Debt	$ 135,200,000
Credit Facility \| Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Maximum Borrowing Capacity										$ 75,000,000
Periodic payment, principal to be paid quarterly				3,100,000
Periodic payment, balloon payment to be paid				166,300,000
Net proceeds used to repay credit facility				$ 45,300,000
Credit Facility \| 2015 Notes
Debt Instrument [Line Items]
Stated interest rate				10.25%
Credit Facility \| Term Loan B Facility
Debt Instrument [Line Items]
Aggregate principal debt amount										250,000,000
Credit Facility \| Delayed Draw Term Loan B Facility
Debt Instrument [Line Items]
Aggregate principal debt amount										$ 150,000,000
Credit Facility \| Senior Credit Facilities
Debt Instrument [Line Items]
Penalty Interest Rate Increase				2.00%
Unsecured Debt \| 2015 Notes
Debt Instrument [Line Items]
Stated interest rate				10.25%	10.25%	10.25%					10.25%
Civil Action
Debt Instrument [Line Items]
Legal settlement amount			$ 15,000,000	$ 15,000,000
First Amendment \| Senior Credit Facilities
Debt Instrument [Line Items]
Payments of Debt Restructuring Costs			$ 500,000
Second Amendment \| Senior Credit Facilities \| Eurodollar
Debt Instrument [Line Items]
Basis Spread on Variable Rate		6.00%
Basis Spread on Variable Rate, Minimum		5.25%
Second Amendment \| Senior Credit Facilities \| Base Rate
Debt Instrument [Line Items]
Basis Spread on Variable Rate		5.00%
Basis Spread on Variable Rate, Minimum		4.25%
Second Amendment \| Second Lien Debt
Debt Instrument [Line Items]
New Debt Permitted		$ 150,000,000.0
Second Amendment \| Unsecured Debt
Debt Instrument [Line Items]
New Debt Permitted		$ 250,000,000.0
Percent of Proceeds Appropriated to Credit Facility		100.00%
Third Amendment \| Senior Credit Facilities
Debt Instrument [Line Items]
Fiscal quarters used in measuring net leverage \| Quarters				4
Fourth Amendment \| Senior Credit Facilities
Debt Instrument [Line Items]
Maximum Borrowing Capacity							$ 60,000,000
Home Health Services
Debt Instrument [Line Items]
Proceeds from discontinued operation									$ 54,200,000

DEBT - 2021 Notes (Details) - USD ($)		12 Months Ended
DEBT - 2021 Notes (Details) - USD ($)	Feb. 11, 2014	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2013	Mar. 25, 2010
2021 Notes
Debt Instrument [Line Items]
Aggregate principal debt amount	$ 200,000,000.0
Stated interest rate	8.875%
Unamortized Discount	$ 5,000,000
Repurchase price percentage offer	101.00%
Proceeds from Issuance of Long-term Debt	$ 194,500,000
2021 Notes \| Redemption Period One
Debt Instrument [Line Items]
Debt Redemption Amount, Maximum	35.00%
Debt Redemption Price	108.88%
Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Repayments of Short-term Debt	$ 59,300,000	$ 17,200,000
Term Loan Facilities
Debt Instrument [Line Items]
Repayments of Short-term Debt		$ 37,000,000
Repayments of Long-term Debt	$ 135,200,000
Unsecured Debt \| 2015 Notes
Debt Instrument [Line Items]
Stated interest rate		10.25%	10.25%	10.25%	10.25%

DEBT - Fair Value of Financial Instruments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Debt Instrument [Line Items]
Long-term Debt	$ 422,757
Term Loan Facilities
Debt Instrument [Line Items]
Long-term Debt	222,757	$ 222,757
2021 Notes
Debt Instrument [Line Items]
Long-term Debt	196,038	$ 195,462
Term loan facilities and 2021 notes
Debt Instrument [Line Items]
Long-term Debt	418,795
Fair Value \| Fair Value, Inputs, Level 1 \| Term Loan Facilities
Debt Instrument [Line Items]
Long-term Debt	0
Fair Value \| Fair Value, Inputs, Level 1 \| 2021 Notes
Debt Instrument [Line Items]
Long-term Debt	0
Fair Value \| Fair Value, Inputs, Level 1 \| Term loan facilities and 2021 notes
Debt Instrument [Line Items]
Long-term Debt	0
Fair Value \| Fair Value, Inputs, Level 2 \| Term Loan Facilities
Debt Instrument [Line Items]
Long-term Debt	196,500
Fair Value \| Fair Value, Inputs, Level 2 \| 2021 Notes
Debt Instrument [Line Items]
Long-term Debt	167,650
Fair Value \| Fair Value, Inputs, Level 2 \| Term loan facilities and 2021 notes
Debt Instrument [Line Items]
Long-term Debt	364,150
Fair Value \| Fair Value, Inputs, Level 3 \| Term Loan Facilities
Debt Instrument [Line Items]
Long-term Debt	0
Fair Value \| Fair Value, Inputs, Level 3 \| 2021 Notes
Debt Instrument [Line Items]
Long-term Debt	0
Fair Value \| Fair Value, Inputs, Level 3 \| Term loan facilities and 2021 notes
Debt Instrument [Line Items]
Long-term Debt	$ 0

DEBT - Deferred Financing Costs (Details) $ in Millions	Dec. 31, 2015 USD ($)
Senior Credit Facilities
Debt Instrument [Line Items]
Net Deferred Finance Costs	$ 24.6
2021 Notes
Debt Instrument [Line Items]
Net Deferred Finance Costs	$ 0.5

DEBT - Future Maturities (Details) $ in Thousands	Dec. 31, 2015 USD ($)
Debt Disclosure [Abstract]
2016	$ 12,550
2017	12,550
2018	12,550
2019	12,550
2020	172,557
Thereafter	200,000
Total future maturities	$ 422,757

DEBT - Schedule of Interest Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Amortization of deferred financing costs	$ 2,864	$ 3,691	$ 2,259
Amortization of debt discount	576	462	0
Loss on extinguishment of debt	0	2,373	15,898
Expense allocated to discontinued operations	0	0	41
Other, net	(600)	(183)	21
Interest expense, net	37,313	40,918	44,130
Senior Secured Revolving Credit Facility
Debt Instrument [Line Items]
Debt interest expense, excluding amortization	2,190	1,829	873
Term Loan Facilities
Debt Instrument [Line Items]
Debt interest expense, excluding amortization	14,680	16,820	10,313
2021 Notes
Debt Instrument [Line Items]
Debt interest expense, excluding amortization	17,603	15,926	0
Prior Revolving Credit Facility
Debt Instrument [Line Items]
Debt interest expense, excluding amortization	0	0	765
2015 Notes
Debt Instrument [Line Items]
Debt interest expense, excluding amortization	$ 0	$ 0	$ 13,960

DEBT - Interest Expense, net (Details)	12 Months Ended
DEBT - Interest Expense, net (Details)	Dec. 31, 2015	Dec. 31, 2014
Debt Disclosure [Abstract]
Interest Rate During Period	11.69%	12.26%

COMMITMENTS AND CONTINGENCIES - Legal Proceedings (Details)				1 Months Ended	12 Months Ended
	Oct. 09, 2015 USD ($)	Apr. 09, 2015 claim	Dec. 23, 2013 USD ($)	Jan. 31, 2016 USD ($)	Dec. 31, 2015 USD ($) payment shares	Dec. 31, 2013 USD ($)	Dec. 07, 2015 USD ($)	Jul. 29, 2015 USD ($)	Jul. 27, 2015 shares	Mar. 09, 2015 shares	Dec. 31, 2014 shares
Legal Proceedings
Series A preferred stock, shares issued (in shares) \| shares					635,822						0
PIPE Transaction
Legal Proceedings
Settlement award to Plaintiff								$ 750,000
Claims filed \| claim		2
Civil Action
Legal Proceedings
Legal settlement amount			$ 15,000,000		$ 15,000,000
Interest rate on annual payments					3.25%
Number of annual payments \| payment					3
PBM Services Payment Delay
Legal Proceedings
Amount due from third party processor							$ 6,800,000
McCormack Shareholder Class Action Litigation
Legal Proceedings
Payments for legal settlements	$ 130,000
Pharmacy Services Asset Sale \| Civil Action
Legal Proceedings
Legal settlement amount						$ 15,000,000
Convertible Preferred Stock
Legal Proceedings
Series A preferred stock, shares issued (in shares) \| shares									10,822	625,000
Class A Warrants
Legal Proceedings
Warrants outstanding (in shares) \| shares									31,025	1,800,000
Class B Warrants
Legal Proceedings
Warrants outstanding (in shares) \| shares									31,025	1,800,000
Subsequent Event
Legal Proceedings
Payments for legal settlements				$ 6,200,000
Fees paid to Relator				200,000
Subsequent Event \| Civil Action
Legal Proceedings
Fees paid to Relator				$ 200,000

COMMITMENTS AND CONTINGENCIES - Leases (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Commitments and Contingencies Disclosure [Abstract]
Rent expense for leased facilities and equipment	$ 7,200	$ 7,600	$ 7,900
Operating Leases
2016	8,271
2017	7,267
2018	5,284
2019	3,048
2020	1,565
2021 and Thereafter	1,111
Total Future Minimum Lease Payments	26,546
Capital Leases
2016	122
2017	62
2018	11
2019	0
2020	0
2021 and Thereafter	0
Total Future Minimum Lease Payments	195
Total
2016	8,393
2017	7,329
2018	5,295
2019	3,048
2020	1,565
2021 and Thereafter	1,111
Total Future Minimum Lease Payments	$ 26,741
Minimum
Future minimum lease payment for operating and capital leases
Capital lease interest rate	3.00%
Maximum
Future minimum lease payment for operating and capital leases
Capital lease interest rate	7.00%

COMMITMENTS AND CONTINGENCIES - Purchase Commitments (Details) $ in Millions	Dec. 31, 2015 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Commitments to purchase prescription drugs	$ 38.5

CONCENTRATION OF RISK (Details) - Sales Revenue	12 Months Ended
CONCENTRATION OF RISK (Details) - Sales Revenue	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
UnitedHealthcare \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	24.00%	22.00%	22.00%
Medicare \| Customer Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	10.00%	11.00%	11.00%
Immune Globulin \| Product Concentration Risk
Concentration Risk [Line Items]
Concentration risk, percentage	17.00%	17.00%	19.00%

INCOME TAXES - Reconciliation of Tax (Benefit) Provision (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Federal	$ 0	$ (886)	$ (866)
State	(76)	(41)	(1,412)
Total current	(76)	(927)	(2,278)
Federal	(18,293)	9,951	3,281
State	(3,163)	2,169	257
Total deferred	(21,456)	12,120	3,538
Tax provision (benefit)	$ (21,532)	$ 11,193	$ 1,260

INCOME TAXES - Temporary Differences That Give Rise to Deferred Tax (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014
Income Tax Disclosure [Abstract]
Reserves not currently deductible	$ 27,467	$ 28,387
Net operating loss carryforwards	91,350	65,097
Goodwill and intangibles (tax deductible)	34,983	8,458
Accrued expenses	654	32
Property basis differences	1,021	301
Stock based compensation	8,245	8,201
Other	715	610
Total deferred tax assets	164,435	111,086
Indefinite-lived goodwill and intangibles	(236)	(18,118)
Less: valuation allowance	(164,435)	(111,086)
Net deferred tax liability	(236)	(18,118)
Deferred taxes	$ (236)	$ (18,118)

INCOME TAXES - Reconciliation of Statutory to Effective Income Tax Rate (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Income Tax Disclosure [Abstract]
Tax (benefit) provision at statutory rate	$ (113,736)	$ (48,554)	$ (24,633)
State tax (benefit) provision, net of federal taxes	(8,356)	(3,959)	(3,239)
Valuation allowance changes affecting income tax expense	57,023	63,641	29,805
Change in tax contingencies	(37)	(109)	(1,157)
Non-deductible transaction costs	0	0	317
Goodwill impairment	43,362	0	0
Other	212	174	167
Tax provision (benefit)	$ (21,532)	$ 11,193	$ 1,260

INCOME TAXES - Unrecognized Tax Benefit (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Reconciliation of Unrecognized Tax Benefits [Roll Forward]
Unrecognized tax benefits, beginning balance	$ 1,096	$ 1,172	$ 2,754
Lapse of statute of limitations	(29)	(76)	(1,582)
Unrecognized tax benefits, ending balance	$ 1,067	$ 1,096	$ 1,172

INCOME TAXES - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013	Dec. 31, 2012
Operating Loss Carryforwards [Line Items]
Valuation allowance	$ (164,435)	$ (111,086)
Accrued interest related to uncertain tax positions	100	100
Unrecognized Tax Benefits	1,067	$ 1,096	$ 1,172	$ 2,754
Gross unrecognized tax benefits that would favorably affect effective income tax rate	100
Federal
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	243,000
NOLs to be recorded in additional paid-in capital when realized	(18,000)
Net operating loss carryforwards subject to annual limitation	18,400
State
Operating Loss Carryforwards [Line Items]
Net operating loss carryforwards	$ 322,700

STOCK-BASED COMPENSATION - Equity Incentive Plan (Details) - 2008 Plan - shares	May 08, 2014	Dec. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Additional shares authorized	2,500,000
Number of shares authorized (in shares)	9,355,000
Shares available for grant		1,240,811

STOCK-BASED COMPENSATION - Employee Stock Purchase Plan (Details) - USD ($) $ / shares in Units, $ in Millions		12 Months Ended
	May 07, 2013	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, par value (in USD per share)		$ 0.0001	$ 0.0001
Employee Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (as a percent)	85.00%
Common stock, par value (in USD per share)		$ 0.0001
Shares available for grant	750,000	564,441
Stock issued during period, (in shares)		185,559
Compensation expense		$ 0.1

STOCK-BASED COMPENSATION - BioScrip/CHS Equity Plan (Details)	Dec. 31, 2015 shares
BioScrip/ CHS Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant	0

STOCK-BASED COMPENSATION - Stock Options (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds from exercise of employee stock compensation plans	$ (50,000)	$ 1,468,000	$ 2,549,000
Unrecognized compensation expense	4,300,000
Total intrinsic value of options exercised	1,500	600,000	3,800,000
Stock Option
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Net proceeds from exercise of employee stock compensation plans	$ 1,600	1,500,000	2,500,000
Vesting period	3 years
Exercise period	10 years
Compensation expense	$ 4,800,000	$ 6,900,000	$ 6,000,000
Grant date fair value of options (in dollars per share)	$ 2.25	$ 4.32	$ 6.24
Weighted-average period for unrecognized compensation expense	1 year 11 months 28 days
Stock Option \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Exercise price (as a percent)	100.00%

STOCK-BASED COMPENSATION - Schedule of Weighted-average Assumptions (Details) - Stock Option	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	62.30%	61.00%	61.80%
Risk-free interest rate	2.20%	2.50%	2.13%
Expected life of options	8 years 9 months 55 days	5 years 8 months 15 days	5 years 6 months
Dividend rate	0.00%	0.00%	0.00%

STOCK-BASED COMPENSATION - Schedule of Stock Option Activity (Details) - Stock Option - USD ($) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Options
Balance at beginning of period, Options	6,837,006
Grants approved	1,436,500
Options exercised	(600)
Options forfeited and expired	(1,637,309)
Balance at end of period, Options	6,635,597	6,837,006
Weighted Average Exercise Price
Beginning Balance, Weighted Average Exercise Price (in dollars per share)	$ 7.65
Granted, Weighted Average Exercise Price (in dollars per share)	3.02
Exercised, Weighted Average Exercise Price (in dollars per share)	2.73
Forfeited and expired, Weighted Average Exercise Price (in dollars per share)	8.42
Ending Balance, Weighted Average Exercise Price (in dollars per share)	$ 6.46	$ 7.65
Aggregate Intrinsic Value	$ 2	$ 4,150
Weighted Average Remaining Contractual Term	5 years 9 months 26 days	7 years 4 months 24 days
Outstanding options less expected forfeitures, Options	6,335,391
Outstanding options less expected forfeitures, Weighted Average Exercise Price (in dollars per share)	$ 6.51
Outstanding options less expected forfeitures, Aggregate Intrinsic Value	$ 2
Outstanding options less expected forfeitures, Weighted Average Remaining Contractual Life	5 years 7 months 26 days
Options exercisable at end of period	4,384,108
Exercisable, Weighted Average Exercise Price (in dollars per share)	$ 7.05
Exercisable, Aggregate Intrinsic Value	$ 2
Exercisable, Weighted Average Remaining Contractual Life	4 years 2 months 13 days

STOCK-BASED COMPENSATION - Schedule of Options Outstanding and Exercisable (Details)	12 Months Ended
	Dec. 31, 2015 $ / shares shares
Options Outstanding and Exercisable
Outstanding Options \| shares	6,635,597
Weighted Average Exercise Price	$ 6.46
Weighted Average Remaining Contractual Life	5 years 8 months 66 days
Options Exercisable \| shares	4,384,108
Weighted Average Exercise Price	$ 7.05
$1.71 - $4.13
Options Outstanding and Exercisable
Minimum range of option exercise price	1.71
Maximum range of option exercise price	$ 4.13
Outstanding Options \| shares	1,567,250
Weighted Average Exercise Price	$ 2.66
Weighted Average Remaining Contractual Life	8 years 4 days
Options Exercisable \| shares	348,250
Weighted Average Exercise Price	$ 2.47
$4.14 - $8.25
Options Outstanding and Exercisable
Minimum range of option exercise price	4.14
Maximum range of option exercise price	$ 8.25
Outstanding Options \| shares	3,885,681
Weighted Average Exercise Price	$ 6.51
Weighted Average Remaining Contractual Life	4 years 9 months 75 days
Options Exercisable \| shares	3,110,026
Weighted Average Exercise Price	$ 6.34
$8.26- $12.38
Options Outstanding and Exercisable
Minimum range of option exercise price	8.26
Maximum range of option exercise price	$ 12.38
Outstanding Options \| shares	762,500
Weighted Average Exercise Price	$ 10.39
Weighted Average Remaining Contractual Life	5 years 4 months 55 days
Options Exercisable \| shares	619,168
Weighted Average Exercise Price	$ 10.25
$12.39 - $14.44
Options Outstanding and Exercisable
Minimum range of option exercise price	12.39
Maximum range of option exercise price	$ 14.44
Outstanding Options \| shares	412,166
Weighted Average Exercise Price	$ 12.91
Weighted Average Remaining Contractual Life	5 years 9 months 97 days
Options Exercisable \| shares	301,331
Weighted Average Exercise Price	$ 12.9
$14.45 - $18.57
Options Outstanding and Exercisable
Minimum range of option exercise price	14.45
Maximum range of option exercise price	$ 18.57
Outstanding Options \| shares	8,000
Weighted Average Exercise Price	$ 16.63
Weighted Average Remaining Contractual Life	7 years 5 months 67 days
Options Exercisable \| shares	5,333
Weighted Average Exercise Price	$ 16.63

STOCK-BASED COMPENSATION - Restricted Stock (Details) - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation expense	$ 0
Compensation expense	400,000	$ 1,600,000	$ 3,500,000
Grant date fair value of awards vested	200,000	3,500,000	500,000
Fair value of awards vested	$ 500,000	$ 2,000,000	$ 500,000
2008 Plan \| Performance Shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
2008 Plan \| Performance Shares \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year
Key Employees \| 2008 Plan \| Restricted Stock \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	3 years
Director \| 2008 Plan \| Restricted Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period	1 year

STOCK-BASED COMPENSATION - Schedule of Restricted Stock Awards (Details) - Restricted Stock - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Restricted Stock Shares
Beginning balance (in shares)	179,997
Granted (in shares)	68,000
Awards Vested (in shares)	(147,000)
Canceled (in shares)	(50,999)
Ending balance (in shares)	49,998	179,997
Weighted Average Award Grant Date Fair Value
Beginning balance (dollars per share)	$ 9.31
Granted (dollars per share)	3.55
Awards Vested (dollars per share)	4.92
Canceled (dollars per share)	11.77
Ending balance (dollars per share)	$ 11.89	$ 9.31
Weighted Average Remaining Recognition Period
Weighted average remaining recognition period	2 years 2 months 12 days	4 months 26 days

STOCK-BASED COMPENSATION - Performance Units (Details) - Key Employees - 2008 Plan - Performance Shares	12 Months Ended
	Dec. 31, 2015 USD ($) shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum annual cash award \| $	$ 1,000,000.0
Grants since inception of plan (in shares) \| shares	0

STOCK-BASED COMPENSATION - Stock Appreciation Rights (Details) - USD ($)		12 Months Ended
	Mar. 09, 2015	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
PIPE transaction issuance costs	$ 4,000,000
Stock Appreciation Rights (SARs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Compensation expense (benefit)		$ (913,000)	$ (20,000)	$ (48,000)
Stock appreciation rights		300,000	320,000
Vesting period		3 years
Exercise period		10 years
PIPE transaction issuance costs		$ 0	$ 0	$ 0
Stock Appreciation Rights (SARs) \| Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Holding period		1 year

STOCK-BASED COMPENSATION - Schedule of SAR Activity (Details) - Stock Appreciation Rights (SARs) - $ / shares	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Stock Appreciation Rights
Beginning balance (in shares)	320,000
Granted (in shares)	0
Exercised (in shares)	0
Canceled (in shares)	(20,000)
Ending balance (in shares)	300,000	320,000
Weighted Average Exercise Price
Beginning balance (dollars per share)	$ 6.65
Granted (dollars per share)	0.00
Exercised (dollars per share)	0.00
Canceled (dollars per share)	9.16
Ending balance (dollars per share)	$ 6.48	$ 6.65
Weighted Average Remaining Recognition Period
Weighted average remaining recognition period	1 day	3 months 19 days

DEFINED CONTRIBUTION PLAN (Details) - USD ($) $ in Millions	12 Months Ended
DEFINED CONTRIBUTION PLAN (Details) - USD ($) $ in Millions	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Defined Contribution Pension and Other Postretirement Plans Disclosure [Abstract]
Maximum annual deferral (as a percent)	100.00%
Matching contributions	$ 1.3	$ 1.6	$ 0.5

SELECTED QUARTERLY FINANCIAL DATA (UNAUDITED) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Selected Quarterly Financial Information [Abstract]
Revenue	$ 243,745	$ 247,224	$ 246,897	$ 244,357	$ 239,744	$ 231,458	$ 230,111	$ 221,341	$ 982,223	$ 922,654	$ 696,473
Gross profit	65,909	65,233	64,818	64,955	63,678	62,687	62,249	62,139	260,915	250,753	206,650
Loss from continuing operations, before income taxes	(15,980)	(28,791)	(264,822)	(15,367)	(60,626)	(37,274)	(17,221)	(23,606)	(324,960)	(138,727)	(70,381)
Income from discontinued operations, net of income taxes	(1,451)	7,457	94	(2,379)	(291)	494	466	1,783	3,721	2,452	1,987
Net loss	$ (18,443)	$ (16,783)	$ (244,807)	$ (19,674)	$ (63,626)	$ (38,710)	$ (19,818)	$ (25,314)	$ (299,707)	$ (147,468)	$ (69,654)
Loss from continuing operations, basic and diluted (in USD per share)	$ (0.28)	$ (0.38)	$ (3.62)	$ (0.28)	$ (0.92)	$ (0.57)	$ (0.30)	$ (0.40)	$ (4.56)	$ (2.19)	$ (1.11)
Income (loss) from discontinued operations, basic and diluted (in USD per share)	(0.02)	0.11	0.00	(0.03)	0.00	0.01	0.01	0.03	0.05	0.04	0.03
Income (loss), basic and diluted (in USD per share)	$ (0.30)	$ (0.27)	$ (3.62)	$ (0.31)	$ (0.92)	$ (0.56)	$ (0.29)	$ (0.37)	$ (4.51)	$ (2.15)	$ (1.08)

- Definition

Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Schedule II -- Valuation and Qualifying Accounts (Details) - Allowance for Doubtful Accounts - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Movement in Valuation Allowances and Reserves [Roll Forward]
Balance at Beginning of Period	$ 66,405	$ 17,735	$ 20,760
Write-Off of Receivables	(47,758)	(30,877)	(22,541)
Charged to Costs and Expenses	41,042	79,547	19,516
Balance at End of Period	$ 59,689	$ 66,405	$ 17,735